0001628280-23-015496.txt : 20230504 0001628280-23-015496.hdr.sgml : 20230504 20230504091512 ACCESSION NUMBER: 0001628280-23-015496 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: R1 RCM Inc. /DE CENTRAL INDEX KEY: 0001910851 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT SERVICES [8741] IRS NUMBER: 874340782 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41428 FILM NUMBER: 23886821 BUSINESS ADDRESS: STREET 1: 434 W. ASCENSION WAY, 6TH FLOOR CITY: MURRAY STATE: UT ZIP: 84123 BUSINESS PHONE: (312) 324-7820 MAIL ADDRESS: STREET 1: 434 W. ASCENSION WAY, 6TH FLOOR CITY: MURRAY STATE: UT ZIP: 84123 FORMER COMPANY: FORMER CONFORMED NAME: PROJECT ROADRUNNER PARENT INC. DATE OF NAME CHANGE: 20220211 10-Q 1 ah-20230331.htm 10-Q ah-20230331
false2023Q10001910851December 31R1 RCM Inc. /DEP9MP1YP1YP1YP1YP1YP3Y00019108512023-01-012023-03-3100019108512023-04-28xbrli:shares00019108512023-03-31iso4217:USD00019108512022-12-310001910851srt:AffiliatedEntityMember2023-03-310001910851srt:AffiliatedEntityMember2022-12-31iso4217:USDxbrli:shares00019108512022-01-012022-03-310001910851us-gaap:CommonStockMember2022-12-310001910851us-gaap:TreasuryStockCommonMember2022-12-310001910851us-gaap:AdditionalPaidInCapitalMember2022-12-310001910851us-gaap:RetainedEarningsMember2022-12-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001910851us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001910851us-gaap:AdditionalPaidInCapitalMemberah:CoyCo2Member2023-01-012023-03-310001910851ah:CoyCo2Member2023-01-012023-03-310001910851us-gaap:CommonStockMember2023-01-012023-03-310001910851us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001910851us-gaap:RetainedEarningsMember2023-01-012023-03-310001910851us-gaap:CommonStockMember2023-03-310001910851us-gaap:TreasuryStockCommonMember2023-03-310001910851us-gaap:AdditionalPaidInCapitalMember2023-03-310001910851us-gaap:RetainedEarningsMember2023-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001910851us-gaap:CommonStockMember2021-12-310001910851us-gaap:TreasuryStockCommonMember2021-12-310001910851us-gaap:AdditionalPaidInCapitalMember2021-12-310001910851us-gaap:RetainedEarningsMember2021-12-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100019108512021-12-310001910851us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001910851us-gaap:CommonStockMember2022-01-012022-03-310001910851us-gaap:TreasuryStockCommonMember2022-01-012022-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001910851us-gaap:RetainedEarningsMember2022-01-012022-03-310001910851us-gaap:CommonStockMember2022-03-310001910851us-gaap:TreasuryStockCommonMember2022-03-310001910851us-gaap:AdditionalPaidInCapitalMember2022-03-310001910851us-gaap:RetainedEarningsMember2022-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100019108512022-03-310001910851ah:SeniorTermLoanMember2023-01-012023-03-310001910851ah:SeniorTermLoanMember2022-01-012022-03-310001910851us-gaap:RevolvingCreditFacilityMember2023-01-012023-03-310001910851us-gaap:RevolvingCreditFacilityMember2022-01-012022-03-310001910851ah:CloudmedMemberah:CloudmedAcquisitionMember2022-01-012022-12-310001910851ah:CloudmedAcquisitionMember2022-06-212022-06-210001910851ah:CloudmedAcquisitionMember2022-06-210001910851ah:CloudmedAcquisitionMember2022-01-012022-03-310001910851ah:RevWorksAcquisitionMember2021-07-012021-09-300001910851ah:RevWorksAcquisitionMember2022-08-012022-08-310001910851ah:RevWorksAcquisitionMember2020-08-31ah:payment0001910851ah:RevWorksAcquisitionMember2020-08-012020-08-310001910851ah:CloudmedAndVisitPayAcquisitionsMember2022-01-012022-03-310001910851ah:NetOperatingFeesMember2023-01-012023-03-310001910851ah:NetOperatingFeesMember2022-01-012022-03-310001910851ah:IncentiveFeesMember2023-01-012023-03-310001910851ah:IncentiveFeesMember2022-01-012022-03-310001910851ah:ModularAndOtherMember2023-01-012023-03-310001910851ah:ModularAndOtherMember2022-01-012022-03-310001910851ah:CloudmedMember2023-01-012023-03-310001910851us-gaap:InvestorMember2023-03-310001910851us-gaap:InvestorMember2022-12-310001910851ah:NetOperatingFeesMember2023-04-012023-03-3100019108512023-04-01ah:IncentiveFeesMember2023-03-310001910851ah:NetOperatingFeesMember2024-01-012023-03-310001910851ah:IncentiveFeesMember2024-01-012023-03-310001910851ah:NetOperatingFeesMember2025-01-012023-03-3100019108512025-01-01ah:IncentiveFeesMember2023-03-3100019108512026-01-01ah:NetOperatingFeesMember2023-03-3100019108512026-01-01ah:IncentiveFeesMember2023-03-310001910851ah:NetOperatingFeesMember2027-01-012023-03-3100019108512027-01-01ah:IncentiveFeesMember2023-03-310001910851ah:NetOperatingFeesMember2028-01-012023-03-310001910851ah:IncentiveFeesMember2028-01-012023-03-310001910851ah:NetOperatingFeesMember2029-01-012023-03-3100019108512029-01-01ah:IncentiveFeesMember2023-03-310001910851ah:NetOperatingFeesMember2023-03-310001910851ah:IncentiveFeesMember2023-03-3100019108512023-04-012023-03-3100019108512024-01-012023-03-3100019108512025-01-012023-03-3100019108512026-01-012023-03-3100019108512027-01-012023-03-3100019108512028-01-012023-03-3100019108512029-01-012023-03-310001910851ah:PhysicianCustomerMember2022-07-012022-09-300001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-03-310001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMember2023-03-310001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMember2022-12-310001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2023-03-310001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2022-12-310001910851us-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2023-03-310001910851us-gaap:RevolvingCreditFacilityMemberah:SecondARCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-210001910851ah:ExistingSeniorSecuredTermLoanAMemberah:SecondARCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-210001910851ah:SecondARCreditAgreementMemberus-gaap:LineOfCreditMemberah:IncrementalSeniorSecuredTermLoanAMember2022-06-210001910851ah:SecondARCreditAgreementMemberah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2022-06-210001910851ah:SecondARCreditAgreementMemberah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMember2023-03-31xbrli:pure0001910851ah:SecondARCreditAgreementMemberah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2023-03-310001910851ah:SecondARCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-210001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-01-012023-03-310001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-03-310001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-03-310001910851us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-01-012023-03-310001910851us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-01-012022-03-310001910851us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-03-310001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-12-310001910851us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-12-3100019108512022-01-012022-12-310001910851ah:ThirdPartyMember2022-07-052022-07-050001910851us-gaap:CostOfSalesMember2023-01-012023-03-310001910851us-gaap:CostOfSalesMember2022-01-012022-03-310001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001910851ah:CoyCo2Member2023-01-012023-03-310001910851ah:ManagementUnitsMember2023-01-012023-03-310001910851us-gaap:RestrictedStockUnitsRSUMember2022-12-310001910851us-gaap:PerformanceSharesMember2022-12-310001910851us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001910851us-gaap:PerformanceSharesMember2023-01-012023-03-310001910851us-gaap:RestrictedStockUnitsRSUMember2023-03-310001910851us-gaap:PerformanceSharesMember2023-03-310001910851us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001910851us-gaap:PerformanceSharesMember2022-01-012022-03-310001910851us-gaap:RestrictedStockUnitsRSUMemberah:CloudmedAcquisitionMember2022-01-012022-12-310001910851ah:RestrictedStockUnitsRSUsAndPerformanceSharesMemberah:CloudmedAcquisitionMember2022-01-012022-12-310001910851us-gaap:PerformanceSharesMembersrt:MinimumMember2023-01-012023-03-310001910851us-gaap:PerformanceSharesMembersrt:MaximumMember2023-01-012023-03-310001910851ah:FormerClassPUnitsMember2022-06-212022-06-210001910851ah:ManagementUnitsMember2022-06-212022-06-210001910851ah:TCPASCRecapitalizationLitigationMemberus-gaap:PendingLitigationMember2021-04-132021-04-19ah:claimah:segment0001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001910851us-gaap:SalesRevenueNetMemberah:CustomerNotAffiliatedwithAscensionHealthMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001910851us-gaap:SalesRevenueNetMemberah:CustomerNotAffiliatedwithAscensionHealthMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001910851ah:AscensionMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001910851ah:AscensionMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-03-31


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q

(Mark One)

    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the quarterly period ended March 31, 2023
OR
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from to
COMMISSION FILE NUMBER: 001-41428
R1 RCM INC.
(Exact name of registrant as specified in its charter)
Delaware87-4340782
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
433 W. Ascension Way
84123
Suite 200
Murray
Utah
(Address of principal executive offices)(Zip code)
(312324-7820
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareRCMNASDAQ
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ    No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerý
Accelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes      No 
As of April 28, 2023, the registrant had 418,202,601 shares of common stock, par value $0.01 per share, outstanding.





Table of Contents




PART I — FINANCIAL INFORMATION
Item 1.Financial Statements
3


R1 RCM Inc.
Consolidated Balance Sheets
(In millions, except share and per share data)


(Unaudited)
 March 31,December 31,
 20232022
Assets
Current assets:
Cash and cash equivalents$104.2 $110.1 
Accounts receivable, net of $16.0 million and $15.1 million allowance as of March 31, 2023 and December 31, 2022, respectively
229.4 235.2 
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of March 31, 2023 and December 31, 2022, respectively
24.9 25.0 
Current portion of contract assets, net81.8 83.9 
Prepaid expenses and other current assets105.2 110.3 
Total current assets545.5 564.5 
Property, equipment and software, net173.8 164.8 
Operating lease right-of-use assets81.0 80.5 
Non-current portion of contract assets, net37.3 32.0 
Non-current portion of deferred contract costs28.2 26.7 
Intangible assets, net1,464.4 1,514.5 
Goodwill2,648.5 2,658.2 
Deferred tax assets10.5 10.4 
Other assets83.4 88.2 
Total assets$5,072.6 $5,139.8 
Liabilities
Current liabilities:
Accounts payable$24.6 $33.4 
Current portion of customer liabilities45.6 57.5 
Current portion of customer liabilities - related party9.4 7.4 
Accrued compensation and benefits84.7 109.0 
Current portion of operating lease liabilities18.8 18.0 
Current portion of long-term debt58.3 53.9 
Accrued expenses and other current liabilities76.7 70.6 
Total current liabilities318.1 349.8 
Non-current portion of customer liabilities5.2 5.0 
Non-current portion of customer liabilities - related party13.2 13.7 
Non-current portion of operating lease liabilities92.7 94.4 
Long-term debt1,707.0 1,732.6 
Deferred tax liabilities192.1 200.7 
Other non-current liabilities24.9 23.1 
Total liabilities2,353.2 2,419.3 
Stockholders’ equity:
Common stock, $0.01 par value, 750,000,000 shares authorized, 442,439,169 shares issued and 418,176,363 shares outstanding at March 31, 2023; 750,000,000 shares authorized, 439,950,125 shares issued and 416,597,885 shares outstanding at December 31, 2022
4.4 4.4 
Additional paid-in capital3,136.2 3,123.2 
Accumulated deficit(121.6)(121.9)
Accumulated other comprehensive loss(4.6)(3.4)
Treasury stock, at cost, 24,262,806 shares as of March 31, 2023; 23,352,240 shares as of December 31, 2022
(295.0)(281.8)
Total stockholders’ equity2,719.4 2,720.5 
Total liabilities and stockholders’ equity$5,072.6 $5,139.8 
See accompanying notes to consolidated financial statements.
4


R1 RCM Inc.
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)
(In millions, except share and per share data)

 
 Three Months Ended March 31,
 20232022
Net services revenue ($216.8 million and $216.7 million for the three months ended March 31, 2023 and 2022, from related party, respectively)
$545.6 $385.7 
Operating expenses:
Cost of services434.7 296.5 
Selling, general and administrative47.0 28.9 
Other expenses30.2 17.1 
Total operating expenses511.9 342.5 
Income from operations33.7 43.2 
Net interest expense30.7 4.7 
Income before income tax provision3.0 38.5 
Income tax provision2.7 9.1 
Net income $0.3 $29.4 
Net income per common share:
Basic$ $0.11 
Diluted$ $0.09 
Weighted average shares used in calculating net income per common share:
Basic417,346,840 278,747,261 
Diluted452,925,789 321,043,371 
Consolidated statements of comprehensive income (loss)
Net income$0.3 $29.4 
Other comprehensive income (loss):
Net change on derivatives designated as cash flow hedges, net of tax(1.7)0.1 
Foreign currency translation adjustments0.5 (1.4)
Total other comprehensive income (loss), net of tax$(1.2)$(1.3)
Comprehensive income (loss)$(0.9)$28.1 
See accompanying notes to consolidated financial statements.
5


R1 RCM Inc.
Consolidated Statements of Stockholders’ Equity (Unaudited)
(In millions, except share and per share data)

 Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmountSharesAmount    
Balance at December 31, 2022439,950,125 $4.4 (23,352,240)$(281.8)$3,123.2 $(121.9)$(3.4)$2,720.5 
Share-based compensation expense— — — — 10.7 — — 10.7 
CoyCo 2 share-based compensation expense— — — — 1.8 — — 1.8 
Issuance of common stock related to share-based compensation plans2,308,591 — — — — — — — 
Exercise of vested stock options180,453 — — — 0.5 — — 0.5 
Acquisition of treasury stock related to share-based compensation plans— — (910,566)(13.2)— — — (13.2)
Net change on derivatives designated as cash flow hedges, net of tax of $0.5 million
— — — — — — (1.7)(1.7)
Foreign currency translation adjustments— — — — — — 0.5 0.5 
Net income— — — — — 0.3 — 0.3 
Balance at March 31, 2023442,439,169 $4.4 (24,262,806)$(295.0)$3,136.2 $(121.6)$(4.6)$2,719.4 
See accompanying notes to consolidated financial statements.

 Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmountSharesAmount    
Balance at December 31, 2021298,320,928 $3.0 (20,094,686)$(215.2)$628.5 $(64.3)$(5.3)$346.7 
Share-based compensation expense— — — — 10.2 — — 10.2 
Issuance of common stock related to share-based compensation plans1,757,955 — — — — — — — 
Exercise of vested stock options77,438 — — — 0.4 — — 0.4 
Acquisition of treasury stock related to share-based compensation plans— — (727,768)(18.7)— — — (18.7)
Repurchase of common stock— — (8,000)(0.2)— — — (0.2)
Net change on derivatives designated as cash flow hedges, net of tax of $0.0 million
— — — — — — 0.1 0.1 
Foreign currency translation adjustments— — — — — — (1.4)(1.4)
Net income— — — — — 29.4 — 29.4 
Balance at March 31, 2022300,156,321 $3.0 (20,830,454)$(234.1)$639.1 $(34.9)$(6.6)$366.5 
See accompanying notes to consolidated financial statements.
6


R1 RCM Inc.
Consolidated Statements of Cash Flows (Unaudited)
(In millions)

 Three Months Ended March 31,
 20232022
Operating activities
Net income$0.3 $29.4 
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization66.0 18.9 
Amortization of debt issuance costs1.4 0.3 
Share-based compensation10.5 10.1 
CoyCo 2 share-based compensation1.8  
Loss on disposal and right-of-use asset write-downs 2.0 
Provision for credit losses1.5  
Deferred income taxes1.8 7.3 
Non-cash lease expense2.9 3.2 
Other 1.5 
Changes in operating assets and liabilities:
Accounts receivable and related party accounts receivable4.7 22.1 
Contract assets(4.0) 
Prepaid expenses and other assets8.2 (20.5)
Accounts payable(10.9)3.2 
Accrued compensation and benefits(24.5)(27.5)
Lease liabilities(4.4)(2.1)
Other liabilities9.7 1.7 
Customer liabilities and customer liabilities - related party(10.3)(18.7)
Net cash provided by operating activities54.7 30.9 
Investing activities
Purchases of property, equipment, and software(23.4)(10.0)
Other(2.2) 
Net cash used in investing activities(25.6)(10.0)
Financing activities
Repayment of senior secured debt(12.4)(4.4)
Repayments on revolver(10.0) 
Exercise of vested stock options0.5 0.4 
Purchase of treasury stock (0.6)
Shares withheld for taxes(13.4)(21.5)
Other(0.1)(0.1)
Net cash used in financing activities(35.4)(26.2)
Effect of exchange rate changes in cash, cash equivalents and restricted cash0.4 (0.9)
Net decrease in cash, cash equivalents and restricted cash(5.9)(6.2)
Cash, cash equivalents and restricted cash, at beginning of period110.1 130.1 
Cash, cash equivalents and restricted cash, at end of period$104.2 $123.9 
Supplemental disclosures of cash flow information
Property, equipment and software purchases not paid$28.0 $23.3 
See accompanying notes to consolidated financial statements.
7



R1 RCM Inc.
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)

1. Business Description and Basis of Presentation
Business Description
R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers.
Basis of Presentation
The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of March 31, 2023, the results of operations of the Company for the three months ended March 31, 2023 and 2022, and the cash flows of the Company for the three months ended March 31, 2023 and 2022. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2023.
When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements included in the Company’s 2022 Form 10-K.
Recently Issued Accounting Standards and Disclosures

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.

2. Acquisitions

Assets acquired and liabilities assumed in a business combination are recorded at their estimated fair value on the date of the acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.

8


Prior Acquisitions

During 2022, the Company acquired the following business:

Company NameDescription of the BusinessDescription of the Acquisition
Revint Holdings, LLC (“Cloudmed”)
Provider of revenue intelligence solutions
Purchased all outstanding equity interests in exchange for shares of common stock of the Company and cash. The shares of common stock received by the Cloudmed sellers are subject to an 18-month lock-up period, which expires December 21, 2023. In addition, the Company replaced certain pre-acquisition awards held by certain Cloudmed sellers with restricted stock units (“RSUs”) of the Company.

The purchase price has been provisionally allocated to assets acquired and liabilities assumed based on their fair value as of the acquisition date. The fair value estimate of assets acquired and liabilities assumed is pending the completion of various elements, including gathering further information to ensure the completeness of assets acquired and liabilities assumed and the finalization of an independent appraisal of their respective fair values, which is subject to final review by the Company’s management. Accordingly, management considers the balances shown in the following table to be preliminary, and there could be adjustments to the consolidated financial statements, including changes in our amortization expense related to the valuation of intangible assets acquired and their respective useful lives, among other adjustments.

The preliminary fair value of assets acquired and liabilities assumed is:
Purchase Price Allocation
Total purchase consideration$3,281.6 
Allocation of consideration to assets acquired and liabilities assumed:
Cash and cash equivalents$32.1 
Accounts receivable61.8 
Current portion of contract assets68.2 
Property, equipment and software5.0 
Operating lease right-of-use assets25.3 
Non-current portion of contract assets23.8 
Intangible assets1,366.6 
Goodwill2,093.9 
Other assets6.7 
Accounts payable(31.9)
Customer liabilities(3.3)
Accrued compensation and benefits(93.4)
Operating lease liabilities(25.4)
Deferred income tax liabilities(235.6)
Other liabilities(12.2)
Net assets acquired$3,281.6 

9


Measurement period adjustments

The Company had various measurement period adjustments due to additional information received since December 31, 2022. The significant adjustments included a reduction to deferred income tax liabilities and a corresponding decrease to goodwill of $9.8 million related to updated tax return information.

RevWorks

In 2020, the Company purchased certain assets relating to the RevWorks services business from Cerner Corporation. In accordance with the purchase agreement, the Company paid the first deferred payment of $12.5 million in the third quarter of 2021. The remaining deferred payment of $12.5 million was payable on the second anniversary of the closing date (August 2022) and is included in other accrued expenses on the Consolidated Balance Sheet as of March 31, 2023 as it had not been paid as of such date.

The two deferred payments related to the RevWorks acquisition were contractual obligations of the Company; however, they are refundable to the Company if certain RevWorks customer revenue targets defined in the purchase agreement for the first two years following the acquisition are not achieved. The parties are currently engaged in arbitration to finalize the remaining deferred payment and contingently refundable consideration amounts. The contingently refundable consideration is stated at an amount approximating the amount expected to be realized and is included in other current assets on the Consolidated Balance Sheet as of March 31, 2023.

Pro Forma Results

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed acquisition had occurred as of January 1, 2021. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are:

Three Months Ended March 31, 2022
Net services revenue$486.4 
Net income$1.4 

Adjustments were made to earnings to adjust depreciation and amortization to reflect the fair value of identified assets acquired, to adjust share-based compensation expense for awards granted in connection with the acquisition, to record the effects of extinguishing the debt of the acquired company and replacing it with the debt of the Company, to adjust timing of acquisition related costs incurred by the Company, and to record the income tax effect of these adjustments.

3. Revenue Recognition
Revenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.

Disaggregation of Revenue

In the following table, revenue is disaggregated by source of revenue:

10


Three Months Ended March 31,
20232022
Net operating fees$361.0 $322.8 
Incentive fees23.6 30.2 
Modular and other (1)161.0 32.7 
Net services revenue$545.6 $385.7 

(1) Modular and other revenue primarily consists of $125.8 million in service fees related to Cloudmed for the three months ended March 31, 2023, revenue integrity solutions, practice management (“PM”) services, physician advisory services (“PAS”), and software subscription revenue.

Contract Balances

The following table provides information about contract assets, net and contract liabilities from contracts with customers:

March 31, 2023December 31, 2022
Contract assets, net
Current$81.8 $83.9 
Non-current37.3 32.0 
Total contract assets, net$119.1 $115.9 
Contract liabilities
Current (1)$11.0 $9.7 
Non-current (2)18.4 18.7 
Total contract liabilities$29.4 $28.4 

(1) Current contract liabilities include $8.8 million and $7.6 million classified in the current portion of customer liabilities and $2.2 million and $2.1 million classified in the current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively.
(2) Non-current contract liabilities include $5.2 million and $5.0 million classified in the non-current portion of customer liabilities and $13.2 million and $13.7 million classified in the non-current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively.

The contract assets, net balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets, net for the three months ended March 31, 2023 were as follows:

Contract Assets, net
Balance as of December 31, 2022
$115.9 
Revenue recognized86.0 
Amounts billed(82.6)
Other (1)(0.2)
Balance as of March 31, 2023
$119.1 

(1) Other primarily includes adjustments made during the period to the allowance for credit losses.


11



Contract Liabilities
Balance as of December 31, 2022
$(28.4)
Advanced billings - January 1, 2023 (1)(91.3)
Advanced billings recognized91.3 
Additions(3.9)
Revenue recognized2.9 
Balance as of March 31, 2023
$(29.4)

(1) The Company records advanced billings to contract liabilities and accounts receivable on the first day of the respective service period, which are earned during the quarter.

Transaction Price Allocated to the Remaining Performance Obligation

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained.

Net operating feesIncentive fees
Remainder of 2023$90.0 $33.0 
202478.1  
202545.7  
202635.6  
202731.2  
202829.8  
Thereafter83.6  
Total$394.0 $33.0 
    
The amounts presented in the table above include variable fee estimates of the Company’s physician groups revenue cycle management (“RCM”) services contracts, fixed fees, and forecasted incentive fees. Fixed fees are typically recognized ratably as the performance obligation is satisfied and forecasted incentive fees are measured cumulatively over the contractually defined performance period.

Estimates of revenue expected to be recognized in future periods exclude unexercised customer options to purchase services within the Company’s PAS contracts that do not represent material rights to the customer.

The Company does not disclose information about remaining performance obligations with an original expected duration of one year or less and has elected an exemption to the disclosure requirements related to estimate variable consideration and an exemption where the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date.

4. Accounts Receivable and Allowance for Credit Losses

Accounts receivable is comprised of invoiced and unbilled balances due from modular services and end-to-end RCM customers, which are presented net after considering cost reimbursements owed to end-to-end RCM customers.

12


The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and business and industry factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay.

The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material.

Movements in the allowance for credit losses related to accounts receivable are as follows:

 Three Months Ended March 31,
 20232022
Beginning balance (1)$15.2 $2.5 
Provision (recoveries)1.1  
Write-offs(0.2)(0.1)
Ending balance (1)$16.1 $2.4 

(1) The 2023 balance includes an allowance for credit losses related to a physician customer of $10.1 million that was established in the third quarter of 2022. Management continues to monitor collections and the financial condition of this customer. No changes were made in the current period.

The Company acquired contract assets through the Cloudmed acquisition. As of March 31, 2023, there was an allowance for credit losses of $2.6 million against total contract assets.

5. Debt

The carrying amounts of debt consist of the following:

March 31, 2023December 31, 2022
Senior Revolver (1)$90.0 $100.0 
Term A Loans1,200.3 1,211.4 
Term B Loan497.5 498.7 
Unamortized discount and issuance costs(22.5)(23.6)
Total debt1,765.3 1,786.5 
Less: Current maturities(58.3)(53.9)
Total long-term debt$1,707.0 $1,732.6 

(1) As of March 31, 2023, the Company had $90.0 million in borrowings, $0.9 million letters of credit outstanding, and $509.1 million of availability under the $600.0 million senior secured revolving credit facility (“Senior Revolver ”).

13


Second Amended and Restated Senior Secured Credit Facilities

On June 21, 2022, the Company, R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), and certain of its subsidiaries entered into a second amended and restated senior credit agreement (the “Second A&R Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan,” and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan,” and together with the Term A Loans, the “Senior Term Loans”), and the $600.0 million Senior Revolver. In conjunction with entering into the Second A&R Credit Agreement, the Company incurred $7.2 million and capitalized $6.4 million of debt issuance costs.

The interest rate as of March 31, 2023 was 7.31% for the Term A Loans and Senior Revolver and 7.81% for the Term B Loan.

The Second A&R Credit Agreement contains a number of financial and non-financial covenants. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of March 31, 2023. The obligations under the Second A&R Credit Agreement are secured by a pledge of 100% of the capital stock of certain domestic subsidiaries owned by the Company and a security interest in substantially all of the Company’s tangible and intangible assets and the tangible and intangible assets of certain domestic subsidiaries.

Debt Maturities

Scheduled maturities of the Company’s long-term debt are summarized as follows:

Scheduled Maturities
Remainder of 2023$41.5 
202467.0 
202567.0 
2026708.3 
2027430.2 
20285.0 
Thereafter468.8 
Total$1,787.8 

For further details on the Second A&R Credit Agreement, refer to Note 10 of the Company’s 2022 Form 10-K.
6. Derivative Financial Instruments

The Company utilizes cash flow hedges to manage its currency risk arising from its global business services centers. As of March 31, 2023, the Company has recorded $1.1 million of unrealized gains in accumulated other comprehensive loss related to foreign currency hedges. The Company estimates that $1.1 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 9 months. Amounts reclassified into cost of services were a net gain of $0.3 million and $0.2 million during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company’s foreign currency forward contracts have maturities extending no later than December 31, 2023, and had a total notional value of $90.2 million.
14



The Company also utilizes cash flow hedges to reduce variability in interest cash flows from its outstanding debt. As of March 31, 2023, the Company has recorded $9.9 million of unrealized gains in accumulated other comprehensive loss related to interest rate swaps. The Company estimates that $8.3 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into interest expense were a net gain of $1.9 million and a net loss of $0.3 million during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company’s interest rate swaps extend no later than June 30, 2025, and had a total notional value of $500.0 million.

The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:

March 31, 2023December 31, 2022
Foreign currency forward contracts
Prepaid expenses and other current assets$1.1 $0.1 
Other accrued expenses 0.5 
Total foreign current forward contracts$1.1 $0.6 
Interest rate swaps
Prepaid expenses and other current assets$8.3 $8.7 
Other assets1.6 5.0 
Other accrued expenses  
Total interest rate swaps$9.9 $13.7 

As of March 31, 2023 and December 31, 2022, the accumulated gain, net of tax, recognized in accumulated other comprehensive loss was $8.2 million and $9.9 million, respectively.

The Company classifies cash flows from its derivative programs as cash flows from operating activities in the Consolidated Statements of Cash Flows. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements.
On July 5, 2022, the Company and Sutter Health (“Sutter”) entered into an agreement regarding the potential purchase of a business that would expand the Company’s service capabilities (the “Sutter Put Right Agreement”). This agreement is effective through approximately the end of 2023 and allows Sutter to sell the business to the Company for $150.0 million, subject to the negotiation of a definitive agreement and the satisfaction of agreed upon closing conditions, including the requirement that the purchase price be deemed to be fair value at the time of the potential transaction. Assuming an agreement is reached, the Company and Sutter would also need to reach agreement as to whether the purchase price would be paid in cash or shares of the Company’s common stock.

7. Share-Based Compensation

The share-based compensation expense relating to the Company’s stock options, RSUs, and performance-based restricted stock units (“PBRSUs”) for the three months ended March 31, 2023 and 2022 was $12.3 million and $10.1 million, respectively, with related tax benefits of approximately $2.6 million and $1.8 million, respectively.

The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense and included in operating activities. The Company recognized $0.5 million and $2.5 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended March 31, 2023 and 2022, respectively.
15


Total share-based compensation costs that have been included in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) were as follows:
 Three Months Ended March 31,
 20232022
Share-Based Compensation Expense Allocation Details:
Cost of services$6.9 $4.3 
Selling, general and administrative5.4 5.8 
Total share-based compensation expense (1)$12.3 $10.1 
(1) Included in the share-based compensation expense above is $1.8 million of CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense for the three months ended March 31, 2023. See further discussion below.
The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. The volatility for the options was calculated based on an analysis of historical volatility. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations. A Monte Carlo simulation was used to estimate the fair value of the Unvested Units (as defined below), which are being amortized over a period of 4 years on a straight-line basis. The volatility for the Unvested Units was calculated based on an analysis of historical and implied volatility.
Stock options
A summary of the options activity during the three months ended March 31, 2023 is shown below:

OptionsWeighted-
Average
Exercise
Price
Outstanding at December 31, 20223,104,413 $3.38 
Granted  
Exercised(180,453)3.05 
Canceled/forfeited(45,865)2.59 
Expired  
Outstanding at March 31, 20232,878,095 $3.41 
Outstanding, vested and exercisable at March 31, 20232,855,175 $3.26 
Outstanding, vested and exercisable at December 31, 20223,080,069 $3.23 
Restricted stock units and performance-based restricted stock units    
A summary of the RSU and PBRSU activity during the three months ended March 31, 2023 is shown below:
16


Weighted-
Average Grant
Date Fair Value
RSUsPBRSUsRSUPBRSU
Outstanding and unvested at December 31, 20223,232,002 6,876,797 $19.07 $19.48 
Granted192,268  10.95  
Performance factor adjustment 792,189  15.95 
Vested(21,705)(2,286,886)20.21 15.95 
Forfeited(110,733)(455,875)20.56 20.28 
Outstanding and unvested at March 31, 20233,291,832 4,926,225 $18.54 $20.48 
Shares surrendered for taxes for the three months ended March 31, 2023
6,908 903,658 
Cost of shares surrendered for taxes for the three months ended March 31, 2023 (in millions)
$0.1 $13.1 
Shares surrendered for taxes for the three months ended March 31, 2022
2,198 725,570 
Cost of shares surrendered for taxes for the three months ended March 31, 2022 (in millions)
$ $18.7 
Upon consummation of the Cloudmed acquisition, outstanding restricted units of Cloudmed were replaced by an aggregate 1,536,220 RSUs of the Company. The Company also issued an aggregate of 3,173,184 inducement RSUs and PBRSUs to certain employees of Cloudmed under Nasdaq Listing Rule 5635(c)(4) pursuant to its newly adopted 2022 Inducement Plan.

The Company’s RSU and PBRSU agreements allow employees to surrender to the Company shares of common stock upon vesting of their RSUs and PBRSUs in lieu of their payment of the required personal employment-related taxes. Shares surrendered for payment of personal employment-related taxes are held in treasury.

Outstanding PBRSUs vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, modular sales revenue, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 9,852,450.
CoyCo 2, L.P. Limited Partnership Units    

As part of the transactions contemplated by the Cloudmed acquisition, equity awards held by certain employees of Cloudmed (“Former Class P Units”) were modified, through a series of transactions, into awards (“Management Units”) of CoyCo 2. The Management Units issued by CoyCo 2 are treated as share-based compensation under ASC 718, Compensation — Stock Compensation.

The Former Class P Units were originally issued to employees of Cloudmed and its affiliates (“Participants”) in connection with and as a part of the compensation and incentive arrangements between Cloudmed and such Participants prior to the consummation of the Cloudmed acquisition. A portion of the Former Class P Units immediately vested upon the closing of the Cloudmed acquisition; however, certain Former Class P Units that were subject to performance-based vesting conditions did not become vested upon the closing of the Cloudmed acquisition (“Unvested Units”). In connection with the Cloudmed acquisition, Cloudmed caused the Former Class P Units, including the Unvested Units, to be converted into Management Units. At the time of the closing of the Cloudmed acquisition, 97,875 Unvested Units were converted into 514,986 Management Units.

17


In general, Unvested Units vest upon the achievement of certain performance criteria, including achievement by CoyCo 2’s owner, New Mountain Capital, L.L.C. (“New Mountain”), of (i) specified multiples of Base Equity Value (“BEV”) (i.e., generally the aggregate equity value of New Mountain’s investment in Cloudmed as of the original grant date), or (ii) specified Multiples on Invested Capital (“MIC”) with respect to New Mountain Capital’s pre-Cloudmed acquisition investment in Cloudmed, and subject to continued service with the Company and its affiliates, including Cloudmed through the applicable vesting date. The Unvested Units are not awards of the Company and the participants will receive no additional shares of the Company upon satisfaction of the vesting criteria. However, GAAP requires the Company recognize the cost of share-based compensation granted by an investor (CoyCo 2) to the Company’s employees and service providers for services that benefit the Company’s operations (hereafter, “CoyCo 2 share-based compensation expense”), and a corresponding capital contribution because the costs are incurred on the Company’s behalf.
8. Other Expenses

Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. The following table summarizes the other expenses recognized for the three months ended March 31, 2023 and 2022.
Three Months Ended March 31,
 20232022
Business acquisition costs (1)$0.1 $6.3 
Integration costs (2)15.8 0.4 
Strategic initiatives (3)8.0 0.3 
Global business services center expansion project in the Philippines (4) 3.1 
Facility-exit charges (5)1.2 4.8 
Other (6)5.1 2.2 
Total other expenses$30.2 $17.1 
(1) These are costs, including legal, consulting, and bank fees, that are directly related to the closing of business acquisitions and include changes to contingent consideration, if applicable.
(2) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective and to achieve synergies expected from business acquisitions. Costs include consulting fees, IT vendor spend, severance, retention, and certain payroll costs.
(3) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts.
(4) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines was the first new organic global business services center country expansion by the Company in approximately 15 years. The Company completed the expansion project in 2022.
(5) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities.
(6) For the three months ended March 31, 2023 and 2022, other includes $5.5 million and $1.1 million, respectively, of expenses related to the Company’s ongoing litigation matters. For further details, refer to Note 11, Commitments and Contingencies.
18


9. Income Taxes

Income tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred.

The Company recognized income tax expense for the three months ended March 31, 2023 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for foreign taxes, state taxes, non-deductible expenses, and discrete items.

The Company recognized income tax expense for the three months ended March 31, 2022 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible expenses, and discrete items.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2019 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from three to six years.

At December 31, 2022, the Company had gross deferred tax assets of $147.6 million, of which $50.0 million related to net operating loss (“NOL”) carryforwards. The Company expects to be profitable, allowing the Company to utilize its NOL carryforwards and other deferred tax assets.

10. Earnings Per Share
Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period.
Diluted net income per share is calculated by adjusting the denominator used in the basic net income per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options and shares issuable upon vesting of RSUs and PBRSUs.
Basic and diluted net income per common share are calculated as follows:
Three Months Ended March 31,
 20232022
Net income$0.3 $29.4 
Basic weighted-average common shares417,346,840 278,747,261 
Add: Effect of dilutive equity awards4,621,205 6,472,685 
Add: Effect of dilutive warrants30,957,744 35,823,425 
Diluted weighted average common shares452,925,789 321,043,371 
Net income per common share (basic)$ $0.11 
Net income per common share (diluted)$ $0.09 
19


Because of their anti-dilutive effect, 768,030 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three months ended March 31, 2023.
For the three months ended March 31, 2022, 43,206 common share equivalents have been excluded from the diluted earnings per share calculation because of their anti-dilutive effect.

11. Commitments and Contingencies

Legal Proceedings

Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows.

On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC. Both complaints allege that TCP-ASC, Ascension Health (“Ascension”), and TowerBrook Capital Partners (“TowerBrook”) controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contain provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The cases have since been consolidated into a single action. All defendants have answered the complaint and discovery has commenced.

On February 18, 2022, plaintiffs filed a supplement to their complaint, naming certain additional defendants and asserting additional claims related to the Company’s agreement to acquire Cloudmed, which was announced on January 10, 2022. The additional claims assert that: (i) TCP-ASC, Ascension, and TowerBrook, along with the Company’s directors (“Individual Defendants”), breached their fiduciary duties by causing the Company to enter into and approving the Cloudmed acquisition, respectively, which plaintiffs claim will perpetuate TCP-ASC’s, Ascension’s, and TowerBrook’s control over the Company and entrench the Individual Defendants by virtue of certain agreements entered into as part of the transaction, including a Second Amended Investor Rights Agreement with TCP-ASC (the “Seconded Amended Investor Rights Agreement”) and an Investor Rights Agreement with Cloudmed (the “Cloudmed Investor Rights Agreement”); and (ii) Cloudmed’s stockholders aided and abetted such breaches. Plaintiffs also allege that certain provisions in the Cloudmed Investor Rights Agreement and the Second Amended Investor Rights Agreement are void under the Company’s charter, bylaws, and the Delaware General Corporation law. The plaintiffs seek a declaratory judgment and an unspecified amount of damages, as well as attorneys’ fees and costs. Trial is scheduled for November 2023. The Company believes it has meritorious defenses to all claims against it and intends to vigorously defend itself against these claims.

In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers (U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.), and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago and was presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties have completed damage and expert discovery. Additional dispositive motions are expected to extend into 2023, with trial, if necessary, likely to be scheduled in 2024. The Company believes it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims.
20


12. Related Party Transactions
This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the Master Professional Services Agreement, including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company’s agreements with Ascension, see Note 1 and Note 19 of the Company’s 2022 Form 10-K. In conjunction with the Cloudmed acquisition, New Mountain became a new related party. There were no material transactions with New Mountain subsequent to the Cloudmed acquisition.
Net services revenue from services provided to Ascension, as well as corresponding accounts receivable and customer liabilities are presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) and the Consolidated Balance Sheets. Since Ascension is the Company’s largest customer, a significant percentage of the Company’s cost of services is associated with providing services to Ascension. However, due to the nature of the Company’s global business services and information technology operations, it is impractical to assign the dollar amount associated with services provided to Ascension.
13. Segments and Customer Concentrations
The Company has determined that it has a single operating segment in accordance with the way that management operates and views the business. All of the Company’s significant operations are organized around the single business of providing management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one operating and reportable segment.
Customers comprising greater than 10% of net services revenue are as follows:
Three Months Ended March 31,
Customer Name20232022
Ascension and its affiliates40 %56 %
Intermountain Healthcare11 %14 %
The loss of customers within the Ascension health system or Intermountain network could have a material adverse impact on the Company’s operations.
As of March 31, 2023 and December 31, 2022, the Company had a concentration of credit risk with Ascension, representing 10% of accounts receivable.
14. Supplemental Financial Information
The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:
 Three Months Ended March 31,
 20232022
Cost of services$15.5 $11.5 
Selling, general and administrative0.4 0.3 
Total depreciation and amortization$15.9 $11.8 
21


Intangible asset amortization expense was $50.1 million and $7.1 million for the three months ended March 31, 2023 and 2022, respectively. Amortization expense for intangible assets is included in cost of services on the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss).

Supplemental cash flow information related to leases are as follows:

Three Months Ended March 31,
20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$6.2 $3.4 
Right-of-use assets obtained in exchange for operating lease obligations:3.1 6.0 
22



Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q to “R1,” “the Company,” “we,” “our,” and “us” mean R1 RCM Inc. and its subsidiaries.

The following discussion and analysis is an integral part of understanding our financial results and is provided as an addition to, and should be read in connection with, our consolidated financial statements and the accompanying notes.

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Undue reliance should not be placed on these statements. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q are forward-looking statements. The words “anticipate,” “believe,” “designed,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “will” or “would” and similar expressions or variations are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements about the acquisition of Cloudmed, our strategic initiatives, our capital plans, our costs, our ability to successfully implement new technologies, our future financial performance, and our liquidity. Such forward-looking statements are based on management’s current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Subsequent events and developments, including actual results or changes in our assumptions, may cause our views to change. We do not undertake to update our forward-looking statements except to the extent required by applicable law. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. Our actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but not limited to, economic downturns and market conditions beyond our control, including periods of inflation; the quality of global financial markets; our ability to timely and successfully achieve the anticipated benefits and potential synergies of the acquisition of Cloudmed; our ability to retain existing customers or acquire new customers; the development of markets for the our revenue cycle management offering; variability in the lead time of prospective customers; competition within the market; breaches or failures of our information security measures or unauthorized access to a customer’s data; delayed or unsuccessful implementation of our technologies or services, or unexpected implementation costs; disruptions in or damages to our global business services centers and third-party operated data centers; the volatility of our stock price; our substantial indebtedness; the ongoing impact of the 2019 Novel Coronavirus (“COVID-19”) pandemic on our business, operating results, and financial condition; and the factors discussed elsewhere in this Quarterly Report on Form 10-Q, and those set forth in Part I, Item 1A of our 2022 Form 10-K and our other filings with the SEC.

The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. Subsequent events and developments may cause our views to change. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.
Overview
Our Business
We are a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. We help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for our customers.
23



We achieve these results for our customers by managing healthcare providers’ revenue cycle operations, which encompass patient registration, insurance and benefit verification, scheduling, medical treatment documentation and coding, bill preparation, and collections from patients and payers. We do so by deploying a unique operating model that leverages our extensive healthcare domain expertise, innovative technology and intelligent automation, and process excellence. We assist our revenue cycle management (“RCM”) customers in managing their revenue cycle operating costs while simultaneously increasing the portion of the maximum potential services revenue they receive. Together, these benefits can generate significant and sustainable improvements in operating margins and cash flows for our customers.

Our largest service offering consists of end-to-end RCM services, which we deploy through an operating partner relationship or a co-managed relationship. Under an operating partner relationship, we provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. Under a co-managed relationship, we leverage our customers’ existing RCM staff and processes, and supplement them with our infused management, subject matter specialists, proprietary technology solutions, and other resources. Under the operating partner model, our employees are the revenue cycle personnel providing services and we typically control third party vendors either through direct contracts or the assumption of the customer’s vendor contracts. As a result, under the operating partner model, we record higher expenses as well as higher revenues related to the negotiated cost to collect. Under the co-managed model, the revenue cycle personnel and third party vendors remain with the customer and those costs do not impact our financial results. For the three months ended March 31, 2023, substantially all of our net operating and incentive fees from end-to-end RCM services were generated under the operating partner model.

We also offer modular solutions, allowing customers to engage us to address specific revenue cycle improvement opportunities, such as revenue intelligence solutions (which were enhanced through the acquisition of Revint Holdings, LLC (“Cloudmed”)), automation solutions, revenue integrity solutions, practice management (“PM”), accounts receivables and denials recovery, physician advisory services (“PAS”), clinical documentation integrity (“CDI”), coding management, business office services, and patient experience.
While we cannot control the changes in the regulatory environment imposed on our customers, we believe that our role becomes increasingly more important to our customers as macroeconomic, regulatory, and healthcare industry conditions continue to impose financial pressure on healthcare providers to manage their operations effectively and efficiently.
We operate our business as a single segment configured with our significant operations and offerings organized around the business of providing RCM services to healthcare providers.
Trends and Economic Conditions

Revenue cycle is a critical function for healthcare providers as they seek to increase process efficiency and maximize cash collected from health insurance companies and patients. Healthcare providers operate their revenue cycle with a combination of labor, software, and services vendors. Third-party vendors offer various solutions including consulting services, software, and other services, including point solutions that cover one or multiple components of the revenue cycle and full outsourcing services, among others. The Centers for Medicare and Medicaid Services projects hospital care and physician care expenditures in the U.S. to amount to $1.5 trillion and $959 billion in 2023, respectively. We estimate the cost of hospital and physician revenue cycle operations to be approximately 5% of revenue, resulting in a market size of approximately $115 billion. According to Research and Markets data as of April 27, 2022, revenue cycle spend is projected to grow at a compounded annual growth rate of 11.6% through 2030.

24



Health systems are currently facing challenges in their revenue cycle operations based on several factors including: (1) more complex and clinical-outcomes based reimbursement, (2) industry consolidation amongst hospitals and across the continuum of care, (3) increasing patient responsibility for their medical bills, (4) healthcare labor shortage, and (5) capital constraints to invest in the revenue cycle given financial difficulties and requirements to invest in improving clinical care. We believe these trends provide opportunities for external RCM vendors that will result in further growth for the industry and our Company.

Growth in economic activity and demand for goods and services, alongside labor shortages and supply chain complications, contributed to high levels of inflation in 2022. We expect inflation to persist in 2023, which may impact our costs for wages and other materials. Inflation may also impact the economic health of our customers, including their ability to pay amounts owed to us. In response to rising inflation, the Federal Reserve Board has raised interest rates and signaled that it may continue to raise rates. Our credit facility interest, in part, is based on a variable interest rate structure which can result in increased cost in periods of rising interest rates. To date, rising interest rates have not had a material impact on our results of operations.

Our incentive fees were impacted by deterioration in payer-reimbursement turnaround times in the second half of 2022. We anticipate modest improvement in payer turnaround times in 2023, relative to the second half of 2022. In addition, we are observing the following trends, which we expect will persist in 2023: (i) we expect reduced growth in our physician business serving emergency department physicians due to regulatory changes that are impacting some of the large groups in the industry and (ii) with recessionary concerns increasing, we could see potential weakness in consumer collections as healthcare bills are de-prioritized.

Other adverse macroeconomic conditions, including but not limited to changes to fiscal and monetary policy and currency fluctuations, could impact macro-level consumer spending trends, which could affect the volume processed on our platform and result in fluctuations to our revenue streams. Certain of our customers may be negatively impacted by these events. In addition, our business and customers continue to face challenges relating to a tight labor market and increased turnover rates. In particular, the current labor market combined with heightened inflation across the globe may increase cost of labor for both us and our customers in 2023 and over time. We plan to continue to invest in technology to help us offset these costs and expect to continue hiring talented employees and providing competitive compensation. Furthermore, recent bank failures and the flow-on effects of those events, including systematic pressures, may cause instability in the banking industry or result in failures at other banks or financial institutions to which we or our customers may face direct or indirect exposure. The bank failures that occurred during the first quarter of 2023 did not directly impact R1 financially. 95% of our cash as of March 31, 2023 was held at four of the five largest banks in the U.S. (by deposits). We maintain the remainder of our cash, which is fully accessible, at smaller or regional banks. The extent to which these macroeconomic conditions will affect our business is uncertain and will depend on political, social, economic, and regulatory forces that are outside of our control. We continue to assess fluctuating macroeconomic events to manage our response.
CONSOLIDATED RESULTS OF OPERATIONS
The following table provides consolidated operating results and other operating data for the periods indicated:
25



 Three Months Ended March 31,2023 vs. 2022
Change
 20232022Amount%
 (In millions, except percentages)
Consolidated Statement of Operations Data:
Net operating fees$361.0 $322.8 $38.2 12 %
Incentive fees23.6 30.2 (6.6)(22)%
Modular and other161.0 32.7 128.3 392 %
Total net services revenue545.6 385.7 159.9 41 %
Operating expenses:
Cost of services434.7 296.5 138.2 47 %
Selling, general and administrative47.0 28.9 18.1 63 %
Other expenses30.2 17.1 13.1 77 %
Total operating expenses511.9 342.5 169.4 49 %
Income from operations33.7 43.2 (9.5)(22)%
Net interest expense30.7 4.7 26.0 553 %
Net income before income tax provision3.0 38.5 (35.5)(92)%
Income tax provision2.7 9.1 (6.4)(70)%
Net income$0.3 $29.4 $(29.1)(99)%
Adjusted EBITDA (1)$142.2 $89.3 $52.9 59 %

(1) Refer to the Non-GAAP Financial Measures section below for a reconciliation of our financial results reported in accordance with GAAP to non-GAAP financial results.
Use of Non-GAAP Financial Information
In order to provide a more comprehensive understanding of the information used by our management team in financial and operational decision-making, we supplement our consolidated financial statements that have been prepared in accordance with GAAP with the non-GAAP financial measure of adjusted EBITDA. Adjusted EBITDA is utilized by our Board and management team as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations; and (ii) as a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation plans for employees.
Adjusted EBITDA
We define adjusted EBITDA as net income (loss) before net interest income/expense, income tax provision/benefit, depreciation and amortization expense, share-based compensation expense, CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense, and other expense items detailed in Note 8, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q, including business acquisition costs, integration costs, strategic initiatives, and the global business services center expansion project in the Philippines.
Although non-GAAP measures are frequently used by investors, securities analysts, and others in their evaluation of companies, these measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under GAAP. Some of these limitations are:
Adjusted EBITDA does not reflect:
Changes in, or cash requirements for, our working capital needs;
26



Share-based compensation expense (including CoyCo 2 share-based compensation expense);
Income tax expenses or cash requirements to pay taxes;
Interest expenses or cash required to pay interest;
Certain other expenses which may require cash payments;
Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted EBITDA does not reflect cash requirements for such replacements or other purchase commitments, including lease commitments; and
Other companies in our industry may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
Reconciliation of GAAP and Non-GAAP Measures
The following table represents a reconciliation of adjusted EBITDA to net income, the most closely comparable GAAP measure, for each of the periods indicated:
 Three Months Ended March 31,2023 vs. 2022
Change
 20232022Amount%
 (In millions, except percentages)
Net income$0.3 $29.4 $(29.1)(99)%
  Net interest expense30.7 4.7 26.0 553 %
  Income tax provision2.7 9.1 (6.4)(70)%
  Depreciation and amortization expense 66.0 18.9 47.1 249 %
  Share-based compensation expense (1)10.5 10.1 0.4 %
CoyCo 2 share-based compensation expense (2)1.8 — 1.8 100 %
  Other expenses (3)30.2 17.1 13.1 77 %
Adjusted EBITDA (non-GAAP)$142.2 $89.3 $52.9 59 %

(1)Share-based compensation expense represents the expense associated with stock options, restricted stock units, and performance-based restricted stock units, as reflected in our Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 7, Share-Based Compensation, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts of share-based compensation expense.
(2)CoyCo 2 share-based compensation expense represents the expense associated with CoyCo 2 limited partnership units, as reflected in our Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 7, Share-Based Compensation, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts of CoyCo 2 share-based compensation expense.
(3)Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. See Note 8, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts included in other expenses.
27



Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022
Net Services Revenue
Net services revenue increased by $159.9 million, or 41%, from $385.7 million for the three months ended March 31, 2022, to $545.6 million for the three months ended March 31, 2023. The increase was driven by a $125.8 million contribution from Cloudmed and net operating fees from new end-to-end customers, partially offset by lower incentive fees.
Cost of Services
Costs of services primarily consists of wages and benefits of personnel that perform services for our customers and any related supplies, equipment, or facility costs utilized by these employees, which includes our global shared service centers in India and the Philippines. It also includes cost of services provided to our customers by vendors directly contracted by R1 or assigned to R1 at contract inception. Cost of services increased by $138.2 million, or 47%, from $296.5 million for the three months ended March 31, 2022, to $434.7 million for the three months ended March 31, 2023. The increase in cost of services was primarily driven by the Cloudmed acquisition and onboarding of new customers, which are reflected in our current revenue growth.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $18.1 million, or 63%, from $28.9 million for the three months ended March 31, 2022, to $47.0 million for the three months ended March 31, 2023. The increase was driven by the Cloudmed acquisition, specifically compensation costs and software licensing and maintenance costs,
and incremental spend in corporate functions to support business growth.
Other Expenses
Other expenses increased by $13.1 million, or 77%, from $17.1 million for the three months ended March 31, 2022, to $30.2 million for the three months ended March 31, 2023. See Note 8, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the details of the costs included in this total for the comparative periods.
Income Taxes
Income tax expense decreased by $6.4 million from $9.1 million for the three months ended March 31, 2022, to $2.7 million for the three months ended March 31, 2023, primarily due to lower pre-tax income. Our effective tax rate (including discrete items) was approximately 90% and 24% for the three months ended March 31, 2023 and 2022, respectively. Our tax rate is also affected by discrete items that may occur in any given year, but are not necessarily consistent from year to year.
CRITICAL ACCOUNTING ESTIMATES
Management considers an accounting estimate to be critical if the accounting estimate requires management to make particularly difficult, subjective, or complex judgments about matters that are inherently uncertain. A summary of our critical accounting estimates is included in Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Application of Critical Accounting Estimates” of our 2022 Form 10-K. There have been no material changes to the critical accounting estimates disclosed in our 2022 Form 10-K.
NEW ACCOUNTING PRONOUNCEMENTS
For additional information regarding new accounting guidance, see Note 1, Business Description and Basis of Presentation, to our consolidated financial statements included in this Quarterly Report on Form 10-Q, which provides a summary of our recently adopted accounting standards and disclosures.
28



LIQUIDITY AND CAPITAL RESOURCES
Our primary sources of liquidity include our cash flows from operations and borrowings under our second amended and restated senior credit agreement (the “Second A&R Credit Agreement”). As of March 31, 2023 and December 31, 2022, we had total available liquidity of $613.3 million and $609.2 million, respectively, reflecting our cash and cash equivalents as well as remaining availability under our senior secured revolving credit facility (the “Senior Revolver”).
Our liquidity is influenced by many factors, including timing of revenue and corresponding cash collections, the amount and timing of investments in strategic initiatives, transaction costs related to business acquisitions, our investments in property, equipment and software, and the use of cash to pay tax withholding obligations upon surrender of shares upon vesting of equity awards. We continue to invest capital in order to achieve our strategic initiatives and successfully integrate acquired companies. As part of our strategic initiatives, we plan to continue to invest in technology to increase the scalability and resiliency of our systems and drive additional value for our customers. We also expect to continue to invest in our global business services infrastructure and capabilities, including further expansion in the Philippines and India, and selectively pursue acquisitions and/or strategic relationships that will enable us to broaden or further enhance our offerings. New business development remains a priority as we plan to continue to boost our sales and marketing efforts. Additionally, we expect to incur costs associated with implementation and transition costs to onboard new customers.
We expect cash and cash equivalents, cash flows from operations, and our availability under the Senior Revolver to continue to be sufficient to fund our operating activities and cash commitments for investing and financing activities, including debt maturities and material capital expenditures, for at least the next 12 months and beyond. Similar to previous material acquisitions, future potential acquisitions may be funded through the incurrence of additional debt if our current credit facilities do not have the required capacity.
Our material cash requirements include the following contractual and other obligations:
Debt
Our indebtedness significantly increased as a result of the Cloudmed acquisition. As of March 31, 2023, we had outstanding debt of $1.8 billion with contractual payments extending through 2029, with $58.3 million payable within 12 months. Future interest payments associated with our debt total $478.4 million, with $124.1 million payable within the next 12 months, based on the floating rates as of March 31, 2023.
Leases
Our significant leasing activity encompasses leases for real estate, including corporate offices, operational facilities, and global business services centers. As of March 31, 2023, we had fixed future lease payments of $137.3 million, with $25.3 million payable within 12 months.
Software Purchase and Services Obligations
Our primary purchase obligations relate to contracts entered into with vendors that supply various software services and products. As of March 31, 2023, we had purchase obligations related to software and service contracts of $283.8 million, with $62.8 million payable within 12 months.
As of March 31, 2023 and December 31, 2022, we had cash and cash equivalents of $104.2 million and $110.1 million, respectively. Cash flows from operating, investing, and financing activities, as reflected in our Consolidated Statements of Cash Flows, are summarized in the following table:
29



 Three Months Ended March 31,
 20232022
 (In millions)
Net cash provided by operating activities$54.7 $30.9 
Net cash used in investing activities$(25.6)$(10.0)
Net cash used in financing activities$(35.4)$(26.2)
Cash Flows from Operating Activities
Cash provided by operating activities increased by $23.8 million from $30.9 million for the three months ended March 31, 2022, to $54.7 million for the three months ended March 31, 2023. Cash provided by operating activities primarily increased due to improved operating results (exclusive of non-cash depreciation and amortization).
Cash Used in Investing Activities
Cash used in investing activities primarily includes our investments in property, equipment and software and our inorganic growth initiatives. Outflows for significant acquisitions have typically been offset by cash inflows from financing activities related to obtaining new debt.
Cash used in investing activities increased by $15.6 million from $10.0 million for the three months ended March 31, 2022, to $25.6 million for the three months ended March 31, 2023. The increase in cash usage is primarily due to higher property, equipment and software spend related to our strategic initiatives and capitalization of software.
Cash Flows from Financing Activities
Cash flows from financing activities primarily relate to borrowings and repayments of debt. In conjunction with acquisitions, we typically borrow additional debt to fund the consideration, either by increasing our existing facilities or refinancing with new facilities. We utilize our revolver to ensure we have sufficient cash on hand to support the needs of the business at any given point in time. Cash flows from financing activities also include cash received from exercises of stock options and the use of cash to pay tax withholding obligations on shares surrendered upon vesting of equity awards, as well as other financing activities.
Cash used in financing activities increased by $9.2 million from $26.2 million for the three months ended March 31, 2022, to $35.4 million for the three months ended March 31, 2023. This change is primarily due to an $18.0 million increase to debt and revolver repayments in 2023 compared to 2022, partially offset by lower amounts of cash required to pay tax withholding obligations for surrendered shares upon vesting of equity awards in 2023.
30



Debt and Financing Arrangements
On June 21, 2022, we entered into a Second A&R Credit Agreement with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan,” and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan,” and together with the Term A Loans, the “Senior Term Loans”), and a $600.0 million Senior Revolver. The Existing Term A Loan requires quarterly payments. Commencing December 31, 2022, we are also required to repay the Incremental Term A Loan and Term B Loan in quarterly principal installments. The Senior Secured Credit Facilities bear interest at a floating rate, which was 7.31% for the Term A Loans and Senior Revolver and 7.81% for the Term B Loan as of March 31, 2023. See Note 6, Derivative Financial Instruments, to our consolidated financial statements included in this Quarterly Report on Form 10-Q for discussion on our interest rate hedging transactions.

As of March 31, 2023, we had drawn $90.0 million and had $509.1 million of remaining availability on our Senior Revolver.

The proceeds from the new Senior Secured Credit Facilities were or will be used, in addition to cash on hand, (1) to refinance, in full, all existing indebtedness under the Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), now a wholly-owned subsidiary of the Company, and certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, and amend and restate all commitments thereunder (the “Refinancing”), (2) to pay certain fees and expenses incurred in connection with the entry into the Second A&R Credit Agreement and the Refinancing, (3) to fund the acquisition of Cloudmed and a holding company reorganization, and to pay the fees, premiums, expenses and other transaction costs incurred in connection therewith, and (4) to finance our working capital needs for general corporate purposes.

The Second A&R Credit Agreement contains a number of financial and non-financial covenants. We are required to maintain minimum consolidated total net leverage and consolidated interest coverage ratios. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of March 31, 2023.

See Note 5, Debt, to our consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

Item 3.Qualitative and Quantitative Disclosures about Market Risk
Interest Rate Sensitivity. Our results of operations and cash flows are subject to fluctuations due to changes in interest rates due to our debt and banking arrangements, which can result in fluctuations in our interest income and expense. As of March 31, 2023, we have hedged $500.0 million of our $1.8 billion outstanding floating rate debt to a fixed rate of 3.01% plus the applicable spread defined in the Second A&R Credit Agreement. The remaining $1.3 billion outstanding is subject to average variable rates of 7.31% for the Term A Loans and Senior Revolver and 7.81% for the Term B Loan as of March 31, 2023. Assuming the current level of borrowings, a one percentage point increase or decrease in interest rates would increase or decrease our annual interest expense on the $1.3 billion subject to variable rates by approximately $13.0 million.
Our interest income is primarily generated from variable rate interest earned on operating cash accounts.
31



Foreign Currency Exchange Risk. Our results of operations and cash flows are subject to fluctuations due to changes in the Indian rupee and Philippine peso because a portion of our operating expenses are incurred by our subsidiaries in India and the Philippines and are denominated in Indian rupees and Philippine pesos, respectively. We do not generate significant revenues outside of the United States. For the three months ended March 31, 2023 and 2022, 9% and 10% of our expenses were denominated in foreign currencies, respectively. As of March 31, 2023 and 2022, we had net assets of $89.3 million and $72.3 million in foreign entities, respectively. Before the impact of our foreign currency hedging activities discussed below, the reduction in earnings from a 10% change in foreign currency spot rates would be $5.1 million and $3.7 million at March 31, 2023 and 2022, respectively.
We have hedge positions that are designated cash flow hedges of certain intercompany charges which have maturities not exceeding December 31, 2023 and are intended to partially offset the impact of foreign currency movements on future costs relating to our global business service centers. For additional information, see Note 6, Derivative Financial Instruments to our consolidated financial statements included in this Quarterly Report on Form 10-Q. These instruments are subject to fluctuations in foreign currency exchange rates and credit risk. Credit risk is managed through careful selection and ongoing evaluation of the financial institutions utilized as counterparties.
For designated cash flow hedges, gains and losses currently recorded in accumulated other comprehensive loss will be reclassified into earnings at the time when certain anticipated intercompany charges are accrued as cost of services. As of March 31, 2023, it was anticipated that approximately $0.8 million of gains, net of tax, currently recorded in accumulated other comprehensive loss will be reclassified into cost of services within the next 9 months.

We use sensitivity analysis to determine the effects that market foreign currency exchange rate fluctuations may have on the fair value of our hedge portfolio. The sensitivity of the hedge portfolio is computed based on the market value of future cash flows as affected by changes in exchange rates. This sensitivity analysis represents the hypothetical changes in value of the hedge position and does not reflect the offsetting gain or loss on the underlying exposure. A 10% change in the levels of foreign currency exchange rates against the U.S. dollar (or other base currency of the hedge if not a U.S. dollar hedge) with all other variables held constant would have resulted in a change in the fair value of our hedge instruments of approximately $8.3 million as of March 31, 2023.

Item 4.Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management including its principal executive officer and principal financial officer to allow timely decisions regarding required disclosures.

In connection with the preparation of this report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. Our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2023, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the first quarter of 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

32



PART II — OTHER INFORMATION
Item 1.Legal Proceedings

Other than the litigation described in Note 11, Commitments and Contingencies, to our consolidated financial statements included in this Quarterly Report on Form 10-Q, we are presently not a party to any material litigation or regulatory proceeding and are not aware of any pending or threatened litigation or regulatory proceeding against us which, individually or in the aggregate, could have a material adverse effect on our business, operating results, financial condition or cash flows.

Item 1A.Risk Factors

There have been no material changes in our risk factors from those disclosed in our 2022 Form 10-K. The risk factors disclosed in Part I, Item 1A of our 2022 Form 10-K, in addition to the other information set forth in this Quarterly Report on Form 10-Q, could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, and/or operating results.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sale of Equity Securities
None.
Issuer Purchases of Equity Securities
The following table provides information about our repurchases of common stock during the periods indicated:
PeriodTotal Number of Shares  Purchased  Average Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)  Maximum Dollar Value of Shares that May Yet be Purchased Under Publicly Announced Plans or Programs (in millions) (1)
January 1, 2023 through January 31, 2023 —   $— —   $453.2 
February 1, 2023 through February 28, 2023— — — 453.2 
March 1, 2023 through March 31, 2023— — — 453.2 
(1)On October 22, 2021, the Board adopted a new repurchase program and authorized the repurchase of up to $200.0 million of our common stock from time to time in the open market or in privately negotiated transactions (the “2021 Repurchase Program”). On January 9, 2022, the Board increased the authorization under the 2021 Repurchase Program to an aggregate amount of up to $500.0 million. The average price paid per share of common stock repurchased under the 2021 Repurchase Program is the execution price, including commissions paid to brokers. The timing and amount of any shares repurchased under the 2021 Repurchase Program will be determined by our management based on its evaluation of market conditions and other factors. The 2021 Repurchase Program may be suspended or discontinued at any time.

33



Item 5.Other Information

Pursuant to the amended and restated offer letter agreement, dated as of November 7, 2022, between Lee Rivas, our Chief Executive Officer, and the Company, Mr. Rivas was entitled to an initial grant of PBRSUs with a target grant date fair value of $6,120,000 with terms to be determined by the Human Capital Committee of the Board of Directors. On May 2, 2023, the Human Capital Committee approved the grant of such award and determined that the award would consist of a mix of PBRSUs and RSUs. The PBRSUs comprise 75% of the target grant date fair value of the award and will vest and be earned upon our achievement of performance-based vesting conditions (which are materially consistent with previously disclosed conditions) on December 31, 2025. The remaining 25% of the target grant date fair value of the award consists of RSUs, which will vest ratably over a three-year period. The Human Capital Committee also approved Mr. Rivas’ annual equity award, which consists of a mix of PBRSUs and RSUs, with terms materially consistent with previously disclosed terms.
34



Item 6.Exhibits

The following are filed or incorporated by reference as a part of this Quarterly Report on Form 10-Q:

(a)
Exhibit NumberExhibit Description
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Furnished herewith.
35



SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
R1 RCM INC.
By:/s/ Lee Rivas
Lee Rivas
Chief Executive Officer
By:/s/ Jennifer Williams
Jennifer Williams
Chief Financial Officer and Treasurer
Date: May 4, 2023
    

36
EX-10.2 2 exhibit102-formofrsuawarda.htm EX-10.2 Document
Exhibit 10.2
GRANT OF RESTRICTED STOCK UNITS
PURSUANT TO THE
R1 RCM INC.
THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN


* * * * *

Participant: ###PARTICIPANT_NAME###

Grant Date: ###GRANT_DATE###

Number of Restricted Stock Units Granted: ###TOTAL_AWARDS###

* * * * *

THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between R1 RCM Inc., a corporation organized in the State of Delaware (the “Company”), and the Participant specified above, pursuant to the R1 RCM Inc. Third Amended and Restated 2010 Stock Incentive Plan, as in effect and as amended from time to time (the “Plan”), which is administered by the Board; and

WHEREAS, it has been determined under the Plan that it would be in the best interests of the Company to grant the Restricted Stock Units (“RSUs”) provided herein to the Participant.

NOW, THEREFORE, in consideration of the mutual covenants and promises hereinafter set forth and for other good and valuable consideration, receipt of which is acknowledged, the parties hereto hereby mutually covenant and agree as follows:
1.Grant of Restricted Stock Units. In consideration of services rendered and to be rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Agreement and in the Plan, as of the Grant Date specified above, an Award consisting of the number of RSUs specified above. Except as otherwise provided by the Plan, the Participant agrees and understands that nothing contained in this Agreement provides, or is intended to provide, the Participant with any protection against potential future dilution of the Participant’s interest in the Company for any reason, and no adjustments shall be made for dividends in cash or other property, distributions or other rights in respect of the shares of common stock underlying the RSUs, except as otherwise specifically provided for in the Plan or this Agreement.
2.Vesting.
(a)Vesting. Subject to the provisions of Sections 2(b), 2(c) and 2(d) below, the RSUs subject to this Award shall become vested as follows, provided that the Participant has not ceased to perform services to the Company for any reason or no reason, with or without cause, prior to each such vesting date:
###VEST_SCHEDULE_TABLE###

Except as provided in Section 2(d) below, there shall be no proportionate or partial vesting in the periods prior to each vesting date and all vesting shall occur only on the appropriate vesting date, subject to the Participant’s continued performance of services to the Company through each applicable vesting date.




(b)Board Discretion to Accelerate Vesting. In addition to the foregoing, the Board may, in its sole discretion, accelerate vesting of the RSUs at any time and for any reason.
(c)Forfeiture. Except as provided in Section 2(d) below, in the event that the Participant ceases to perform services to the Company for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation. The Participant shall have no further rights with respect to any RSUs that are so forfeited. If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.
(d)Good Leaver Treatment. If the Participant incurs a Good Leaver Termination (as defined below) on or after the first anniversary of the Grant Date but prior to the final vesting date, provided that the Participant has continuously provided services to the Company between the Grant Date and the effective date of the Good Leaver Termination, then the vesting condition shall be deemed satisfied with respect to the next tranche of RSUs vesting on the immediately following vesting date for a pro-rata amount of the RSUs (the “Pro-Rata Shares”), with such amount to be determined by multiplying the RSUs that would vest on the next vesting date absent termination by a fraction, the numerator of which is the number of days from the last vesting date through and including the effective date of termination, and the denominator of which is 365. The Pro Rata Shares shall vest on the effective date of such termination. For purposes of this Section 2(d), the following terms shall have the meanings set forth opposite such terms below:
i.Cause,” with respect to the Participant, shall be defined as that term is defined in the Participant’s offer letter, employment agreement, change in control agreement, or other similar agreement; or if there is no such definition, “Cause” means any of: (A) the Participant’s conviction for, or plea of guilty or nolo contendere to, a felony; (B) the Participant engaging in conduct that constitutes gross neglect or willful misconduct and that, in either case, results in material economic or reputational harm to the Company; (C) the Participant’s willful breach of any provision of this Agreement or any applicable non-disclosure, non-competition, non-solicitation or other similar restrictive covenant obligation owed to the Company; (D) the Participant’s repeated refusal, or failure to undertake good faith efforts, to perform his or her material employment duties and responsibilities for the Company; or (E) the Participant engaging in willful misconduct resulting in or intended to result in direct personal gain to him or her at the Company’s expense.
ii.Disability,” with respect to the Participant, means the Participant has been unable, with or without reasonable accommodation and due to physical or mental incapacity, to substantially and satisfactorily perform his or her duties and responsibilities hereunder for a period of one hundred eighty days out of any consecutive three hundred sixty-five days, as determined by the Committee in its reasonable discretion.

iii. “Good Leaver Termination,” with respect to the Participant, means any termination of the Participant’s services to the Company that is: (A) due to the Participant’s death, (B) due to the Participant’s Disability, or (C) due to a termination of services by the Company without Cause, but only if, in the case of each of the foregoing clauses (A) through (C), circumstances constituting Cause do not exist at the time of termination.
2



3.Delivery of Shares.
(a)General. Subject to the provisions of Section 3(b) hereof, within thirty (30) days following the vesting of the RSUs, the Participant shall receive the number of shares of common stock that correspond to the number of RSUs that have become vested on the applicable vesting date, less any shares withheld by the Company pursuant to Section 8 hereof.
(b)Blackout Periods. If the Participant is subject to any Company “blackout” policy or other trading restriction imposed by the Company on the date such distribution would otherwise be made pursuant to Section 3(a) hereof, such distribution shall be instead made on the earlier of (i) the date that the Participant is not subject to any such policy or restriction and (ii) the later of (A) the end of the calendar year in which such distribution would otherwise have been made and (B) a date that is immediately prior to the expiration of two and one-half months following the date such distribution would otherwise have been made hereunder.
4.Restrictions on Transfer. No portion of the RSUs may be sold, assigned, transferred, encumbered, hypothecated or pledged by the Participant, other than to the Company as a result of forfeiture of the RSUs as provided herein, except that the Participant may transfer such unvested RSUs: (a) to or for the benefit of any spouse, children, parents, uncles, aunts, siblings, grandchildren and any other relatives approved by the Compensation Committee (collectively, “Approved Relatives”) or to a trust established solely for the benefit of the Participant and/or Approved Relatives, provided that such RSUs shall remain subject to this Agreement (including without limitation the vesting and forfeiture provisions set forth in Section 2 and the restrictions on transfer set forth in this Section 4) and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement; or (b) as part of the sale of all or substantially all of the shares of capital stock of the Company (including pursuant to a merger or consolidation). The Company shall not be required (i) to transfer on its books any of the RSUs which have been transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of the RSUs or to pay dividends to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.
5.Restrictive Legends. The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates, if any, representing shares of common stock issued pursuant to this Agreement. The Participant shall, at the request of the Company, promptly present to the Company any and all certificates, if any, representing shares of common stock acquired pursuant to this Agreement in the possession of the Participant in order to carry out the provisions of this Section 5.
6.Rights as Stockholder. Except as otherwise provided herein, the Participant shall have no rights as a stockholder with respect to any shares of common stock covered by any RSU unless and until the Participant has become the holder of record of such shares. Cash dividends on the number of shares of common stock issuable hereunder shall be credited to a dividend book entry account on behalf of the Participant with respect to each RSU granted to the Participant, provided that such cash dividends shall not be deemed to be reinvested in shares of common stock and shall be held uninvested and without interest and paid in cash at the same time that the shares of common stock underlying the RSUs are delivered to the Participant in accordance with the provisions hereof. Stock dividends on shares of common stock shall be credited to a dividend book entry account on behalf of the Participant with respect to each RSU granted to the Participant, provided that such stock dividends shall be paid in shares of common stock at the same time that the shares of common stock underlying the RSUs are delivered to the Participant in accordance with the provisions hereof.
3



7.Provisions of the Plan. This Agreement is subject to the provisions of the Plan (including, without limitation, any amendments thereto adopted at any time and from time to time unless such amendments are expressly intended not to apply to the RSUs awarded hereunder), a copy of which is furnished to the Participant with this Agreement. Except as provided otherwise herein, any capitalized term not defined in this Agreement shall have the same meaning as is ascribed thereto in the Plan. The Participant hereby acknowledges receipt of a true copy of the Plan and that the Participant has read the Plan carefully and fully understands its content. In the event of any conflict between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall control.
8.Withholding. The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs. On each date on which the RSUs vest, the Company shall deliver written notice to the Participant of the amount of withholding taxes due with respect to the vesting of the RSUs that vest on such date. The Participant shall satisfy such tax withholding obligations by transferring to the Company, on each date on which RSUs vest under this Agreement, such number of shares that are issuable on such date as have a fair market value (calculated using the last reported sale price of the common stock of the Company on the New York Stock Exchange or the NASDAQ, as applicable (or, if the Company’s common stock is not then traded on the New York Stock Exchange or the NASDAQ, then on any other United States stock exchange upon which the Company’s common stock is then listed, or otherwise as reported through the facilities of the OTC Markets Group, Inc.) on the trading date immediately prior to such vesting date) equal to the amount of the Company’s tax withholding obligation in connection with the vesting of such RSUs (such withholding method, a “Surrender”), unless, prior to any vesting date, the Compensation Committee determines that a Surrender shall not be available to the Participant, in which case, the Participant shall be required to satisfy the Participant’s tax obligations hereunder in a manner permitted by the Plan upon the vesting date.
9.Restrictive Covenants.
(a)General. This award represents a substantial economic benefit to the Participant. The Participant, by virtue of such Participant's role with the Company, has access to, and is involved in the formulation of, certain confidential and secret information of the Company regarding its operations and each Participant could materially harm the business of the Company by competing with the Company or soliciting employees or customers of the Company
(b)Non-Solicitation. During the time in which Participant performs services for the Company and for a period of eighteen (18) months after the Participant ceases to perform services for the Company, regardless of the reason, Participant shall not, directly or indirectly, either alone or in conjunction with any person, firm, association, company or corporation:
ii.Hire, recruit, solicit or otherwise attempt to employ or retain or enter into any business relationship with, any person who is or was an employee of the Company within the twelve (12) month period immediately preceding the cessation of Participant’s service with the Company; or
(i) Solicit the sale of any products or services that are similar to or competitive with products or services offered by, manufactured by, designed by, or distributed by Company, to any person, company or entity which was or is a customer or potential customer of Company for such products or services.
(c)Non-Disclosure.
4



(i) Participant will not, without the Company’s prior written permission, directly or indirectly, utilize for any purpose other than for a legitimate business purpose solely on behalf of the Company, or directly or indirectly, disclose to anyone outside of the Company, either during or after Participant’s relationship with the Company ends, the Company’s Confidential Information, as long as such matters remain Confidential Information.
(ii) This Agreement shall not prohibit Participant from (A) revealing evidence of criminal wrongdoing to law enforcement, (B) disclosing or discussing concerns regarding regulatory or legal compliance with any governmental agency or entity to the extent that such disclosures or discussions are protected under any whistleblower protection provisions of Federal or state laws or regulations or (C) divulging the Company’s Confidential Information by order of court or agency of competent jurisdiction. However, Participant shall promptly inform the Company of any such situations and shall take such reasonable steps to prevent disclosure of the Company’s Confidential Information until the Company has been informed of such requested disclosure and the Company has had an opportunity to respond to the court or agency.
(d)Return of Company Property. Participant agrees that, in the event that Participant’s service to the Company is terminated for any reason, Participant shall immediately return all of the Company’s property, including without limitation, (i) tools, pagers, computers, printers, key cards, documents or other tangible property of the Company, and (ii) the Company’s Confidential Information in any media, including paper or electronic form, and Participant shall not retain in Participant’s possession any copies of such information.
(e)Ownership of Software and Inventions. All discoveries, designs, improvements, ideas, inventions, software, whether patentable or copyrightable or not, shall be works-made-for-hire and Company shall be deemed the sole owner throughout the universe of any and all rights of whatsoever nature therein, with the rights to use the same in perpetuity in any manner the Company determines in its sole discretion without any further payment to Participant whatsoever. If, for any reason, any of such results and proceeds which relate to the business shall not legally be a work-for-hire and/or there are any rights which do not accrue to the Company under the preceding sentence, then Participant hereby irrevocably assigns and agrees to quitclaim any and all of Participant’s right, title and interest thereto including, without limitation, any and all copyrights, patents, trade secrets, trademarks and/or other rights of whatsoever nature therein, whether or not now or hereafter known, existing, contemplated, recognized or developed to the Company, and the Company shall have the right to use the same in perpetuity throughout the universe in any manner the Company determines without any further payment to Participant whatsoever. Participant shall, from time to time, as may be reasonably requested by the Company, at the Company’s expense, do any and all things which the Company may deem useful or desirable to establish or document the Company’s exclusive ownership of any and all rights in any such results and proceeds, including, without limitation, the execution of appropriate copyright and/or patent applications or assignments. To the extent Participant has any rights in the results and proceeds of Participant’s services that cannot be assigned in the manner described above, Participant unconditionally and irrevocably waives the enforcement of such rights. Notwithstanding anything to the contrary set forth herein, works developed by the Participant (i) which are developed independently from the work developed for the Company regardless of whether such work was developed before or after the Participant performed services for the Company; or (ii) applications independently developed which are unrelated to the business and which Participant develops during non-business hours using non-business property shall not be deemed work for hire and shall not be the exclusive property of the Company.
5



(f)Non-Competition.
(i) During the time in which Participant performs services for the Company and for a period of twelve (12) months after the cessation of Participant’s service to the Company, regardless of the reason, Participant shall not, directly or indirectly, either alone or in conjunction with any person, firm, association, company or corporation, within the Restricted Area, own, manage, operate, or participate in the ownership, management, operation, or control of, or be employed by or provide services to, any entity which is in competition with the Company.
(ii) Notwithstanding anything to the contrary, nothing in this Paragraph (f) prohibits Participant from being a passive owner of not more than one percent (1%) of the outstanding stock of any class of a corporation which is publicly traded, so long as Participant has no active participation in the business of such corporation.
(g)Acknowledgments. Participant acknowledges and agrees that the restrictions contained in this Agreement with respect to time, geographical area and scope of activity are reasonable and do not impose a greater restraint than is necessary to protect the goodwill and other legitimate business interests of the Company and that the Participant has had the opportunity to review the provisions of this Agreement with his legal counsel. In particular, the Participant agrees and acknowledges (i) that the Company is currently engaging in business and actively marketing its services and products throughout the United States, (ii) that Participant’s duties and responsibilities for the Company are co-extensive with the entire scope of the Company's business, (iii) that the Company has spent significant time and effort developing and protecting the confidentiality of its methods of doing business, technology, customer lists, long term customer relationships and trade secrets, and (iv) that such methods, technology, customer lists, customer relationships and trade secrets have significant value.
(h)Enforcement. The Participant agrees that the restrictions contained in this Agreement are necessary for the protection of the business, the Confidential Information, customer relationships and goodwill of the Company and are considered by the Participant to be reasonable for that purpose and that the scope of restricted activities, the geographic scope and the duration of the restrictions set forth in this Agreement are considered by the Participant to be reasonable. The Participant further agrees that any breach of any of the restrictive covenants in this Agreement would cause the Company substantial, continuing and irrevocable harm for which money damages would be inadequate and therefore, in the event of any such breach or any threatened breach, in addition to such other remedies as may be available, the Company shall be entitled to specific performance and injunctive relief. This Agreement shall not in any way limit the remedies in law or equity otherwise available to the Company or its Affiliates. The Participant further agrees that to the extent any provision or portion of the restrictive covenants of this Agreement shall be held, found or deemed to be unreasonable, unlawful or unenforceable by a court of competent jurisdiction, then any such provision or portion thereof shall be deemed to be modified to the extent necessary in order that any such provision or portion thereof shall be legally enforceable to the fullest extent permitted by applicable law. Without limitation to any other remedies available hereunder or at law in the event of any breach of any of the restrictive covenants in this Agreement by Participant, the Participant agrees that (i) any shares of Restricted Stock issued by the Company to the Participant pursuant to this Agreement shall be forfeited for no consideration and (ii) in the event that the Participant sold the shares of Restricted Stock issued to the Participant pursuant to this Agreement, then the Participant shall be required to pay to the Company in cash, within thirty (30) days of a request by the Company for such payment, the price at which the Participant sold the shares.
(i)Severability; Modification. It is expressly agreed by Participant that:
6



(i) Modification. If, at the time of enforcement of this Agreement, a court holds that the duration, geographical area or scope of activity restrictions stated herein are unreasonable under circumstances then existing or impose a greater restraint than is necessary to protect the goodwill and other business interests of the Company, Participant agrees that the maximum duration, scope or area reasonable under such circumstances will be substituted for the stated duration, scope or area and that the court will be allowed to revise the restrictions contained herein to cover the maximum duration, scope and area permitted by law, in all cases giving effect to the intent of the parties that the restrictions contained herein be given effect to the broadest extent possible; and
(ii) Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under applicable law, such invalidity, illegality or unenforceability will not affect any other provision, but this Agreement will be reformed, construed and enforced as if such invalid, illegal or unenforceable provision had never been contained herein.
(j)Non-Disparagement. Participant understands and agrees that Participant will not disparage the Company, its officers, directors, administrators, representatives, employees, contractors, consultants or customers and will not engage in any communications or other conduct which might interfere with the relationship between the Company and its current, former, or prospective employees, contractors, consultants, customers, suppliers, regulatory entities, and/or any other persons or entities.
(k)Definitions.
(i) Confidential Information. “Confidential Information” as used in this Agreement shall include the Company’s trade secrets as defined under Illinois law, as well as any other information or material which is not generally known to the public, and which (A) is generated, collected by or utilized in the operations of the Company’s business and relates to the actual or anticipated business, research or development of the Company; or (B) is suggested by or results from any task assigned to Participant by the Company or work performed by Participant for or on behalf of the Company. Confidential Information shall not be considered generally known to the public if Participant or others improperly reveal such information to the public without the Company’s express written consent and/or in violation of an obligation of confidentiality to the Company. Examples of Confidential Information include, but are not limited to, all customer, client, supplier and vendor lists, budget information, contents of any database, contracts, product designs, technical know-how, engineering data, pricing and cost information, research and development work, software, business plans, proprietary data, projections, market research, perceptual studies, strategic plans, marketing information, financial information (including financial statements), sales information, training manuals, employee lists and compensation of employees, and all other competitively sensitive information with respect to the Company, whether or not it is in tangible form, and including without limitation any of the foregoing contained or described on paper or in computer software or other storage devices, as the same may exist from time to time.
(ii) Restricted Area. For purposes of this Agreement, the term “Restricted Area” shall mean the United States of America.
10.Miscellaneous.
(a)Compliance with Laws. The grant of RSUs and the issuance of shares of common stock hereunder shall be subject to, and shall comply with, any applicable requirements
7



of any foreign and U.S. federal and state securities laws, rules and regulations (including, without limitation, the provisions of the Securities Act, the Exchange Act and in each case any respective rules and regulations promulgated thereunder) and any other law, rule regulation or exchange requirement applicable thereto. The Company shall not be obligated to issue the RSUs or any shares of common stock pursuant to this Agreement if any such issuance would violate any such requirements. As a condition to the settlement of the RSUs, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate to evidence compliance with any applicable law or regulation.
(b)Authority of Compensation Committee. In making any decisions or taking any actions with respect to the matters covered by this Agreement, the Compensation Committee shall have all of the authority and discretion, and shall be subject to all of the protections, provided for in the Plan. All decisions and actions by the Compensation Committee with respect to this Agreement shall be made in the Compensation Committee’s discretion and shall be final and binding on the Participant.
(c)No Right to Continued Service. The Participant acknowledges and agrees that this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company.
(d)Acquired Rights. The Participant acknowledges and agrees that: (a) the Company may terminate or amend the Plan at any time; (b) the award of RSUs made under this Agreement is completely independent of any other award or grant and is made at the sole discretion of the Company; (c) no past grants or awards (including, without limitation, the RSUs awarded hereunder) give the Participant any right to any grants or awards in the future whatsoever; and (d) any benefits granted under this Agreement are not part of the Participant’s ordinary salary, and shall not be considered as part of such salary in the event of severance, redundancy or resignation.
(e)Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.
(f)Exclusive Jurisdiction/Venue. All disputes that arise from or relate to this Agreement shall be decided exclusively by binding arbitration in Cook County, Illinois under the Commercial Arbitration Rules of the American Arbitration Association. The parties agree that the arbitrator’s award shall be final, and may be filed with and enforced as a final judgment by any court of competent jurisdiction. Notwithstanding the foregoing, any disputes related to the enforcement of the restrictive covenants contained in Section 9 of this Agreement shall be subject to and determined under Delaware law and adjudicated in Illinois courts.
(g)Notices. Any notice hereunder by the Participant shall be given to the Company in writing and such notice shall be deemed duly given only upon receipt thereof by the General Counsel of the Company. Any notice hereunder by the Company shall be given to the Participant in writing and such notice shall be deemed duly given only upon receipt thereof at such address as the Participant may have on file with the Company.
(h)Headings. The titles and headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be a part of this Agreement.
8



(i)Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same instrument.
(j)Severability. The invalidity or unenforceability of any provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.
(k)Binding Agreement; Assignment. This Agreement shall inure to the benefit of, be binding upon, and be enforceable by the Company and its successors and assigns. The Participant shall not assign any part of this Agreement without the prior express written consent of the Company.
(l)Entire Agreement; Amendment. This Agreement, together with the Plan, contains the entire agreement between the parties hereto with respect to the subject matter contained herein, and supersedes all prior agreements or prior understandings, whether written or oral, between the parties relating to such subject matter. The Committee shall have the right, in its sole discretion, to modify or amend this Agreement from time to time in accordance with and as provided in the Plan. This Agreement may also be modified or amended by a writing signed by both the Company and the Participant. The Company shall give written notice to the Participant of any such modification or amendment of this Agreement as soon as practicable after the adoption thereof.
(m)Further Assurances. Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall execute and deliver all such other agreements, certificates, instruments and documents as either party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the Plan and the consummation of the transactions contemplated thereunder.
[Remainder of Page Intentionally Left Blank]
9



IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

R1 RCM INC.

By:

Name:

Title:



I hereby acknowledge that I have read this Agreement, have received and read the Plan, and understand and agree to comply with the terms and conditions of this Agreement and the Plan.
 
 
PARTICIPANT ACCEPTANCE

__________________________________
                        

###PARTICIPANT_NAME###


10

EX-10.3 3 exhibit103-formofrsuawardf.htm EX-10.3 Document
Exhibit 10.3
GRANT OF RESTRICTED STOCK UNITS
PURSUANT TO THE
R1 RCM INC.
THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN
* * * * *
Participant: ###PARTICIPANT_NAME###
Grant Date: ###GRANT_DATE###
Number of Restricted Stock Units Granted: ###TOTAL_AWARDS###
* * * * *
THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between R1 RCM Inc., a corporation organized in the State of Delaware (the “Company”), and the Participant specified above, pursuant to the R1 RCM Inc. Third Amended and Restated 2010 Stock Incentive Plan, as in effect and as amended from time to time (the “Plan”), which is administered by the Board; and
WHEREAS, it has been determined under the Plan that it would be in the best interests of the Company to grant the Restricted Stock Units (“RSUs”) provided herein to the Participant.
NOW, THEREFORE, in consideration of the mutual covenants and promises hereinafter set forth and for other good and valuable consideration, receipt of which is acknowledged, the parties hereto hereby mutually covenant and agree as follows:
1.Grant of Restricted Stock Units. In consideration of services rendered and to be rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Agreement and in the Plan, as of the Grant Date specified above, an Award consisting of the number of RSUs specified above. Except as otherwise provided by the Plan, the Participant agrees and understands that nothing contained in this Agreement provides, or is intended to provide, the Participant with any protection against potential future dilution of the Participant’s interest in the Company for any reason, and no adjustments shall be made for dividends in cash or other property, distributions or other rights in respect of the shares of common stock underlying the RSUs, except as otherwise specifically provided for in the Plan or this Agreement.
2.Vesting.
(a)Vesting. Subject to the provisions of Sections 2(b), 2(c) and 2(d) below, the RSUs subject to this Award shall become vested as follows, provided that the Participant has not ceased to perform services to the Company for any reason or no reason, with or without cause, prior to each such Vesting Date:
###VEST_SCHEDULE_TABLE###

Except as provided in Section 2(d) below, there shall be no proportionate or partial vesting in the periods prior to each Vesting Date and all vesting shall occur only on the appropriate Vesting Date, subject to the Participant’s continued performance of services to the Company through each applicable Vesting Date.



(b)Board Discretion to Accelerate Vesting. In addition to the foregoing, the Board may, in its sole discretion, accelerate vesting of the RSUs at any time and for any reason.
(c)Forfeiture. Except as provided in Section 2(d) below, in the event that the Participant ceases to perform services to the Company for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation. The Participant shall have no further rights with respect to any RSUs that are so forfeited. If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.
(d)Good Leaver Treatment. If the Participant incurs a Good Leaver Termination (as defined below) prior to the final Vesting Date, provided that the Participant has continuously provided services to the Company between the Grant Date and the effective date of the Good Leaver Termination, then the vesting condition shall be deemed satisfied with respect to 100% of the RSUs. For purposes of this Section 2(d), the following terms shall have the meanings set forth opposite such terms below:
i.Cause,” with respect to the Participant, shall be defined as that term is defined in the Participant’s offer letter, employment agreement, change in control agreement, or other similar agreement; or if there is no such definition, “Cause” means any of: (A) the Participant’s conviction for, or plea of guilty or nolo contendere to, a felony; (B) the Participant engaging in conduct that constitutes gross neglect or willful misconduct and that, in either case, results in material economic or reputational harm to the Company; (C) the Participant’s willful breach of any provision of this Agreement or any applicable non-disclosure, non-competition, non- solicitation or other similar restrictive covenant obligation owed to the Company; (D) the Participant’s repeated refusal, or failure to undertake good faith efforts, to perform his or her material employment duties and responsibilities for the Company; or (E) the Participant engaging in willful misconduct resulting in or intended to result in direct personal gain to him or her at the Company’s expense.
ii.Disability,” with respect to the Participant, means the Participant has been unable, with or without reasonable accommodation and due to physical or mental incapacity, to substantially and satisfactorily perform his or her duties and responsibilities hereunder for a period of one hundred eighty days out of any consecutive three hundred sixty-five days, as determined by the Human Capital Committee in its reasonable discretion.
2


iii.Good Leaver Termination,” with respect to the Participant, means any termination of the Participant’s services to the Company that is: (A) due to the Participant’s death, (B) due to the Participant’s Disability, or (C) due to a termination of services by the Company (x) because the Company determines in its sole discretion to eliminate or otherwise restructure the Participant’s position, unless the Participant is offered another position within the Company, or (y) due to the sale of a facility, division, or subsidiary, unless the Participant is offered another position by the purchaser, but only if, in the case of each of the foregoing clauses (A) through (C), circumstances constituting Cause do not exist at the time of termination.
3.Delivery of Shares.
(a)General. Subject to the provisions of Section 3(b) hereof, within thirty (30) days following each Vesting Date, the Participant shall receive the number of shares of common stock that correspond to the number of RSUs that have become vested on the applicable Vesting Date, less any shares withheld by the Company pursuant to Section 8 hereof.
(b)Blackout Periods. If the Participant is subject to any Company “blackout” policy or other trading restriction imposed by the Company on the date such distribution would otherwise be made pursuant to Section 3(a) hereof, such distribution shall be instead made on the earlier of (i) the date that the Participant is not subject to any such policy or restriction and (ii) the later of (A) the end of the calendar year in which such distribution would otherwise have been made and (B) a date that is immediately prior to the expiration of two and one-half months following the date such distribution would otherwise have been made hereunder.
4.Restrictions on Transfer. No portion of the RSUs may be sold, assigned, transferred, encumbered, hypothecated or pledged by the Participant, other than to the Company as a result of forfeiture of the RSUs as provided herein, except that the Participant may transfer such unvested RSUs: (a) to or for the benefit of any spouse, children, parents, uncles, aunts, siblings, grandchildren and any other relatives approved by the Human Capital Committee (collectively, “Approved Relatives”) or to a trust established solely for the benefit of the Participant and/or Approved Relatives, provided that such RSUs shall remain subject to this Agreement (including without limitation the vesting and forfeiture provisions set forth in Section 2 and the restrictions on transfer set forth in this Section 4) and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement; or (b) as part of the sale of all or substantially all of the shares of capital stock of the Company (including pursuant to a merger or consolidation). The Company shall not be required (i) to transfer on its books any of the RSUs which have been transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of the RSUs or to pay dividends to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.
5.Restrictive Legends. The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates, if any, representing shares of common stock issued pursuant to this Agreement. The Participant shall, at the request of the Company, promptly present to the Company any and all certificates, if any, representing shares of common stock acquired pursuant to this Agreement in the possession of the Participant in order to carry out the provisions of this Section 5.
3


6.Rights as Stockholder. Except as otherwise provided herein, the Participant shall have no rights as a stockholder with respect to any shares of common stock covered by any RSU unless and until the Participant has become the holder of record of such shares. Cash dividends on the number of shares of common stock issuable hereunder shall be credited to a dividend book entry account on behalf of the Participant with respect to each RSU granted to the Participant, provided that such cash dividends shall not be deemed to be reinvested in shares of common stock and shall be held uninvested and without interest and paid in cash at the same time that the shares of common stock underlying the RSUs are delivered to the Participant in accordance with the provisions hereof. Stock dividends on shares of common stock shall be credited to a dividend book entry account on behalf of the Participant with respect to each RSU granted to the Participant, provided that such stock dividends shall be paid in shares of common stock at the same time that the shares of common stock underlying the RSUs are delivered to the Participant in accordance with the provisions hereof.
7.Provisions of the Plan. This Agreement is subject to the provisions of the Plan (including, without limitation, any amendments thereto adopted at any time and from time to time unless such amendments are expressly intended not to apply to the RSUs awarded hereunder), a copy of which is furnished to the Participant with this Agreement. Except as provided otherwise herein, any capitalized term not defined in this Agreement shall have the same meaning as is ascribed thereto in the Plan. The Participant hereby acknowledges receipt of a true copy of the Plan and that the Participant has read the Plan carefully and fully understands its content. In the event of any conflict between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall control.
8.Withholding. The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs. On each date on which the RSUs vest, the Company shall deliver written notice to the Participant of the amount of withholding taxes due with respect to the vesting of the RSUs that vest on such date. The Participant shall satisfy such tax withholding obligations by transferring to the Company, on each date on which RSUs vest under this Agreement, such number of shares that are issuable on such date as have a fair market value (calculated using the last reported sale price of the common stock of the Company on the New York Stock Exchange or the NASDAQ, as applicable (or, if the Company’s common stock is not then traded on the New York Stock Exchange or the NASDAQ, then on any other United States stock exchange upon which the Company’s common stock is then listed, or otherwise as reported through the facilities of the OTC Markets Group, Inc.) on the trading date immediately prior to such Vesting Date) equal to the amount of the Company’s tax withholding obligation in connection with the vesting of such RSUs (such withholding method, a “Surrender”), unless, prior to any Vesting Date, the Human Capital Committee determines that a Surrender shall not be available to the Participant, in which case, the Participant shall be required to satisfy the Participant’s tax obligations hereunder in a manner permitted by the Plan upon the Vesting Date.
9.Restrictive Covenants.
(a)General. This award represents a substantial economic benefit to the Participant. The Participant, by virtue of such Participant’s role with the Company, has access to, and is involved in the formulation of, certain confidential and secret information of the Company regarding its operations and each Participant could materially harm the business of the Company by competing with the Company or soliciting employees or customers of the Company
4


(b)Non-Solicitation. During the time in which Participant performs services for the Company and for a period of eighteen (18) months after the Participant ceases to perform services for the Company, regardless of the reason, Participant shall not, directly or indirectly, either alone or in conjunction with any person, firm, association, company or corporation:
(i)Hire, recruit, solicit or otherwise attempt to employ or retain or enter into any business relationship with, any person who is or was an employee of the Company within the twelve (12) month period immediately preceding the cessation of Participant’s service with the Company; or
(ii)Solicit the sale of any products or services that are similar to or competitive with products or services offered by, manufactured by, designed by, or distributed by Company, to any person, company or entity which was or is a customer or potential customer of Company for such products or services.
(c)Non-Disclosure.
(i)Participant will not, without the Company’s prior written permission, directly or indirectly, utilize for any purpose other than for a legitimate business purpose solely on behalf of the Company, or directly or indirectly, disclose to anyone outside of the Company, either during or after Participant’s relationship with the Company ends, the Company’s Confidential Information, as long as such matters remain Confidential Information.
(ii)This Agreement shall not prohibit Participant from (A) revealing evidence of criminal wrongdoing to law enforcement, (B) disclosing or discussing concerns regarding regulatory or legal compliance with any governmental agency or entity to the extent that such disclosures or discussions are protected under any whistleblower protection provisions of Federal or state laws or regulations or (C) divulging the Company’s Confidential Information by order of court or agency of competent jurisdiction. However, Participant shall promptly inform the Company of any such situations and shall take such reasonable steps to prevent disclosure of the Company’s Confidential Information until the Company has been informed of such requested disclosure and the Company has had an opportunity to respond to the court or agency.
(d)Return of Company Property. Participant agrees that, in the event that Participant’s service to the Company is terminated for any reason, Participant shall immediately return all of the Company’s property, including without limitation, (i) tools, pagers, computers, printers, key cards, documents or other tangible property of the Company, and (ii) the Company’s Confidential Information in any media, including paper or electronic form, and Participant shall not retain in Participant’s possession any copies of such information.
5


(e)Ownership of Software and Inventions. All discoveries, designs, improvements, ideas, inventions, software, whether patentable or copyrightable or not, shall be works-made-for-hire and Company shall be deemed the sole owner throughout the universe of any and all rights of whatsoever nature therein, with the rights to use the same in perpetuity in any manner the Company determines in its sole discretion without any further payment to Participant whatsoever. If, for any reason, any of such results and proceeds which relate to the business shall not legally be a work-for-hire and/or there are any rights which do not accrue to the Company under the preceding sentence, then Participant hereby irrevocably assigns and agrees to quitclaim any and all of Participant’s right, title and interest thereto including, without limitation, any and all copyrights, patents, trade secrets, trademarks and/or other rights of whatsoever nature therein, whether or not now or hereafter known, existing, contemplated, recognized or developed to the Company, and the Company shall have the right to use the same in perpetuity throughout the universe in any manner the Company determines without any further payment to Participant whatsoever. Participant shall, from time to time, as may be reasonably requested by the Company, at the Company’s expense, do any and all things which the Company may deem useful or desirable to establish or document the Company’s exclusive ownership of any and all rights in any such results and proceeds, including, without limitation, the execution of appropriate copyright and/or patent applications or assignments. To the extent Participant has any rights in the results and proceeds of Participant’s services that cannot be assigned in the manner described above, Participant unconditionally and irrevocably waives the enforcement of such rights. Notwithstanding anything to the contrary set forth herein, works developed by the Participant (i) which are developed independently from the work developed for the Company regardless of whether such work was developed before or after the Participant performed services for the Company; or (ii) applications independently developed which are unrelated to the business and which Participant develops during non-business hours using non- business property shall not be deemed work for hire and shall not be the exclusive property of the Company.
(f)Non-Competition.
(i)During the time in which Participant performs services for the Company and for a period of twelve (12) months after the cessation of Participant’s service to the Company, regardless of the reason, Participant shall not, directly or indirectly, either alone or in conjunction with any person, firm, association, company or corporation, within the Restricted Area, own, manage, operate, or participate in the ownership, management, operation, or control of, or be employed by or provide services to, any entity which is in competition with the Company.
(ii)Notwithstanding anything to the contrary, nothing in this Paragraph (f) prohibits Participant from being a passive owner of not more than one percent (1%) of the outstanding stock of any class of a corporation which is publicly traded, so long as Participant has no active participation in the business of such corporation.
6


(g)Acknowledgments. Participant acknowledges and agrees that the restrictions contained in this Agreement with respect to time, geographical area and scope of activity are reasonable and do not impose a greater restraint than is necessary to protect the goodwill and other legitimate business interests of the Company and that the Participant has had the opportunity to review the provisions of this Agreement with his legal counsel. In particular, the Participant agrees and acknowledges (i) that the Company is currently engaging in business and actively marketing its services and products throughout the United States, (ii) that Participant’s duties and responsibilities for the Company are co-extensive with the entire scope of the Company’s business, (iii) that the Company has spent significant time and effort developing and protecting the confidentiality of its methods of doing business, technology, customer lists, long term customer relationships and trade secrets, and (iv) that such methods, technology, customer lists, customer relationships and trade secrets have significant value.
(h)Enforcement. The Participant agrees that the restrictions contained in this Agreement are necessary for the protection of the business, the Confidential Information, customer relationships and goodwill of the Company and are considered by the Participant to be reasonable for that purpose and that the scope of restricted activities, the geographic scope and the duration of the restrictions set forth in this Agreement are considered by the Participant to be reasonable. The Participant further agrees that any breach of any of the restrictive covenants in this Agreement would cause the Company substantial, continuing and irrevocable harm for which money damages would be inadequate and therefore, in the event of any such breach or any threatened breach, in addition to such other remedies as may be available, the Company shall be entitled to specific performance and injunctive relief. This Agreement shall not in any way limit the remedies in law or equity otherwise available to the Company or its Affiliates. The Participant further agrees that to the extent any provision or portion of the restrictive covenants of this Agreement shall be held, found or deemed to be unreasonable, unlawful or unenforceable by a court of competent jurisdiction, then any such provision or portion thereof shall be deemed to be modified to the extent necessary in order that any such provision or portion thereof shall be legally enforceable to the fullest extent permitted by applicable law. Without limitation to any other remedies available hereunder or at law in the event of any breach of any of the restrictive covenants in this Agreement by Participant, the Participant agrees that (i) any shares of Restricted Stock issued by the Company to the Participant pursuant to this Agreement shall be forfeited for no consideration and (ii) in the event that the Participant sold the shares of Restricted Stock issued to the Participant pursuant to this Agreement, then the Participant shall be required to pay to the Company in cash, within thirty (30) days of a request by the Company for such payment, the price at which the Participant sold the shares.
(i)Severability; Modification. It is expressly agreed by Participant that:
(i)Modification. If, at the time of enforcement of this Agreement, a court holds that the duration, geographical area or scope of activity restrictions stated herein are unreasonable under circumstances then existing or impose a greater restraint than is necessary to protect the goodwill and other business interests of the Company, Participant agrees that the maximum duration, scope or area reasonable under such circumstances will be substituted for the stated duration, scope or area and that the court will be allowed to revise the restrictions contained herein to cover the maximum duration, scope and area permitted by law, in all cases giving effect to the intent of the parties that the restrictions contained herein be given effect to the broadest extent possible; and
7


(ii)Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under applicable law, such invalidity, illegality or unenforceability will not affect any other provision, but this Agreement will be reformed, construed and enforced as if such invalid, illegal or unenforceable provision had never been contained herein.
(j)Non-Disparagement. Participant understands and agrees that Participant will not disparage the Company, its officers, directors, administrators, representatives, employees, contractors, consultants or customers and will not engage in any communications or other conduct which might interfere with the relationship between the Company and its current, former, or prospective employees, contractors, consultants, customers, suppliers, regulatory entities, and/or any other persons or entities.
(k)Definitions.
(i)Confidential Information. “Confidential Information” as used in this Agreement shall include the Company’s trade secrets as defined under Illinois law, as well as any other information or material which is not generally known to the public, and which (A) is generated, collected by or utilized in the operations of the Company’s business and relates to the actual or anticipated business, research or development of the Company; or (B) is suggested by or results from any task assigned to Participant by the Company or work performed by Participant for or on behalf of the Company. Confidential Information shall not be considered generally known to the public if Participant or others improperly reveal such information to the public without the Company’s express written consent and/or in violation of an obligation of confidentiality to the Company. Examples of Confidential Information include, but are not limited to, all customer, client, supplier and vendor lists, budget information, contents of any database, contracts, product designs, technical know-how, engineering data, pricing and cost information, research and development work, software, business plans, proprietary data, projections, market research, perceptual studies, strategic plans, marketing information, financial information (including financial statements), sales information, training manuals, employee lists and compensation of employees, and all other competitively sensitive information with respect to the Company, whether or not it is in tangible form, and including without limitation any of the foregoing contained or described on paper or in computer software or other storage devices, as the same may exist from time to time.
(ii)Restricted Area. For purposes of this Agreement, the term “Restricted Area” shall mean the United States of America.
10.Miscellaneous.
(a)Compliance with Laws. The grant of RSUs and the issuance of shares of common stock hereunder shall be subject to, and shall comply with, any applicable requirements of any foreign and U.S. federal and state securities laws, rules and regulations (including, without limitation, the provisions of the Securities Act, the Exchange Act and in each case any respective rules and regulations promulgated thereunder) and any other law, rule regulation or exchange requirement applicable thereto. The Company shall not be obligated to issue the RSUs or any shares of common stock pursuant to this Agreement if any such issuance would violate any such requirements. As a condition to the settlement of the RSUs, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate to evidence compliance with any applicable law or regulation.
8


(b)Authority of Human Capital Committee. In making any decisions or taking any actions with respect to the matters covered by this Agreement, the Human Capital Committee shall have all of the authority and discretion, and shall be subject to all of the protections, provided for in the Plan. All decisions and actions by the Human Capital Committee with respect to this Agreement shall be made in the Human Capital Committee’s discretion and shall be final and binding on the Participant.
(c)No Right to Continued Service. The Participant acknowledges and agrees that this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company.
(d)Acquired Rights. The Participant acknowledges and agrees that: (a) the Company may terminate or amend the Plan at any time; (b) the award of RSUs made under this Agreement is completely independent of any other award or grant and is made at the sole discretion of the Company; (c) no past grants or awards (including, without limitation, the RSUs awarded hereunder) give the Participant any right to any grants or awards in the future whatsoever; and (d) any benefits granted under this Agreement are not part of the Participant’s ordinary salary, and shall not be considered as part of such salary in the event of severance, redundancy or resignation.
(e)Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.
(f)Exclusive Jurisdiction/Venue. All disputes that arise from or relate to this Agreement shall be decided exclusively by binding arbitration in Cook County, Illinois under the Commercial Arbitration Rules of the American Arbitration Association. The parties agree that the arbitrator’s award shall be final, and may be filed with and enforced as a final judgment by any court of competent jurisdiction. Notwithstanding the foregoing, any disputes related to the enforcement of the restrictive covenants contained in Section 9 of this Agreement shall be subject to and determined under Delaware law and adjudicated in Illinois courts.
(g)Notices. Any notice hereunder by the Participant shall be given to the Company in writing and such notice shall be deemed duly given only upon receipt thereof by the General Counsel of the Company. Any notice hereunder by the Company shall be given to the Participant in writing and such notice shall be deemed duly given only upon receipt thereof at such address as the Participant may have on file with the Company.
(h)Headings. The titles and headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be a part of this Agreement.
(i)Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same instrument.
(j)Severability. The invalidity or unenforceability of any provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.
9


(k)Binding Agreement; Assignment. This Agreement shall inure to the benefit of, be binding upon, and be enforceable by the Company and its successors and assigns. The Participant shall not assign any part of this Agreement without the prior express written consent of the Company.
(l)Entire Agreement; Amendment. This Agreement, together with the Plan, contains the entire agreement between the parties hereto with respect to the subject matter contained herein, and supersedes all prior agreements or prior understandings, whether written or oral, between the parties relating to such subject matter. The Human Capital Committee shall have the right, in its sole discretion, to modify or amend this Agreement from time to time in accordance with and as provided in the Plan. This Agreement may also be modified or amended by a writing signed by both the Company and the Participant. The Company shall give written notice to the Participant of any such modification or amendment of this Agreement as soon as practicable after the adoption thereof.
(m)Further Assurances. Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall execute and deliver all such other agreements, certificates, instruments and documents as either party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the Plan and the consummation of the transactions contemplated thereunder.
[Remainder of Page Intentionally Left Blank]
10


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
R1 RCM INC.
By:
Name:
Title:
I hereby acknowledge that I have read this Agreement, have received and read the Plan, and understand and agree to comply with the terms and conditions of this Agreement and the Plan.
PARTICIPANT ACCEPTANCE

###PARTICIPANT_NAME###
[Name of Participant]

EX-31.1 4 exhibit311-q12023.htm EX-31.1 Document

Exhibit 31.1


Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 
I, Lee Rivas, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of R1 RCM Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 4, 2023
/s/ Lee Rivas     
Lee Rivas
Chief Executive Officer
(Principal Executive Officer)


EX-31.2 5 exhibit312-q12023.htm EX-31.2 Document

Exhibit 31.2


 
Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 
I, Jennifer Williams, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of R1 RCM Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 4, 2023
/s/ Jennifer Williams
Jennifer Williams
Chief Financial Officer and Treasurer
(Principal Financial Officer)


EX-32.1 6 exhibit321-q12023.htm EX-32.1 Document

Exhibit 32.1

 
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 
In connection with the Quarterly Report on Form 10-Q of R1 RCM Inc. (the “Company”) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Lee Rivas, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2023
/s/ Lee Rivas         
Lee Rivas
Chief Executive Officer
(Principal Executive Officer)




EX-32.2 7 exhibit322-q12023.htm EX-32.2 Document

Exhibit 32.2

 
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 
In connection with the Quarterly Report on Form 10-Q of R1 RCM Inc. (the “Company”) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Jennifer Williams, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2023
/s/ Jennifer Williams       
Jennifer Williams
Chief Financial Officer and Treasurer
(Principal Financial Officer)


 





EX-101.SCH 8 ah-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business Description and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Accounts Receivable and Allowance for Credit Losses link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Other Expenses link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Segments and Customer Concentrations link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Business Description and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Accounts Receivable and Allowance for Credit Losses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Other Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Segments and Customer Concentrations (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Acquisitions - Pro Forma Results (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Revenue Recognition - Changes to Contract Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Debt - Carrying Amounts of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Debt - Carrying Amounts of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Debt - Scheduled Maturities of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Derivative Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Share-Based Compensation - Compensation Expense Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Share-Based Compensation - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Share-Based Compensation - Other Than Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Other Expenses - Schedule of Other Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Segments and Customer Concentrations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Segments and Customer Concentrations - Concentration Risk by Customer (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Supplemental Financial Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Supplemental Financial Information - Schedule of Supplemental Cash Flow Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 ah-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 ah-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 ah-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Provision (recoveries) Increase in allowance Accounts Receivable, Credit Loss Expense (Reversal) Related Party Transactions [Abstract] Related Party Transactions [Abstract] Deferred tax assets Deferred Income Tax Assets, Net Long-term debt Total Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Facility-exit charges Business Exit Costs 2025 Long-Term Debt, Maturity, Year Two Customer liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Non-Options Awards Activity Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Credit agreement, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital Ascension and its affiliates Ascension [Member] Ascension [Member] Other Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Exercise of vested stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Interest rate Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Schedule of Fair Value of Total Consideration Paid and Schedule of Acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Other Other Noncash Income (Expense) Property, equipment and software, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Term A Loans Senior Secured Term Loan A [Member] Senior Secured Term Loan A Acquisition of treasury stock related to share-based compensation plans Treasury Stock, Value, Acquired, Cost Method Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Net income Net income Net Income (Loss) Attributable to Parent Antidilutive common share equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Scheduled Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Equity Component [Domain] Equity Component [Domain] Related Party [Domain] Related Party [Domain] Treasury Stock, Common, Value Treasury Stock, Common, Value Total contract assets, net Balance as of December 31, 2022 Balance as of March 31, 2023 Contract with Customer, Asset, after Allowance for Credit Loss Hedging Designation [Domain] Hedging Designation [Domain] Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Canceled/forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Incentive fees Incentive fees Incentive Fees [Member] Incentive Fees [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liabilities Operating Lease, Liability, Current Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Cash paid for amounts included in the measurement of lease liabilities: Lease, Cost [Abstract] Amounts billed Contract With Customer, Asset, Amounts Billed Contract With Customer, Asset, Amounts Billed Canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Receivables [Abstract] Receivables [Abstract] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables CoyCo 2 share-based compensation Share-Based Payment Arrangement, Noncash Expense From Acquisition Share-Based Payment Arrangement, Noncash Expense From Acquisition Legal Entity [Axis] Legal Entity [Axis] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Number of deferred payments Payments To Acquire Businesses, Number Of Payments Payments To Acquire Businesses, Number Of Payments Revenue Recognition and Deferred Revenue [Abstract] Total liabilities Liabilities Performance factor adjustment (in dollars per share) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Senior Revolver Revolving Credit Facility [Member] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Global business services center expansion project in the Philippines Facility Costs, Included In Acquisition Evaluation And Integration Costs Facility Costs, Included In Acquisition Evaluation And Integration Costs Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding and unvested at beginning of period (in dollars per share) Outstanding and unvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Debt Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Other Other Restructuring Costs Concentration Risk [Table] Concentration Risk [Table] Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of March 31, 2023 and December 31, 2022, respectively Accounts Receivable, Related Parties, Current Non-current Contract With Customer, Liability, Including Related Party, Noncurrent Contract With Customer, Liability, Including Related Party, Noncurrent Unrealized gains reported in accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 2026 Long-Term Debt, Maturity, Year Three Related Party Affiliated Entity [Member] Revenue Revenue Benchmark [Member] Schedule of Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Summary Depreciation and Amortization Expense Schedule Of Depreciation And Amortization [Table Text Block] Schedule Of Depreciation And Amortization [Table Text Block] Total assets Assets Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net income per common share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] PBRSUs Performance Shares [Member] Number of years since new country entry Number Of Years Since New Country Entry Number Of Years Since New Country Entry Interest rate swaps Interest Rate Swap [Member] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Current portion of long-term debt Less: Current maturities Long-Term Debt, Current Maturities Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Accrued compensation and benefits Employee-related Liabilities, Current Line of Credit Line of Credit [Member] Income before income tax provision Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Deferred income taxes Deferred Income Taxes and Tax Credits Earnings Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Add: Effect of dilutive warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Award Type [Domain] Award Type [Domain] Nonvested award, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Derivative Contract [Domain] Derivative Contract [Domain] Entity Registrant Name Entity Registrant Name Net income Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax Entity Address, City or Town Entity Address, City or Town Deferred tax assets related to operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Intermountain Healthcare Customer Not Affiliated with Ascension Health [Member] Customer Not Affiliated with Ascension Health [Member] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Debt covenant, secured obligation pledged, capital stock of certain domestic subsidiaries, percent Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent Treasury Stock Treasury Stock, Common [Member] Operating lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Trading Symbol Trading Symbol Entity File Number Entity File Number Treasury stock, shares (in shares) Beginning Balance (in shares) Ending Balance (in shares) Treasury Stock, Common, Shares Non-current portion of customer liabilities Contract with Customer, Liability, Noncurrent Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Additions Contract With Customer, Liability, Additions Contract With Customer, Liability, Additions Payments to acquire business, number of payments, refund period, if circumstances met Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met Acquisitions Business Combination Disclosure [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Concentration percentage Concentration Risk, Percentage Schedule of Other Expenses Schedule of Other Operating Cost and Expense, by Component [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Net services revenue, from related parties Revenue from Related Parties Credit Facility [Domain] Credit Facility [Domain] Intangible asset amortization expense Amortization of Intangible Assets Cloudmed and VisitPay Acquisitions Cloudmed And VisitPay Acquisitions [Member] Cloudmed And VisitPay Acquisitions Basic (in dollars per share) Net income per common share (basic) (in dollars per share) Earnings Per Share, Basic Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Operating lease right-of-use assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Payments to acquire business Payments To Acquire Businesses, Gross, Financing Activities Payments To Acquire Businesses, Gross, Financing Activities Cloudmed Cloudmed Acquisition [Member] Cloudmed Acquisition Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Schedule of Transaction Price Allocated to the Remaining Performance Obligation Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] TCP-ASC Recapitalization Litigation TCP-ASC Recapitalization Litigation [Member] TCP-ASC Recapitalization Litigation Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] 2028 Long-Term Debt, Maturity, Year Five Accumulated Deficit Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Litigation Status [Domain] Litigation Status [Domain] Common Stock Common Stock [Member] Schedule of Share-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Modular and other Modular And Other [Member] Modular And Other Number of reporting segments Number of Reportable Segments Purchase of treasury stock Payments for Repurchase of Common Stock Loss on disposal and right-of-use asset write-downs Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs Thereafter Long-Term Debt, Maturity, after Year Five Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Document Quarterly Report Document Quarterly Report Letters of Credit Letter of Credit [Member] Current assets: Assets, Current [Abstract] Non-current portion of operating lease liabilities Operating Lease, Liability, Noncurrent Strategic initiatives Acquisition Evaluation And Integration Costs Acquisition Evaluation And Integration Costs Statistical Measurement [Axis] Statistical Measurement [Axis] Acquisition of treasury stock related to share-based compensation plans (in shares) Treasury Stock, Shares, Acquired Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Current portion of contract assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer Accumulated deficit Retained Earnings (Accumulated Deficit) Non-current portion of contract assets, net Non-current Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Contract assets, net Contract with Customer, Asset, after Allowance for Credit Loss, Classified [Abstract] Accounts receivable, net of $16.0 million and $15.1 million allowance as of March 31, 2023 and December 31, 2022, respectively Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Non-current portion of contract assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer Litigation Case [Domain] Litigation Case [Domain] Outstanding, vested and exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party Transactions Related Party Transactions Disclosure [Text Block] Schedule of Pro Forma Results Business Acquisition, Pro Forma Information [Table Text Block] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Net interest expense Interest Income (Expense), Nonoperating, Net Document Fiscal Year Focus Document Fiscal Year Focus Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Repurchases of common stock (in shares) Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired Outstanding and unvested at beginning of period (in shares) Outstanding and unvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Decrease in deferred income tax liability Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Third Party Third Party [Member] Third Party Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Stock Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Income from operations Operating Income (Loss) Derivative, fair value, net Derivative, Fair Value, Net Recently Issued Accounting Standards and Disclosures New Accounting Pronouncements, Policy [Policy Text Block] Litigation Status [Axis] Litigation Status [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Goodwill Adjustments to reconcile net income to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax provision Income Tax Expense (Benefit) Debt issuance costs incurred Debt Issuance Costs, Line of Credit Arrangements, Gross Deferred tax liabilities Deferred Income Tax Liabilities, Net Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Lease liabilities Increase (Decrease) In Lease Liabilities Increase (Decrease) In Lease Liabilities Cost of services Cost of Goods and Services Sold Derivative [Line Items] Derivative [Line Items] Diluted (in shares) Diluted weighted average common shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative liability Derivative Liability Debt issuance costs, capitalized Debt Issuance Costs, Line of Credit Arrangements, Net Loss Contingencies [Line Items] Loss Contingencies [Line Items] Advanced billings recognized Contract With Customer, Liability Advanced Billings Recognized Contract With Customer, Liability Advanced Billings Recognized Accounts Receivable Accounts Receivable [Member] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Term B Loan Senior Secured Term Loan B [Member] Senior Secured Term Loan B Common stock, $0.01 par value, 750,000,000 shares authorized, 442,439,169 shares issued and 418,176,363 shares outstanding at March 31, 2023; 750,000,000 shares authorized, 439,950,125 shares issued and 416,597,885 shares outstanding at December 31, 2022 Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Integration costs Business Combination, Integration Related Costs Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Non-cash lease expense Lease Expense, Noncash Lease Expense, Noncash Gains to be reclassified within next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Net operating fees Net operating fees Net Operating Fees [Member] Net Operating Fees [Member] Cash, cash equivalents and restricted cash, at beginning of period Cash, cash equivalents and restricted cash, at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Existing Term A Loan Existing Senior Secured Term Loan A [Member] Existing Senior Secured Term Loan A Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Net income (loss) available to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Foreign Currency Hedges Foreign currency forward contracts Foreign Exchange Forward [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Exercise of vested stock options Proceeds from Stock Options Exercised Common stock, shares issued (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Current portion of customer liabilities Contract with Customer, Liability, Current Property, equipment and software purchases not paid Capital Expenditures Incurred but Not yet Paid Business acquisition costs Business Combination, Acquisition Related Costs Income Statement Location [Domain] Income Statement Location [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Number of complaints filed Loss Contingency, New Claims Filed, Number Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Net services revenue Business Acquisition, Pro Forma Revenue Entity Current Reporting Status Entity Current Reporting Status Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Repurchases of common stock Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method Other assets Other Assets, Noncurrent Net change on derivatives designated as cash flow hedges, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Revenue recognized Contract With Customer, Asset, Revenue Recognized Contract With Customer, Asset, Revenue Recognized Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Outstanding, vested and exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Non-current portion of deferred contract costs Capitalized Contract Cost, Net, Noncurrent Operating expenses: Operating Costs and Expenses [Abstract] Schedule of Fair Value of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Management Units Management Units [Member] Management Units Derivative [Table] Derivative [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Incremental Term A Loan Incremental Senior Secured Term Loan A [Member] Incremental Senior Secured Term Loan A Unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net CoyCo 2 CoyCo 2 [Member] CoyCo 2 Maximum exercisable (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes in cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Operating cash flows for operating leases Operating Lease, Payments Advanced billings Contract With Customer, Liability Advanced Billings Contract With Customer, Liability Advanced Billings Other Expenses Other Income and Other Expense Disclosure [Text Block] Contract liabilities Contract with Customer, Liability [Abstract] Accounts receivable, allowance Accounts Receivable, Allowance for Credit Loss, Current Exercise of vested stock options Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total debt Long-Term Debt Number of shares vesting if targets conditions met, potential percentage Share-Based Compensation Arrangement, By Share-Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Target Conditions Met, Percentage Share Based Compensation Arrangement, By Share Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Conditions Met, Percentage Common stock, shares authorized (in shares) Common Stock, Shares Authorized Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Current portion of customer liabilities - related party Contract With Customer, Liability, Related Party, Current Contract With Customer, Liability, Related Party, Current Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Lock-up period Business Combination, Lock-Up Period Business Combination, Lock-Up Period Customer liabilities and customer liabilities - related party Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Designated as Hedging Instrument Designated as Hedging Instrument [Member] Senior Term Loan Senior Term Loan [Member] Senior Term Loan Accumulated gain, net of tax, recognized in other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Revenue recognized Contract with Customer, Liability, Revenue Recognized Business Acquisition [Line Items] Business Acquisition [Line Items] Smaller Reporting Company Entity Small Business Net change on derivatives designated as cash flow hedges, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Second A&R Credit Agreement Second A&R Credit Agreement [Member] Second A&R Credit Agreement Investor Investor [Member] Revenue expected to be recognized in the future related to unsatisfied performance obligations, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Schedule of Customer Concentration, Net Services Revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Cash Flow, Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Related tax benefits Share-Based Payment Arrangement, Expense, Tax Benefit Title of 12(b) Security Title of 12(b) Security Business Description and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Replacement awards issued to Cloudmed equity award holders (in shares) Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares Total operating expenses Costs and Expenses Derivative asset, noncurrent Derivative Asset, Noncurrent Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Total contract liabilities Contract With Customer, Liability, Including Related Party Contract With Customer, Liability, Including Related Party Issuance of common stock related to share-based compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Non-current portion of customer liabilities - related party Contract With Customer, Liability, Related Party, Noncurrent Contract With Customer, Liability, Related Party, Noncurrent Segments and Customer Concentrations Segment Reporting Disclosure [Text Block] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Contract with Customer, Liabilities [Roll Forward] Contract with Customer, Liabilities [Abstract] Contract with Customer, Liabilities [Rollfarward] Income tax benefit Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Derivatives, net gain (loss) reclassified Derivative, Gain (Loss) on Derivative, Net Liabilities Liabilities and Equity [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Decrease in goodwill Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Remainder of 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year Weighted average shares used in calculating net income per common share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accounts payable Accounts Payable, Current Consolidated statements of comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Number of units converted in Transaction Agreement (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement Hedging Relationship [Domain] Hedging Relationship [Domain] 2027 Long-Term Debt, Maturity, Year Four Hedging Designation [Axis] Hedging Designation [Axis] Entity Filter Category Entity Filer Category Physician Customer Physician Customer [Member] Physician Customer Basic (in shares) Basic weighted-average common shares (in shares) Weighted Average Number of Shares Outstanding, Basic Potential business combination, expected purchase price Potential Business Combination, Price Of Acquisition, Expected Potential Business Combination, Price Of Acquisition, Expected Share-based compensation expense Total share-based compensation expense Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Total depreciation and amortization Depreciation, Depletion, And Amortization, Excluding Intangible Assets Depreciation, Depletion, And Amortization, Excluding Intangible Assets Notional amount Derivative, Notional Amount Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Schedule of Carrying Values Long-Term Debt Schedule of Debt [Table Text Block] Net services revenue ($216.8 million and $216.7 million for the three months ended March 31, 2023 and 2022, from related party, respectively) Net services revenue Revenue from Contract with Customer, Excluding Assessed Tax Current portion of customer liabilities Contract With Customer, Liability, Current, Excluding Advanced Billings Contract With Customer, Liability, Current, Excluding Advanced Billings Cover page. Cover [Abstract] Pending Litigation Pending Litigation [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Other Contract With Customer, Asset, Other Contract With Customer, Asset, Other Contract assets, allowance Contract with Customer, Asset, Allowance for Credit Loss Share-Based Compensation Share-Based Payment Arrangement [Text Block] Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Revenue Recognition Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Contract assets Increase (Decrease) in Contract with Customer, Asset Derivative asset, current Derivative Asset, Current Shares withheld for taxes Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Amortization of debt issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Related Party [Axis] Related Party [Axis] Statute of limitations minimum Statute Of Limitations Minimum Statute Of Limitations Minimum Repayment of senior secured debt and Repayments on revolver Repayments of Long-Term Lines of Credit Add: Effect of dilutive equity awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Accounts receivable and related party accounts receivable Increase (Decrease) in Receivables Performance factor adjustment (in shares) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Gross deferred tax assets Deferred Tax Assets, Gross Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Cloudmed Cloudmed [Member] Cloudmed Net income (loss) available to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Diluted (in dollars per share) Net income per common share (diluted) (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Property, equipment and software Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software Customer Concentration Risk Customer Concentration Risk [Member] Other expenses Total other expenses Other General Expense Current Contract With Customer, Liability, Including Related Party, Current Contract With Customer, Liability, Including Related Party, Current Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount Revenue, Remaining Performance Obligation, Amount Schedule of Allowance for Credit Losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Other Proceeds from (Payments for) Other Financing Activities Share-based compensation expense capitalized to deferred contract costs Share-Based Payment Arrangement, Amount Capitalized Balance as of December 31, 2022 Balance as of March 31, 2023 Contract with Customer, Liability Product and Service [Axis] Product and Service [Axis] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Non-current portion of customer liabilities Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings Borrowing availability Line of Credit Facility, Remaining Borrowing Capacity Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Credit Facility [Axis] Credit Facility [Axis] Accounts Receivable and Allowance for Credit Losses Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Allocation of consideration to assets acquired and liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number RSUs and PBRSUs Restricted Stock Units (RSUs) And Performance Shares [Member] Restricted Stock Units (RSUs) And Performance Shares Statute of limitations maximum Statute Of Limitations Maximum Statute Of Limitations Maximum Schedule of Disaggregated Revenue By Source Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Current portion of contract assets, net Current Contract with Customer, Asset, after Allowance for Credit Loss, Current Shares surrendered for taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Litigation expenses Litigation Settlement, Expense Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity Central Index Key Entity Central Index Key Accrued compensation and benefits Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits Former Class P Units Former Class P Units [Member] Former Class P Units Weighted- Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Cost of shares surrendered for taxes Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Total purchase consideration Business Combination, Consideration Transferred Accrued expenses and other current liabilities Other Accrued Liabilities, Current Entity [Domain] Entity [Domain] City Area Code City Area Code Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Contract with Customer, Asset [Roll Forward] Contract with Customer, Asset [Roll Forward] Contract with Customer, Asset 2024 Long-Term Debt, Maturity, Year One Share-based compensation Share-Based Payment Arrangement, Noncash Expense Other non-current liabilities Other Liabilities, Noncurrent Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property, equipment, and software Payments to Acquire Property, Plant, and Equipment Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] RevWorks RevWorks Acquisition [Member] RevWorks Acquisition Schedule of Basic and Diluted Net Income (Loss) Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use assets obtained in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of services Cost of services Cost of Sales [Member] Customer [Domain] Customer [Domain] EX-101.PRE 12 ah-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
3 Months Ended
Mar. 31, 2023
Apr. 28, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-41428  
Entity Registrant Name R1 RCM Inc. /DE  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 87-4340782  
Entity Address, Address Line One 433 W. Ascension Way  
Entity Address, Address Line Two Suite 200  
Entity Address, City or Town Murray  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84123  
City Area Code 312  
Local Phone Number 324-7820  
Title of 12(b) Security Common stock, par value $0.01 per share  
Trading Symbol RCM  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filter Category Large Accelerated Filer  
Smaller Reporting Company false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   418,202,601
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001910851  
Current Fiscal Year End Date --12-31  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 104.2 $ 110.1
Accounts receivable, net of $16.0 million and $15.1 million allowance as of March 31, 2023 and December 31, 2022, respectively 229.4 235.2
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of March 31, 2023 and December 31, 2022, respectively 24.9 25.0
Current portion of contract assets, net 81.8 83.9
Prepaid expenses and other current assets 105.2 110.3
Total current assets 545.5 564.5
Property, equipment and software, net 173.8 164.8
Operating lease right-of-use assets 81.0 80.5
Non-current portion of contract assets, net 37.3 32.0
Non-current portion of deferred contract costs 28.2 26.7
Intangible assets, net 1,464.4 1,514.5
Goodwill 2,648.5 2,658.2
Deferred tax assets 10.5 10.4
Other assets 83.4 88.2
Total assets 5,072.6 5,139.8
Current liabilities:    
Accounts payable 24.6 33.4
Current portion of customer liabilities 45.6 57.5
Current portion of customer liabilities - related party 9.4 7.4
Accrued compensation and benefits 84.7 109.0
Current portion of operating lease liabilities 18.8 18.0
Current portion of long-term debt 58.3 53.9
Accrued expenses and other current liabilities 76.7 70.6
Total current liabilities 318.1 349.8
Non-current portion of customer liabilities 5.2 5.0
Non-current portion of customer liabilities - related party 13.2 13.7
Non-current portion of operating lease liabilities 92.7 94.4
Long-term debt 1,707.0 1,732.6
Deferred tax liabilities 192.1 200.7
Other non-current liabilities 24.9 23.1
Total liabilities 2,353.2 2,419.3
Stockholders’ equity:    
Common stock, $0.01 par value, 750,000,000 shares authorized, 442,439,169 shares issued and 418,176,363 shares outstanding at March 31, 2023; 750,000,000 shares authorized, 439,950,125 shares issued and 416,597,885 shares outstanding at December 31, 2022 4.4 4.4
Additional paid-in capital 3,136.2 3,123.2
Accumulated deficit (121.6) (121.9)
Accumulated other comprehensive loss (4.6) (3.4)
Treasury Stock, Common, Value (295.0) (281.8)
Total stockholders’ equity 2,719.4 2,720.5
Total liabilities and stockholders’ equity $ 5,072.6 $ 5,139.8
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Accounts receivable, allowance $ 16.0 $ 15.1
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 442,439,169 439,950,125
Common stock, shares outstanding (in shares) 418,176,363 416,597,885
Treasury stock, shares (in shares) 24,262,806 23,352,240
Related Party    
Accounts receivable, allowance $ 0.1 $ 0.1
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Net services revenue ($216.8 million and $216.7 million for the three months ended March 31, 2023 and 2022, from related party, respectively) $ 545.6 $ 385.7
Operating expenses:    
Cost of services 434.7 296.5
Selling, general and administrative 47.0 28.9
Other expenses 30.2 17.1
Total operating expenses 511.9 342.5
Income from operations 33.7 43.2
Net interest expense 30.7 4.7
Income before income tax provision 3.0 38.5
Income tax provision 2.7 9.1
Net income $ 0.3 $ 29.4
Net income per common share:    
Basic (in dollars per share) $ 0 $ 0.11
Diluted (in dollars per share) $ 0 $ 0.09
Weighted average shares used in calculating net income per common share:    
Basic (in shares) 417,346,840 278,747,261
Diluted (in shares) 452,925,789 321,043,371
Consolidated statements of comprehensive income (loss)    
Net income $ 0.3 $ 29.4
Other comprehensive income (loss):    
Net change on derivatives designated as cash flow hedges, net of tax (1.7) 0.1
Foreign currency translation adjustments 0.5 (1.4)
Total other comprehensive income (loss), net of tax (1.2) (1.3)
Comprehensive income (loss) $ (0.9) $ 28.1
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Net services revenue, from related parties $ 216.8 $ 216.7
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Millions
Total
CoyCo 2
Common Stock
Treasury Stock
Additional Paid-In Capital
Additional Paid-In Capital
CoyCo 2
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2021     298,320,928          
Beginning Balance (in shares) at Dec. 31, 2021       (20,094,686)        
Beginning Balance at Dec. 31, 2021 $ 346.7   $ 3.0 $ (215.2) $ 628.5   $ (64.3) $ (5.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense 10.2       10.2      
Issuance of common stock related to share-based compensation plans (in shares)     1,757,955          
Exercise of vested stock options (in shares)     77,438          
Exercise of vested stock options 0.4       0.4      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (727,768)        
Acquisition of treasury stock related to share-based compensation plans (18.7)     $ (18.7)        
Repurchases of common stock (in shares)       (8,000)        
Repurchases of common stock (0.2)     $ (0.2)        
Net change on derivatives designated as cash flow hedges, net of tax 0.1             0.1
Foreign currency translation adjustments (1.4)             (1.4)
Net income 29.4           29.4  
Ending Balance (in shares) at Mar. 31, 2022     300,156,321          
Ending Balance (in shares) at Mar. 31, 2022       (20,830,454)        
Ending Balance at Mar. 31, 2022 $ 366.5   $ 3.0 $ (234.1) 639.1   (34.9) (6.6)
Beginning Balance (in shares) at Dec. 31, 2022 439,950,125   439,950,125          
Beginning Balance (in shares) at Dec. 31, 2022 (23,352,240)     (23,352,240)        
Beginning Balance at Dec. 31, 2022 $ 2,720.5   $ 4.4 $ (281.8) 3,123.2   (121.9) (3.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense $ 10.7 $ 1.8     10.7 $ 1.8    
Issuance of common stock related to share-based compensation plans (in shares)     2,308,591          
Exercise of vested stock options (in shares) 180,453   180,453          
Exercise of vested stock options $ 0.5       0.5      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (910,566)        
Acquisition of treasury stock related to share-based compensation plans (13.2)     $ (13.2)        
Net change on derivatives designated as cash flow hedges, net of tax (1.7)             (1.7)
Foreign currency translation adjustments 0.5             0.5
Net income $ 0.3           0.3  
Ending Balance (in shares) at Mar. 31, 2023 442,439,169   442,439,169          
Ending Balance (in shares) at Mar. 31, 2023 (24,262,806)     (24,262,806)        
Ending Balance at Mar. 31, 2023 $ 2,719.4   $ 4.4 $ (295.0) $ 3,136.2   $ (121.6) $ (4.6)
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Accumulated Other Comprehensive Loss    
Net change on derivatives designated as cash flow hedges, tax $ 0.5 $ 0.0
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities    
Net income $ 0.3 $ 29.4
Adjustments to reconcile net income to net cash provided by operations:    
Depreciation and amortization 66.0 18.9
Amortization of debt issuance costs 1.4 0.3
Share-based compensation 10.5 10.1
CoyCo 2 share-based compensation 1.8 0.0
Loss on disposal and right-of-use asset write-downs 0.0 2.0
Provision for credit losses 1.5 0.0
Deferred income taxes 1.8 7.3
Non-cash lease expense 2.9 3.2
Other 0.0 1.5
Changes in operating assets and liabilities:    
Accounts receivable and related party accounts receivable 4.7 22.1
Contract assets (4.0) 0.0
Prepaid expenses and other assets 8.2 (20.5)
Accounts payable (10.9) 3.2
Accrued compensation and benefits (24.5) (27.5)
Lease liabilities (4.4) (2.1)
Other liabilities 9.7 1.7
Customer liabilities and customer liabilities - related party (10.3) (18.7)
Net cash provided by operating activities 54.7 30.9
Investing activities    
Purchases of property, equipment, and software (23.4) (10.0)
Other (2.2) 0.0
Net cash used in investing activities (25.6) (10.0)
Financing activities    
Exercise of vested stock options 0.5 0.4
Purchase of treasury stock 0.0 (0.6)
Shares withheld for taxes (13.4) (21.5)
Other (0.1) (0.1)
Net cash used in financing activities (35.4) (26.2)
Effect of exchange rate changes in cash, cash equivalents and restricted cash 0.4 (0.9)
Net decrease in cash, cash equivalents and restricted cash (5.9) (6.2)
Cash, cash equivalents and restricted cash, at beginning of period 110.1 130.1
Cash, cash equivalents and restricted cash, at end of period 104.2 123.9
Supplemental disclosures of cash flow information    
Property, equipment and software purchases not paid 28.0 23.3
Senior Term Loan    
Financing activities    
Repayment of senior secured debt and Repayments on revolver (12.4) (4.4)
Senior Revolver    
Financing activities    
Repayment of senior secured debt and Repayments on revolver $ (10.0) $ 0.0
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Business Description and Basis of Presentation
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Description and Basis of Presentation Business Description and Basis of Presentation
Business Description
R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers.
Basis of Presentation
The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of March 31, 2023, the results of operations of the Company for the three months ended March 31, 2023 and 2022, and the cash flows of the Company for the three months ended March 31, 2023 and 2022. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2023.
When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements included in the Company’s 2022 Form 10-K.
Recently Issued Accounting Standards and Disclosures

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions
3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions AcquisitionsAssets acquired and liabilities assumed in a business combination are recorded at their estimated fair value on the date of the acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.
Prior Acquisitions

During 2022, the Company acquired the following business:

Company NameDescription of the BusinessDescription of the Acquisition
Revint Holdings, LLC (“Cloudmed”)
Provider of revenue intelligence solutions
Purchased all outstanding equity interests in exchange for shares of common stock of the Company and cash. The shares of common stock received by the Cloudmed sellers are subject to an 18-month lock-up period, which expires December 21, 2023. In addition, the Company replaced certain pre-acquisition awards held by certain Cloudmed sellers with restricted stock units (“RSUs”) of the Company.

The purchase price has been provisionally allocated to assets acquired and liabilities assumed based on their fair value as of the acquisition date. The fair value estimate of assets acquired and liabilities assumed is pending the completion of various elements, including gathering further information to ensure the completeness of assets acquired and liabilities assumed and the finalization of an independent appraisal of their respective fair values, which is subject to final review by the Company’s management. Accordingly, management considers the balances shown in the following table to be preliminary, and there could be adjustments to the consolidated financial statements, including changes in our amortization expense related to the valuation of intangible assets acquired and their respective useful lives, among other adjustments.

The preliminary fair value of assets acquired and liabilities assumed is:
Purchase Price Allocation
Total purchase consideration$3,281.6 
Allocation of consideration to assets acquired and liabilities assumed:
Cash and cash equivalents$32.1 
Accounts receivable61.8 
Current portion of contract assets68.2 
Property, equipment and software5.0 
Operating lease right-of-use assets25.3 
Non-current portion of contract assets23.8 
Intangible assets1,366.6 
Goodwill2,093.9 
Other assets6.7 
Accounts payable(31.9)
Customer liabilities(3.3)
Accrued compensation and benefits(93.4)
Operating lease liabilities(25.4)
Deferred income tax liabilities(235.6)
Other liabilities(12.2)
Net assets acquired$3,281.6 
Measurement period adjustments

The Company had various measurement period adjustments due to additional information received since December 31, 2022. The significant adjustments included a reduction to deferred income tax liabilities and a corresponding decrease to goodwill of $9.8 million related to updated tax return information.

RevWorks

In 2020, the Company purchased certain assets relating to the RevWorks services business from Cerner Corporation. In accordance with the purchase agreement, the Company paid the first deferred payment of $12.5 million in the third quarter of 2021. The remaining deferred payment of $12.5 million was payable on the second anniversary of the closing date (August 2022) and is included in other accrued expenses on the Consolidated Balance Sheet as of March 31, 2023 as it had not been paid as of such date.

The two deferred payments related to the RevWorks acquisition were contractual obligations of the Company; however, they are refundable to the Company if certain RevWorks customer revenue targets defined in the purchase agreement for the first two years following the acquisition are not achieved. The parties are currently engaged in arbitration to finalize the remaining deferred payment and contingently refundable consideration amounts. The contingently refundable consideration is stated at an amount approximating the amount expected to be realized and is included in other current assets on the Consolidated Balance Sheet as of March 31, 2023.

Pro Forma Results

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed acquisition had occurred as of January 1, 2021. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are:

Three Months Ended March 31, 2022
Net services revenue$486.4 
Net income$1.4 

Adjustments were made to earnings to adjust depreciation and amortization to reflect the fair value of identified assets acquired, to adjust share-based compensation expense for awards granted in connection with the acquisition, to record the effects of extinguishing the debt of the acquired company and replacing it with the debt of the Company, to adjust timing of acquisition related costs incurred by the Company, and to record the income tax effect of these adjustments.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition
3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Revenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.

Disaggregation of Revenue

In the following table, revenue is disaggregated by source of revenue:
Three Months Ended March 31,
20232022
Net operating fees$361.0 $322.8 
Incentive fees23.6 30.2 
Modular and other (1)161.0 32.7 
Net services revenue$545.6 $385.7 

(1) Modular and other revenue primarily consists of $125.8 million in service fees related to Cloudmed for the three months ended March 31, 2023, revenue integrity solutions, practice management (“PM”) services, physician advisory services (“PAS”), and software subscription revenue.

Contract Balances

The following table provides information about contract assets, net and contract liabilities from contracts with customers:

March 31, 2023December 31, 2022
Contract assets, net
Current$81.8 $83.9 
Non-current37.3 32.0 
Total contract assets, net$119.1 $115.9 
Contract liabilities
Current (1)$11.0 $9.7 
Non-current (2)18.4 18.7 
Total contract liabilities$29.4 $28.4 

(1) Current contract liabilities include $8.8 million and $7.6 million classified in the current portion of customer liabilities and $2.2 million and $2.1 million classified in the current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively.
(2) Non-current contract liabilities include $5.2 million and $5.0 million classified in the non-current portion of customer liabilities and $13.2 million and $13.7 million classified in the non-current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively.

The contract assets, net balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets, net for the three months ended March 31, 2023 were as follows:

Contract Assets, net
Balance as of December 31, 2022
$115.9 
Revenue recognized86.0 
Amounts billed(82.6)
Other (1)(0.2)
Balance as of March 31, 2023
$119.1 

(1) Other primarily includes adjustments made during the period to the allowance for credit losses.
Contract Liabilities
Balance as of December 31, 2022
$(28.4)
Advanced billings - January 1, 2023 (1)(91.3)
Advanced billings recognized91.3 
Additions(3.9)
Revenue recognized2.9 
Balance as of March 31, 2023
$(29.4)

(1) The Company records advanced billings to contract liabilities and accounts receivable on the first day of the respective service period, which are earned during the quarter.

Transaction Price Allocated to the Remaining Performance Obligation

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained.

Net operating feesIncentive fees
Remainder of 2023$90.0 $33.0 
202478.1 — 
202545.7 — 
202635.6 — 
202731.2 — 
202829.8 — 
Thereafter83.6 — 
Total$394.0 $33.0 
    
The amounts presented in the table above include variable fee estimates of the Company’s physician groups revenue cycle management (“RCM”) services contracts, fixed fees, and forecasted incentive fees. Fixed fees are typically recognized ratably as the performance obligation is satisfied and forecasted incentive fees are measured cumulatively over the contractually defined performance period.

Estimates of revenue expected to be recognized in future periods exclude unexercised customer options to purchase services within the Company’s PAS contracts that do not represent material rights to the customer.
The Company does not disclose information about remaining performance obligations with an original expected duration of one year or less and has elected an exemption to the disclosure requirements related to estimate variable consideration and an exemption where the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Accounts Receivable and Allowance for Credit Losses
3 Months Ended
Mar. 31, 2023
Receivables [Abstract]  
Accounts Receivable and Allowance for Credit Losses Accounts Receivable and Allowance for Credit LossesAccounts receivable is comprised of invoiced and unbilled balances due from modular services and end-to-end RCM customers, which are presented net after considering cost reimbursements owed to end-to-end RCM customers.
The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and business and industry factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay.

The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material.

Movements in the allowance for credit losses related to accounts receivable are as follows:

 Three Months Ended March 31,
 20232022
Beginning balance (1)$15.2 $2.5 
Provision (recoveries)1.1 — 
Write-offs(0.2)(0.1)
Ending balance (1)$16.1 $2.4 

(1) The 2023 balance includes an allowance for credit losses related to a physician customer of $10.1 million that was established in the third quarter of 2022. Management continues to monitor collections and the financial condition of this customer. No changes were made in the current period.

The Company acquired contract assets through the Cloudmed acquisition. As of March 31, 2023, there was an allowance for credit losses of $2.6 million against total contract assets.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Debt
3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Debt Debt
The carrying amounts of debt consist of the following:

March 31, 2023December 31, 2022
Senior Revolver (1)$90.0 $100.0 
Term A Loans1,200.3 1,211.4 
Term B Loan497.5 498.7 
Unamortized discount and issuance costs(22.5)(23.6)
Total debt1,765.3 1,786.5 
Less: Current maturities(58.3)(53.9)
Total long-term debt$1,707.0 $1,732.6 

(1) As of March 31, 2023, the Company had $90.0 million in borrowings, $0.9 million letters of credit outstanding, and $509.1 million of availability under the $600.0 million senior secured revolving credit facility (“Senior Revolver ”).
Second Amended and Restated Senior Secured Credit Facilities

On June 21, 2022, the Company, R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), and certain of its subsidiaries entered into a second amended and restated senior credit agreement (the “Second A&R Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan,” and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan,” and together with the Term A Loans, the “Senior Term Loans”), and the $600.0 million Senior Revolver. In conjunction with entering into the Second A&R Credit Agreement, the Company incurred $7.2 million and capitalized $6.4 million of debt issuance costs.

The interest rate as of March 31, 2023 was 7.31% for the Term A Loans and Senior Revolver and 7.81% for the Term B Loan.

The Second A&R Credit Agreement contains a number of financial and non-financial covenants. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of March 31, 2023. The obligations under the Second A&R Credit Agreement are secured by a pledge of 100% of the capital stock of certain domestic subsidiaries owned by the Company and a security interest in substantially all of the Company’s tangible and intangible assets and the tangible and intangible assets of certain domestic subsidiaries.

Debt Maturities

Scheduled maturities of the Company’s long-term debt are summarized as follows:

Scheduled Maturities
Remainder of 2023$41.5 
202467.0 
202567.0 
2026708.3 
2027430.2 
20285.0 
Thereafter468.8 
Total$1,787.8 

For further details on the Second A&R Credit Agreement, refer to Note 10 of the Company’s 2022 Form 10-K.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Financial Instruments
3 Months Ended
Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial InstrumentsThe Company utilizes cash flow hedges to manage its currency risk arising from its global business services centers. As of March 31, 2023, the Company has recorded $1.1 million of unrealized gains in accumulated other comprehensive loss related to foreign currency hedges. The Company estimates that $1.1 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 9 months. Amounts reclassified into cost of services were a net gain of $0.3 million and $0.2 million during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company’s foreign currency forward contracts have maturities extending no later than December 31, 2023, and had a total notional value of $90.2 million.
The Company also utilizes cash flow hedges to reduce variability in interest cash flows from its outstanding debt. As of March 31, 2023, the Company has recorded $9.9 million of unrealized gains in accumulated other comprehensive loss related to interest rate swaps. The Company estimates that $8.3 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into interest expense were a net gain of $1.9 million and a net loss of $0.3 million during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company’s interest rate swaps extend no later than June 30, 2025, and had a total notional value of $500.0 million.

The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:

March 31, 2023December 31, 2022
Foreign currency forward contracts
Prepaid expenses and other current assets$1.1 $0.1 
Other accrued expenses— 0.5 
Total foreign current forward contracts$1.1 $0.6 
Interest rate swaps
Prepaid expenses and other current assets$8.3 $8.7 
Other assets1.6 5.0 
Other accrued expenses— — 
Total interest rate swaps$9.9 $13.7 

As of March 31, 2023 and December 31, 2022, the accumulated gain, net of tax, recognized in accumulated other comprehensive loss was $8.2 million and $9.9 million, respectively.

The Company classifies cash flows from its derivative programs as cash flows from operating activities in the Consolidated Statements of Cash Flows. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements.
On July 5, 2022, the Company and Sutter Health (“Sutter”) entered into an agreement regarding the potential purchase of a business that would expand the Company’s service capabilities (the “Sutter Put Right Agreement”). This agreement is effective through approximately the end of 2023 and allows Sutter to sell the business to the Company for $150.0 million, subject to the negotiation of a definitive agreement and the satisfaction of agreed upon closing conditions, including the requirement that the purchase price be deemed to be fair value at the time of the potential transaction. Assuming an agreement is reached, the Company and Sutter would also need to reach agreement as to whether the purchase price would be paid in cash or shares of the Company’s common stock.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation
3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
The share-based compensation expense relating to the Company’s stock options, RSUs, and performance-based restricted stock units (“PBRSUs”) for the three months ended March 31, 2023 and 2022 was $12.3 million and $10.1 million, respectively, with related tax benefits of approximately $2.6 million and $1.8 million, respectively.

The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense and included in operating activities. The Company recognized $0.5 million and $2.5 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended March 31, 2023 and 2022, respectively.
Total share-based compensation costs that have been included in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) were as follows:
 Three Months Ended March 31,
 20232022
Share-Based Compensation Expense Allocation Details:
Cost of services$6.9 $4.3 
Selling, general and administrative5.4 5.8 
Total share-based compensation expense (1)$12.3 $10.1 
(1) Included in the share-based compensation expense above is $1.8 million of CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense for the three months ended March 31, 2023. See further discussion below.
The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. The volatility for the options was calculated based on an analysis of historical volatility. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations. A Monte Carlo simulation was used to estimate the fair value of the Unvested Units (as defined below), which are being amortized over a period of 4 years on a straight-line basis. The volatility for the Unvested Units was calculated based on an analysis of historical and implied volatility.
Stock options
A summary of the options activity during the three months ended March 31, 2023 is shown below:

OptionsWeighted-
Average
Exercise
Price
Outstanding at December 31, 20223,104,413 $3.38 
Granted— — 
Exercised(180,453)3.05 
Canceled/forfeited(45,865)2.59 
Expired— — 
Outstanding at March 31, 20232,878,095 $3.41 
Outstanding, vested and exercisable at March 31, 20232,855,175 $3.26 
Outstanding, vested and exercisable at December 31, 20223,080,069 $3.23 
Restricted stock units and performance-based restricted stock units    
A summary of the RSU and PBRSU activity during the three months ended March 31, 2023 is shown below:
Weighted-
Average Grant
Date Fair Value
RSUsPBRSUsRSUPBRSU
Outstanding and unvested at December 31, 20223,232,002 6,876,797 $19.07 $19.48 
Granted192,268 — 10.95 — 
Performance factor adjustment— 792,189 — 15.95 
Vested(21,705)(2,286,886)20.21 15.95 
Forfeited(110,733)(455,875)20.56 20.28 
Outstanding and unvested at March 31, 20233,291,832 4,926,225 $18.54 $20.48 
Shares surrendered for taxes for the three months ended March 31, 2023
6,908 903,658 
Cost of shares surrendered for taxes for the three months ended March 31, 2023 (in millions)
$0.1 $13.1 
Shares surrendered for taxes for the three months ended March 31, 2022
2,198 725,570 
Cost of shares surrendered for taxes for the three months ended March 31, 2022 (in millions)
$— $18.7 
Upon consummation of the Cloudmed acquisition, outstanding restricted units of Cloudmed were replaced by an aggregate 1,536,220 RSUs of the Company. The Company also issued an aggregate of 3,173,184 inducement RSUs and PBRSUs to certain employees of Cloudmed under Nasdaq Listing Rule 5635(c)(4) pursuant to its newly adopted 2022 Inducement Plan.

The Company’s RSU and PBRSU agreements allow employees to surrender to the Company shares of common stock upon vesting of their RSUs and PBRSUs in lieu of their payment of the required personal employment-related taxes. Shares surrendered for payment of personal employment-related taxes are held in treasury.

Outstanding PBRSUs vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, modular sales revenue, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 9,852,450.
CoyCo 2, L.P. Limited Partnership Units    

As part of the transactions contemplated by the Cloudmed acquisition, equity awards held by certain employees of Cloudmed (“Former Class P Units”) were modified, through a series of transactions, into awards (“Management Units”) of CoyCo 2. The Management Units issued by CoyCo 2 are treated as share-based compensation under ASC 718, Compensation — Stock Compensation.

The Former Class P Units were originally issued to employees of Cloudmed and its affiliates (“Participants”) in connection with and as a part of the compensation and incentive arrangements between Cloudmed and such Participants prior to the consummation of the Cloudmed acquisition. A portion of the Former Class P Units immediately vested upon the closing of the Cloudmed acquisition; however, certain Former Class P Units that were subject to performance-based vesting conditions did not become vested upon the closing of the Cloudmed acquisition (“Unvested Units”). In connection with the Cloudmed acquisition, Cloudmed caused the Former Class P Units, including the Unvested Units, to be converted into Management Units. At the time of the closing of the Cloudmed acquisition, 97,875 Unvested Units were converted into 514,986 Management Units.
In general, Unvested Units vest upon the achievement of certain performance criteria, including achievement by CoyCo 2’s owner, New Mountain Capital, L.L.C. (“New Mountain”), of (i) specified multiples of Base Equity Value (“BEV”) (i.e., generally the aggregate equity value of New Mountain’s investment in Cloudmed as of the original grant date), or (ii) specified Multiples on Invested Capital (“MIC”) with respect to New Mountain Capital’s pre-Cloudmed acquisition investment in Cloudmed, and subject to continued service with the Company and its affiliates, including Cloudmed through the applicable vesting date. The Unvested Units are not awards of the Company and the participants will receive no additional shares of the Company upon satisfaction of the vesting criteria. However, GAAP requires the Company recognize the cost of share-based compensation granted by an investor (CoyCo 2) to the Company’s employees and service providers for services that benefit the Company’s operations (hereafter, “CoyCo 2 share-based compensation expense”), and a corresponding capital contribution because the costs are incurred on the Company’s behalf.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Other Expenses
3 Months Ended
Mar. 31, 2023
Other Income and Expenses [Abstract]  
Other Expenses Other Expenses
Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. The following table summarizes the other expenses recognized for the three months ended March 31, 2023 and 2022.
Three Months Ended March 31,
 20232022
Business acquisition costs (1)$0.1 $6.3 
Integration costs (2)15.8 0.4 
Strategic initiatives (3)8.0 0.3 
Global business services center expansion project in the Philippines (4)— 3.1 
Facility-exit charges (5)1.2 4.8 
Other (6)5.1 2.2 
Total other expenses$30.2 $17.1 
(1) These are costs, including legal, consulting, and bank fees, that are directly related to the closing of business acquisitions and include changes to contingent consideration, if applicable.
(2) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective and to achieve synergies expected from business acquisitions. Costs include consulting fees, IT vendor spend, severance, retention, and certain payroll costs.
(3) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts.
(4) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines was the first new organic global business services center country expansion by the Company in approximately 15 years. The Company completed the expansion project in 2022.
(5) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities.
(6) For the three months ended March 31, 2023 and 2022, other includes $5.5 million and $1.1 million, respectively, of expenses related to the Company’s ongoing litigation matters. For further details, refer to Note 11, Commitments and Contingencies.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Income tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred.

The Company recognized income tax expense for the three months ended March 31, 2023 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for foreign taxes, state taxes, non-deductible expenses, and discrete items.

The Company recognized income tax expense for the three months ended March 31, 2022 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible expenses, and discrete items.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2019 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from three to six years.
At December 31, 2022, the Company had gross deferred tax assets of $147.6 million, of which $50.0 million related to net operating loss (“NOL”) carryforwards. The Company expects to be profitable, allowing the Company to utilize its NOL carryforwards and other deferred tax assets.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period.
Diluted net income per share is calculated by adjusting the denominator used in the basic net income per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options and shares issuable upon vesting of RSUs and PBRSUs.
Basic and diluted net income per common share are calculated as follows:
Three Months Ended March 31,
 20232022
Net income$0.3 $29.4 
Basic weighted-average common shares417,346,840 278,747,261 
Add: Effect of dilutive equity awards4,621,205 6,472,685 
Add: Effect of dilutive warrants30,957,744 35,823,425 
Diluted weighted average common shares452,925,789 321,043,371 
Net income per common share (basic)$— $0.11 
Net income per common share (diluted)$— $0.09 
Because of their anti-dilutive effect, 768,030 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three months ended March 31, 2023. For the three months ended March 31, 2022, 43,206 common share equivalents have been excluded from the diluted earnings per share calculation because of their anti-dilutive effect.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings

Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows.

On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC. Both complaints allege that TCP-ASC, Ascension Health (“Ascension”), and TowerBrook Capital Partners (“TowerBrook”) controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contain provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The cases have since been consolidated into a single action. All defendants have answered the complaint and discovery has commenced.

On February 18, 2022, plaintiffs filed a supplement to their complaint, naming certain additional defendants and asserting additional claims related to the Company’s agreement to acquire Cloudmed, which was announced on January 10, 2022. The additional claims assert that: (i) TCP-ASC, Ascension, and TowerBrook, along with the Company’s directors (“Individual Defendants”), breached their fiduciary duties by causing the Company to enter into and approving the Cloudmed acquisition, respectively, which plaintiffs claim will perpetuate TCP-ASC’s, Ascension’s, and TowerBrook’s control over the Company and entrench the Individual Defendants by virtue of certain agreements entered into as part of the transaction, including a Second Amended Investor Rights Agreement with TCP-ASC (the “Seconded Amended Investor Rights Agreement”) and an Investor Rights Agreement with Cloudmed (the “Cloudmed Investor Rights Agreement”); and (ii) Cloudmed’s stockholders aided and abetted such breaches. Plaintiffs also allege that certain provisions in the Cloudmed Investor Rights Agreement and the Second Amended Investor Rights Agreement are void under the Company’s charter, bylaws, and the Delaware General Corporation law. The plaintiffs seek a declaratory judgment and an unspecified amount of damages, as well as attorneys’ fees and costs. Trial is scheduled for November 2023. The Company believes it has meritorious defenses to all claims against it and intends to vigorously defend itself against these claims.

In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers (U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.), and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago and was presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties have completed damage and expert discovery. Additional dispositive motions are expected to extend into 2023, with trial, if necessary, likely to be scheduled in 2024. The Company believes it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the Master Professional Services Agreement, including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company’s agreements with Ascension, see Note 1 and Note 19 of the Company’s 2022 Form 10-K. In conjunction with the Cloudmed acquisition, New Mountain became a new related party. There were no material transactions with New Mountain subsequent to the Cloudmed acquisition.
Net services revenue from services provided to Ascension, as well as corresponding accounts receivable and customer liabilities are presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) and the Consolidated Balance Sheets. Since Ascension is the Company’s largest customer, a significant percentage of the Company’s cost of services is associated with providing services to Ascension. However, due to the nature of the Company’s global business services and information technology operations, it is impractical to assign the dollar amount associated with services provided to Ascension.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Segments and Customer Concentrations
3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segments and Customer Concentrations Segments and Customer Concentrations
The Company has determined that it has a single operating segment in accordance with the way that management operates and views the business. All of the Company’s significant operations are organized around the single business of providing management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one operating and reportable segment.
Customers comprising greater than 10% of net services revenue are as follows:
Three Months Ended March 31,
Customer Name20232022
Ascension and its affiliates40 %56 %
Intermountain Healthcare11 %14 %
The loss of customers within the Ascension health system or Intermountain network could have a material adverse impact on the Company’s operations.
As of March 31, 2023 and December 31, 2022, the Company had a concentration of credit risk with Ascension, representing 10% of accounts receivable.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Financial Information
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Financial Information Supplemental Financial Information
The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:
 Three Months Ended March 31,
 20232022
Cost of services$15.5 $11.5 
Selling, general and administrative0.4 0.3 
Total depreciation and amortization$15.9 $11.8 
Intangible asset amortization expense was $50.1 million and $7.1 million for the three months ended March 31, 2023 and 2022, respectively. Amortization expense for intangible assets is included in cost of services on the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss).

Supplemental cash flow information related to leases are as follows:

Three Months Ended March 31,
20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$6.2 $3.4 
Right-of-use assets obtained in exchange for operating lease obligations:3.1 6.0 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Business Description and Basis of Presentation (Policies)
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of March 31, 2023, the results of operations of the Company for the three months ended March 31, 2023 and 2022, and the cash flows of the Company for the three months ended March 31, 2023 and 2022. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2023.
When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates.
Recently Issued Accounting Standards and Disclosures
Recently Issued Accounting Standards and Disclosures

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.
Revenue Recognition Revenue RecognitionRevenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions (Tables)
3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Fair Value of Total Consideration Paid and Schedule of Acquisitions
During 2022, the Company acquired the following business:

Company NameDescription of the BusinessDescription of the Acquisition
Revint Holdings, LLC (“Cloudmed”)
Provider of revenue intelligence solutions
Purchased all outstanding equity interests in exchange for shares of common stock of the Company and cash. The shares of common stock received by the Cloudmed sellers are subject to an 18-month lock-up period, which expires December 21, 2023. In addition, the Company replaced certain pre-acquisition awards held by certain Cloudmed sellers with restricted stock units (“RSUs”) of the Company.
Schedule of Fair Value of Assets Acquired and Liabilities Assumed
The preliminary fair value of assets acquired and liabilities assumed is:
Purchase Price Allocation
Total purchase consideration$3,281.6 
Allocation of consideration to assets acquired and liabilities assumed:
Cash and cash equivalents$32.1 
Accounts receivable61.8 
Current portion of contract assets68.2 
Property, equipment and software5.0 
Operating lease right-of-use assets25.3 
Non-current portion of contract assets23.8 
Intangible assets1,366.6 
Goodwill2,093.9 
Other assets6.7 
Accounts payable(31.9)
Customer liabilities(3.3)
Accrued compensation and benefits(93.4)
Operating lease liabilities(25.4)
Deferred income tax liabilities(235.6)
Other liabilities(12.2)
Net assets acquired$3,281.6 
Schedule of Pro Forma Results
The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed acquisition had occurred as of January 1, 2021. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are:

Three Months Ended March 31, 2022
Net services revenue$486.4 
Net income$1.4 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregated Revenue By Source In the following table, revenue is disaggregated by source of revenue:
Three Months Ended March 31,
20232022
Net operating fees$361.0 $322.8 
Incentive fees23.6 30.2 
Modular and other (1)161.0 32.7 
Net services revenue$545.6 $385.7 
(1) Modular and other revenue primarily consists of $125.8 million in service fees related to Cloudmed for the three months ended March 31, 2023, revenue integrity solutions, practice management (“PM”) services, physician advisory services (“PAS”), and software subscription revenue.
Schedule of Contract Assets and Contract Liabilities
The following table provides information about contract assets, net and contract liabilities from contracts with customers:

March 31, 2023December 31, 2022
Contract assets, net
Current$81.8 $83.9 
Non-current37.3 32.0 
Total contract assets, net$119.1 $115.9 
Contract liabilities
Current (1)$11.0 $9.7 
Non-current (2)18.4 18.7 
Total contract liabilities$29.4 $28.4 

(1) Current contract liabilities include $8.8 million and $7.6 million classified in the current portion of customer liabilities and $2.2 million and $2.1 million classified in the current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively.
(2) Non-current contract liabilities include $5.2 million and $5.0 million classified in the non-current portion of customer liabilities and $13.2 million and $13.7 million classified in the non-current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively.

The contract assets, net balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets, net for the three months ended March 31, 2023 were as follows:

Contract Assets, net
Balance as of December 31, 2022
$115.9 
Revenue recognized86.0 
Amounts billed(82.6)
Other (1)(0.2)
Balance as of March 31, 2023
$119.1 

(1) Other primarily includes adjustments made during the period to the allowance for credit losses.
Contract Liabilities
Balance as of December 31, 2022
$(28.4)
Advanced billings - January 1, 2023 (1)(91.3)
Advanced billings recognized91.3 
Additions(3.9)
Revenue recognized2.9 
Balance as of March 31, 2023
$(29.4)

(1) The Company records advanced billings to contract liabilities and accounts receivable on the first day of the respective service period, which are earned during the quarter.
Schedule of Transaction Price Allocated to the Remaining Performance Obligation
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained.

Net operating feesIncentive fees
Remainder of 2023$90.0 $33.0 
202478.1 — 
202545.7 — 
202635.6 — 
202731.2 — 
202829.8 — 
Thereafter83.6 — 
Total$394.0 $33.0 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Accounts Receivable and Allowance for Credit Losses (Tables)
3 Months Ended
Mar. 31, 2023
Receivables [Abstract]  
Schedule of Allowance for Credit Losses
Movements in the allowance for credit losses related to accounts receivable are as follows:

 Three Months Ended March 31,
 20232022
Beginning balance (1)$15.2 $2.5 
Provision (recoveries)1.1 — 
Write-offs(0.2)(0.1)
Ending balance (1)$16.1 $2.4 
(1) The 2023 balance includes an allowance for credit losses related to a physician customer of $10.1 million that was established in the third quarter of 2022. Management continues to monitor collections and the financial condition of this customer. No changes were made in the current period.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Debt (Tables)
3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Carrying Values Long-Term Debt
The carrying amounts of debt consist of the following:

March 31, 2023December 31, 2022
Senior Revolver (1)$90.0 $100.0 
Term A Loans1,200.3 1,211.4 
Term B Loan497.5 498.7 
Unamortized discount and issuance costs(22.5)(23.6)
Total debt1,765.3 1,786.5 
Less: Current maturities(58.3)(53.9)
Total long-term debt$1,707.0 $1,732.6 

(1) As of March 31, 2023, the Company had $90.0 million in borrowings, $0.9 million letters of credit outstanding, and $509.1 million of availability under the $600.0 million senior secured revolving credit facility (“Senior Revolver ”).
Scheduled Maturities of Long-term Debt
Scheduled maturities of the Company’s long-term debt are summarized as follows:

Scheduled Maturities
Remainder of 2023$41.5 
202467.0 
202567.0 
2026708.3 
2027430.2 
20285.0 
Thereafter468.8 
Total$1,787.8 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Instruments and Hedging Activities (Tables)
3 Months Ended
Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location
The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:

March 31, 2023December 31, 2022
Foreign currency forward contracts
Prepaid expenses and other current assets$1.1 $0.1 
Other accrued expenses— 0.5 
Total foreign current forward contracts$1.1 $0.6 
Interest rate swaps
Prepaid expenses and other current assets$8.3 $8.7 
Other assets1.6 5.0 
Other accrued expenses— — 
Total interest rate swaps$9.9 $13.7 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation Expense
Total share-based compensation costs that have been included in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) were as follows:
 Three Months Ended March 31,
 20232022
Share-Based Compensation Expense Allocation Details:
Cost of services$6.9 $4.3 
Selling, general and administrative5.4 5.8 
Total share-based compensation expense (1)$12.3 $10.1 
(1) Included in the share-based compensation expense above is $1.8 million of CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense for the three months ended March 31, 2023. See further discussion below.
Schedule of Stock Options Activity
A summary of the options activity during the three months ended March 31, 2023 is shown below:

OptionsWeighted-
Average
Exercise
Price
Outstanding at December 31, 20223,104,413 $3.38 
Granted— — 
Exercised(180,453)3.05 
Canceled/forfeited(45,865)2.59 
Expired— — 
Outstanding at March 31, 20232,878,095 $3.41 
Outstanding, vested and exercisable at March 31, 20232,855,175 $3.26 
Outstanding, vested and exercisable at December 31, 20223,080,069 $3.23 
Schedule of Non-Options Awards Activity A summary of the RSU and PBRSU activity during the three months ended March 31, 2023 is shown below:
Weighted-
Average Grant
Date Fair Value
RSUsPBRSUsRSUPBRSU
Outstanding and unvested at December 31, 20223,232,002 6,876,797 $19.07 $19.48 
Granted192,268 — 10.95 — 
Performance factor adjustment— 792,189 — 15.95 
Vested(21,705)(2,286,886)20.21 15.95 
Forfeited(110,733)(455,875)20.56 20.28 
Outstanding and unvested at March 31, 20233,291,832 4,926,225 $18.54 $20.48 
Shares surrendered for taxes for the three months ended March 31, 2023
6,908 903,658 
Cost of shares surrendered for taxes for the three months ended March 31, 2023 (in millions)
$0.1 $13.1 
Shares surrendered for taxes for the three months ended March 31, 2022
2,198 725,570 
Cost of shares surrendered for taxes for the three months ended March 31, 2022 (in millions)
$— $18.7 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Other Expenses (Tables)
3 Months Ended
Mar. 31, 2023
Other Income and Expenses [Abstract]  
Schedule of Other Expenses The following table summarizes the other expenses recognized for the three months ended March 31, 2023 and 2022.
Three Months Ended March 31,
 20232022
Business acquisition costs (1)$0.1 $6.3 
Integration costs (2)15.8 0.4 
Strategic initiatives (3)8.0 0.3 
Global business services center expansion project in the Philippines (4)— 3.1 
Facility-exit charges (5)1.2 4.8 
Other (6)5.1 2.2 
Total other expenses$30.2 $17.1 
(1) These are costs, including legal, consulting, and bank fees, that are directly related to the closing of business acquisitions and include changes to contingent consideration, if applicable.
(2) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective and to achieve synergies expected from business acquisitions. Costs include consulting fees, IT vendor spend, severance, retention, and certain payroll costs.
(3) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts.
(4) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines was the first new organic global business services center country expansion by the Company in approximately 15 years. The Company completed the expansion project in 2022.
(5) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities.
(6) For the three months ended March 31, 2023 and 2022, other includes $5.5 million and $1.1 million, respectively, of expenses related to the Company’s ongoing litigation matters. For further details, refer to Note 11, Commitments and Contingencies.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Tables)
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Income (Loss) Per Common Share
Basic and diluted net income per common share are calculated as follows:
Three Months Ended March 31,
 20232022
Net income$0.3 $29.4 
Basic weighted-average common shares417,346,840 278,747,261 
Add: Effect of dilutive equity awards4,621,205 6,472,685 
Add: Effect of dilutive warrants30,957,744 35,823,425 
Diluted weighted average common shares452,925,789 321,043,371 
Net income per common share (basic)$— $0.11 
Net income per common share (diluted)$— $0.09 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Segments and Customer Concentrations (Tables)
3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Schedule of Customer Concentration, Net Services Revenue
Customers comprising greater than 10% of net services revenue are as follows:
Three Months Ended March 31,
Customer Name20232022
Ascension and its affiliates40 %56 %
Intermountain Healthcare11 %14 %
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Financial Information (Tables)
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary Depreciation and Amortization Expense
The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:
 Three Months Ended March 31,
 20232022
Cost of services$15.5 $11.5 
Selling, general and administrative0.4 0.3 
Total depreciation and amortization$15.9 $11.8 
Schedule of Cash Flow, Supplemental Cash Flow Information
Supplemental cash flow information related to leases are as follows:

Three Months Ended March 31,
20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$6.2 $3.4 
Right-of-use assets obtained in exchange for operating lease obligations:3.1 6.0 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 21, 2022
USD ($)
Aug. 31, 2022
USD ($)
Aug. 31, 2020
payment
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2022
Cloudmed            
Business Acquisition [Line Items]            
Total purchase consideration $ 3,281.6          
Decrease in deferred income tax liability       $ 9.8    
Decrease in goodwill       $ 9.8    
RevWorks            
Business Acquisition [Line Items]            
Payments to acquire business   $ 12.5     $ 12.5  
Number of deferred payments | payment     2      
Payments to acquire business, number of payments, refund period, if circumstances met     2 years      
Cloudmed | Cloudmed            
Business Acquisition [Line Items]            
Lock-up period           18 months
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Jun. 21, 2022
Mar. 31, 2023
Dec. 31, 2022
Allocation of consideration to assets acquired and liabilities assumed:      
Goodwill   $ 2,648.5 $ 2,658.2
Cloudmed      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Total purchase consideration $ 3,281.6    
Allocation of consideration to assets acquired and liabilities assumed:      
Cash and cash equivalents 32.1    
Accounts receivable 61.8    
Current portion of contract assets 68.2    
Property, equipment and software 5.0    
Operating lease right-of-use assets 25.3    
Non-current portion of contract assets 23.8    
Intangible assets 1,366.6    
Goodwill 2,093.9    
Other assets 6.7    
Accounts payable (31.9)    
Customer liabilities (3.3)    
Accrued compensation and benefits (93.4)    
Operating lease liabilities (25.4)    
Deferred income tax liabilities (235.6)    
Other liabilities (12.2)    
Net assets acquired $ 3,281.6    
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Pro Forma Results (Details) - Cloudmed and VisitPay Acquisitions
$ in Millions
3 Months Ended
Mar. 31, 2022
USD ($)
Business Acquisition [Line Items]  
Net services revenue $ 486.4
Net income $ 1.4
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Net services revenue $ 545.6 $ 385.7
Net operating fees    
Disaggregation of Revenue [Line Items]    
Net services revenue 361.0 322.8
Incentive fees    
Disaggregation of Revenue [Line Items]    
Net services revenue 23.6 30.2
Modular and other    
Disaggregation of Revenue [Line Items]    
Net services revenue 161.0 $ 32.7
Cloudmed    
Disaggregation of Revenue [Line Items]    
Net services revenue $ 125.8  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Schedule of Contract Balances (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Contract assets, net    
Current $ 81.8 $ 83.9
Non-current 37.3 32.0
Total contract assets, net 119.1 115.9
Contract liabilities    
Current 11.0 9.7
Non-current 18.4 18.7
Total contract liabilities 29.4 28.4
Current portion of customer liabilities 8.8 7.6
Non-current portion of customer liabilities 5.2 5.0
Investor    
Contract liabilities    
Current portion of customer liabilities 2.2 2.1
Non-current portion of customer liabilities $ 13.2 $ 13.7
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Changes to Contract Assets (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2023
USD ($)
Contract with Customer, Asset [Roll Forward]  
Balance as of December 31, 2022 $ 115,900
Revenue recognized 86,000
Amounts billed (82,600)
Other (200)
Balance as of March 31, 2023 119,100
Contract with Customer, Liabilities [Roll Forward]  
Balance as of December 31, 2022 (28,400)
Advanced billings (91,300)
Advanced billings recognized 91,300
Additions (3,900)
Revenue recognized 2,900
Balance as of March 31, 2023 $ (29,400)
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details)
$ in Millions
Mar. 31, 2023
USD ($)
Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 394.0
Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 33.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 90.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 33.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 78.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 45.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 35.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 31.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 29.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 83.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Sep. 30, 2022
Mar. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Beginning balance $ 15.2   $ 2.5
Provision (recoveries) 1.1   0.0
Write-offs (0.2)   (0.1)
Ending balance 16.1   2.4
Increase in allowance $ 1.1   $ 0.0
Physician Customer      
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Provision (recoveries)   $ 10.1  
Increase in allowance   $ 10.1  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Accounts Receivable and Allowance for Credit Losses - Narratives (Details)
$ in Millions
Mar. 31, 2023
USD ($)
Receivables [Abstract]  
Contract assets, allowance $ 2.6
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Carrying Amounts of Debt (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Long-term debt $ 1,787.8  
Unamortized discount and issuance costs (22.5) $ (23.6)
Total debt 1,765.3 1,786.5
Less: Current maturities (58.3) (53.9)
Total long-term debt 1,707.0 1,732.6
Line of Credit | Senior Revolver    
Debt Instrument [Line Items]    
Long-term debt 90.0 100.0
Borrowing availability 509.1  
Line of Credit | Term A Loans    
Debt Instrument [Line Items]    
Long-term debt 1,200.3 1,211.4
Line of Credit | Term B Loan    
Debt Instrument [Line Items]    
Long-term debt 497.5 $ 498.7
Line of Credit | Letters of Credit    
Debt Instrument [Line Items]    
Long-term debt $ 0.9  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Narrative (Details) - Line of Credit - Second A&R Credit Agreement - USD ($)
Mar. 31, 2023
Jun. 21, 2022
Debt Instrument [Line Items]    
Debt covenant, secured obligation pledged, capital stock of certain domestic subsidiaries, percent   100.00%
Term A Loans    
Debt Instrument [Line Items]    
Interest rate 7.31%  
Existing Term A Loan    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity   $ 691,300,000
Incremental Term A Loan    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity   540,000,000
Term B Loan    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity   500,000,000
Interest rate 7.81%  
Senior Revolver    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity   600,000,000
Debt issuance costs incurred   7,200,000
Debt issuance costs, capitalized   $ 6,400,000
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Scheduled Maturities of Long-Term Debt (Details)
$ in Millions
Mar. 31, 2023
USD ($)
Debt Disclosure [Abstract]  
Remainder of 2023 $ 41.5
2024 67.0
2025 67.0
2026 708.3
2027 430.2
2028 5.0
Thereafter 468.8
Total $ 1,787.8
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Financial Instruments - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Jul. 05, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Derivative [Line Items]        
Accumulated gain, net of tax, recognized in other comprehensive loss   $ 8,200,000   $ 9,900,000
Third Party        
Derivative [Line Items]        
Potential business combination, expected purchase price $ 150,000,000      
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Hedges        
Derivative [Line Items]        
Unrealized gains reported in accumulated other comprehensive loss   1,100,000    
Gains to be reclassified within next 12 months   1,100,000    
Derivatives, net gain (loss) reclassified   300,000 $ 200,000  
Notional amount   90,200,000    
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps        
Derivative [Line Items]        
Unrealized gains reported in accumulated other comprehensive loss   9,900,000    
Gains to be reclassified within next 12 months   8,300,000    
Derivatives, net gain (loss) reclassified   1,900,000 $ (300,000)  
Notional amount   $ 500,000,000    
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) - Cash Flow Hedging - Designated as Hedging Instrument - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Foreign currency forward contracts    
Derivative [Line Items]    
Derivative asset, current $ 1.1 $ 0.1
Derivative liability 0.0 0.5
Derivative, fair value, net 1.1 0.6
Interest rate swaps    
Derivative [Line Items]    
Derivative asset, current 8.3 8.7
Derivative asset, noncurrent 1.6 5.0
Derivative liability 0.0 0.0
Derivative, fair value, net $ 9.9 $ 13.7
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Jun. 21, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense   $ 12.3 $ 10.1  
Related tax benefits   2.6 1.8  
Income tax benefit   $ 0.5 $ 2.5  
RSUs and PBRSUs | Cloudmed        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Replacement awards issued to Cloudmed equity award holders (in shares)       3,173,184
RSUs | Cloudmed        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Replacement awards issued to Cloudmed equity award holders (in shares)       1,536,220
PBRSUs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Maximum exercisable (in shares)   9,852,450    
PBRSUs | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares vesting if targets conditions met, potential percentage   0.00%    
PBRSUs | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares vesting if targets conditions met, potential percentage   200.00%    
Former Class P Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of units converted in Transaction Agreement (in shares) 97,875      
Management Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Nonvested award, cost not yet recognized, period for recognition   4 years    
Number of units converted in Transaction Agreement (in shares) 514,986      
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Compensation Expense Allocation (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total share-based compensation expense $ 12.3 $ 10.1
CoyCo 2    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Share-based compensation expense capitalized to deferred contract costs 1.8  
Cost of services    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total share-based compensation expense 6.9 4.3
Selling, general and administrative    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total share-based compensation expense $ 5.4 $ 5.8
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Stock Options Activity (Details) - $ / shares
3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Options    
Outstanding at beginning of period (in shares) 3,104,413  
Granted (in shares) 0  
Exercised (in shares) (180,453)  
Canceled/forfeited (in shares) (45,865)  
Expired (in shares) 0  
Outstanding at end of period (in shares) 2,878,095  
Outstanding, vested and exercisable at end of period (in shares) 2,855,175 3,080,069
Weighted- Average Exercise Price    
Outstanding at beginning of period (in dollars per share) $ 3.38  
Granted (in dollars per share) 0  
Exercised (in dollars per share) 3.05  
Canceled/forfeited (in dollars per share) 2.59  
Expired (in dollars per share) 0  
Outstanding at end of period (in dollars per share) 3.41  
Outstanding, vested and exercisable at end of period (in dollars per share) $ 3.26 $ 3.23
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Other Than Stock Options Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
RSUs    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding and unvested at beginning of period (in shares) 3,232,002  
Granted (in shares) 192,268  
Performance factor adjustment (in shares) 0  
Vested (in shares) (21,705)  
Forfeited (in shares) (110,733)  
Outstanding and unvested at end of period (in shares) 3,291,832  
Weighted- Average Grant Date Fair Value    
Outstanding and unvested at beginning of period (in dollars per share) $ 19.07  
Granted (in dollars per share) 10.95  
Performance factor adjustment (in dollars per share) 0  
Vested (in dollars per share) 20.21  
Forfeited (in dollars per share) 20.56  
Outstanding and unvested at end of period (in dollars per share) $ 18.54  
Shares surrendered for taxes (in shares) 6,908 2,198
Cost of shares surrendered for taxes $ 0.1 $ 0.0
PBRSUs    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding and unvested at beginning of period (in shares) 6,876,797  
Granted (in shares) 0  
Performance factor adjustment (in shares) 792,189  
Vested (in shares) (2,286,886)  
Forfeited (in shares) (455,875)  
Outstanding and unvested at end of period (in shares) 4,926,225  
Weighted- Average Grant Date Fair Value    
Outstanding and unvested at beginning of period (in dollars per share) $ 19.48  
Granted (in dollars per share) 0  
Performance factor adjustment (in dollars per share) 15.95  
Vested (in dollars per share) 15.95  
Forfeited (in dollars per share) 20.28  
Outstanding and unvested at end of period (in dollars per share) $ 20.48  
Shares surrendered for taxes (in shares) 903,658 725,570
Cost of shares surrendered for taxes $ 13.1 $ 18.7
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Other Expenses - Schedule of Other Expenses (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Other Income and Expenses [Abstract]    
Business acquisition costs $ 0.1 $ 6.3
Integration costs 15.8 0.4
Strategic initiatives 8.0 0.3
Global business services center expansion project in the Philippines 0.0 3.1
Facility-exit charges 1.2 4.8
Other 5.1 2.2
Total other expenses $ 30.2 17.1
Number of years since new country entry 15 years  
Litigation expenses $ 5.5 $ 1.1
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Federal statutory tax rate 21.00%  
Statute of limitations minimum 3 years  
Statute of limitations maximum 6 years  
Gross deferred tax assets   $ 147.6
Deferred tax assets related to operating loss carryforwards   $ 50.0
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Earnings Per Share [Abstract]    
Net income (loss) available to common stockholders, basic $ 0.3 $ 29.4
Net income (loss) available to common stockholders, diluted $ 0.3 $ 29.4
Basic weighted-average common shares (in shares) 417,346,840 278,747,261
Add: Effect of dilutive equity awards (in shares) 4,621,205 6,472,685
Add: Effect of dilutive warrants (in shares) 30,957,744 35,823,425
Diluted weighted average common shares (in shares) 452,925,789 321,043,371
Net income per common share (basic) (in dollars per share) $ 0 $ 0.11
Net income per common share (diluted) (in dollars per share) $ 0 $ 0.09
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share - Narrative (Details) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Earnings Per Share [Abstract]    
Antidilutive common share equivalents (in shares) 768,030 43,206
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies - Narrative (Details)
Apr. 19, 2021
claim
TCP-ASC Recapitalization Litigation | Pending Litigation  
Loss Contingencies [Line Items]  
Number of complaints filed 2
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Segments and Customer Concentrations - Narrative (Details) - segment
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Number of operating segments 1  
Number of reporting segments 1  
Customer Concentration Risk | Accounts Receivable | Ascension and its affiliates    
Segment Reporting Information [Line Items]    
Concentration percentage 10.00% 10.00%
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Segments and Customer Concentrations - Concentration Risk by Customer (Details) - Revenue - Customer Concentration Risk
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Ascension and its affiliates    
Concentration Risk [Line Items]    
Concentration percentage 40.00% 56.00%
Intermountain Healthcare    
Concentration Risk [Line Items]    
Concentration percentage 11.00% 14.00%
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Line Items]    
Total depreciation and amortization $ 15.9 $ 11.8
Cost of services    
Property, Plant and Equipment [Line Items]    
Total depreciation and amortization 15.5 11.5
Selling, general and administrative    
Property, Plant and Equipment [Line Items]    
Total depreciation and amortization $ 0.4 $ 0.3
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Financial Information - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Intangible asset amortization expense $ 50.1 $ 7.1
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Financial Information - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows for operating leases $ 6.2 $ 3.4
Right-of-use assets obtained in exchange for operating lease obligations $ 3.1 $ 6.0
XML 74 ah-20230331_htm.xml IDEA: XBRL DOCUMENT 0001910851 2023-01-01 2023-03-31 0001910851 2023-04-28 0001910851 2023-03-31 0001910851 2022-12-31 0001910851 srt:AffiliatedEntityMember 2023-03-31 0001910851 srt:AffiliatedEntityMember 2022-12-31 0001910851 2022-01-01 2022-03-31 0001910851 us-gaap:CommonStockMember 2022-12-31 0001910851 us-gaap:TreasuryStockCommonMember 2022-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001910851 us-gaap:RetainedEarningsMember 2022-12-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001910851 ah:CoyCo2Member us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001910851 ah:CoyCo2Member 2023-01-01 2023-03-31 0001910851 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001910851 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001910851 us-gaap:CommonStockMember 2023-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2023-03-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001910851 us-gaap:RetainedEarningsMember 2023-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001910851 us-gaap:CommonStockMember 2021-12-31 0001910851 us-gaap:TreasuryStockCommonMember 2021-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001910851 us-gaap:RetainedEarningsMember 2021-12-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001910851 2021-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001910851 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001910851 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001910851 us-gaap:CommonStockMember 2022-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2022-03-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001910851 us-gaap:RetainedEarningsMember 2022-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001910851 2022-03-31 0001910851 ah:SeniorTermLoanMember 2023-01-01 2023-03-31 0001910851 ah:SeniorTermLoanMember 2022-01-01 2022-03-31 0001910851 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-03-31 0001910851 us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-03-31 0001910851 ah:CloudmedAcquisitionMember ah:CloudmedMember 2022-01-01 2022-12-31 0001910851 ah:CloudmedAcquisitionMember 2022-06-21 2022-06-21 0001910851 ah:CloudmedAcquisitionMember 2022-06-21 0001910851 ah:CloudmedAcquisitionMember 2022-01-01 2022-03-31 0001910851 ah:RevWorksAcquisitionMember 2021-07-01 2021-09-30 0001910851 ah:RevWorksAcquisitionMember 2022-08-01 2022-08-31 0001910851 ah:RevWorksAcquisitionMember 2020-08-31 0001910851 ah:RevWorksAcquisitionMember 2020-08-01 2020-08-31 0001910851 ah:CloudmedAndVisitPayAcquisitionsMember 2022-01-01 2022-03-31 0001910851 ah:NetOperatingFeesMember 2023-01-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2022-01-01 2022-03-31 0001910851 ah:IncentiveFeesMember 2023-01-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2022-01-01 2022-03-31 0001910851 ah:ModularAndOtherMember 2023-01-01 2023-03-31 0001910851 ah:ModularAndOtherMember 2022-01-01 2022-03-31 0001910851 ah:CloudmedMember 2023-01-01 2023-03-31 0001910851 us-gaap:InvestorMember 2023-03-31 0001910851 us-gaap:InvestorMember 2022-12-31 0001910851 ah:NetOperatingFeesMember 2023-04-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2023-04-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2024-01-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2024-01-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2025-01-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2025-01-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2026-01-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2026-01-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2027-01-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2027-01-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2028-01-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2028-01-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2029-01-01 2023-03-31 0001910851 ah:IncentiveFeesMember 2029-01-01 2023-03-31 0001910851 ah:NetOperatingFeesMember 2023-03-31 0001910851 ah:IncentiveFeesMember 2023-03-31 0001910851 2023-04-01 2023-03-31 0001910851 2024-01-01 2023-03-31 0001910851 2025-01-01 2023-03-31 0001910851 2026-01-01 2023-03-31 0001910851 2027-01-01 2023-03-31 0001910851 2028-01-01 2023-03-31 0001910851 2029-01-01 2023-03-31 0001910851 ah:PhysicianCustomerMember 2022-07-01 2022-09-30 0001910851 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-03-31 0001910851 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001910851 ah:SeniorSecuredTermLoanAMember us-gaap:LineOfCreditMember 2023-03-31 0001910851 ah:SeniorSecuredTermLoanAMember us-gaap:LineOfCreditMember 2022-12-31 0001910851 ah:SeniorSecuredTermLoanBMember us-gaap:LineOfCreditMember 2023-03-31 0001910851 ah:SeniorSecuredTermLoanBMember us-gaap:LineOfCreditMember 2022-12-31 0001910851 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2023-03-31 0001910851 us-gaap:RevolvingCreditFacilityMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:ExistingSeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:IncrementalSeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:SeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2023-03-31 0001910851 ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2023-03-31 0001910851 ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-03-31 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-03-31 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001910851 2022-01-01 2022-12-31 0001910851 ah:ThirdPartyMember 2022-07-05 2022-07-05 0001910851 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001910851 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001910851 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001910851 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001910851 ah:CoyCo2Member 2023-01-01 2023-03-31 0001910851 ah:ManagementUnitsMember 2023-01-01 2023-03-31 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001910851 us-gaap:PerformanceSharesMember 2022-12-31 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001910851 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001910851 us-gaap:PerformanceSharesMember 2023-03-31 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001910851 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0001910851 us-gaap:RestrictedStockUnitsRSUMember ah:CloudmedAcquisitionMember 2022-01-01 2022-12-31 0001910851 ah:RestrictedStockUnitsRSUsAndPerformanceSharesMember ah:CloudmedAcquisitionMember 2022-01-01 2022-12-31 0001910851 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001910851 srt:MaximumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001910851 ah:FormerClassPUnitsMember 2022-06-21 2022-06-21 0001910851 ah:ManagementUnitsMember 2022-06-21 2022-06-21 0001910851 ah:TCPASCRecapitalizationLitigationMember us-gaap:PendingLitigationMember 2021-04-13 2021-04-19 0001910851 ah:AscensionMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001910851 ah:AscensionMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001910851 ah:CustomerNotAffiliatedwithAscensionHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001910851 ah:CustomerNotAffiliatedwithAscensionHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001910851 ah:AscensionMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001910851 ah:AscensionMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 shares iso4217:USD iso4217:USD shares ah:payment pure ah:claim ah:segment false 2023 Q1 0001910851 --12-31 R1 RCM Inc. /DE P9M P1Y P1Y P1Y P1Y P1Y P3Y 10-Q true 2023-03-31 false 001-41428 DE 87-4340782 433 W. Ascension Way 84123 Suite 200 Murray UT 312 324-7820 Common stock, par value $0.01 per share RCM NASDAQ Yes Yes Large Accelerated Filer false false false 418202601 104200000 110100000 16000000 15100000 229400000 235200000 100000 100000 24900000 25000000.0 81800000 83900000 105200000 110300000 545500000 564500000 173800000 164800000 81000000.0 80500000 37300000 32000000.0 28200000 26700000 1464400000 1514500000 2648500000 2658200000 10500000 10400000 83400000 88200000 5072600000 5139800000 24600000 33400000 45600000 57500000 9400000 7400000 84700000 109000000.0 18800000 18000000.0 58300000 53900000 76700000 70600000 318100000 349800000 5200000 5000000.0 13200000 13700000 92700000 94400000 1707000000 1732600000 192100000 200700000 24900000 23100000 2353200000 2419300000 0.01 0.01 750000000 442439169 418176363 750000000 439950125 416597885 4400000 4400000 3136200000 3123200000 -121600000 -121900000 -4600000 -3400000 24262806 23352240 295000000.0 281800000 2719400000 2720500000 5072600000 5139800000 216800000 216700000 545600000 385700000 434700000 296500000 47000000.0 28900000 30200000 17100000 511900000 342500000 33700000 43200000 -30700000 -4700000 3000000.0 38500000 2700000 9100000 300000 29400000 0 0.11 0 0.09 417346840 278747261 452925789 321043371 300000 29400000 -1700000 100000 500000 -1400000 -1200000 -1300000 -900000 28100000 439950125 4400000 23352240 -281800000 3123200000 -121900000 -3400000 2720500000 10700000 10700000 1800000 1800000 2308591 180453 500000 500000 910566 13200000 13200000 500000 -1700000 -1700000 500000 500000 300000 300000 442439169 4400000 24262806 -295000000.0 3136200000 -121600000 -4600000 2719400000 298320928 3000000.0 20094686 -215200000 628500000 -64300000 -5300000 346700000 10200000 10200000 1757955 77438 400000 400000 727768 18700000 18700000 8000 200000 200000 0 100000 100000 -1400000 -1400000 29400000 29400000 300156321 3000000.0 20830454 -234100000 639100000 -34900000 -6600000 366500000 300000 29400000 66000000.0 18900000 1400000 300000 10500000 10100000 1800000 0 0 -2000000.0 1500000 0 1800000 7300000 2900000 3200000 0 -1500000 -4700000 -22100000 4000000.0 0 -8200000 20500000 -10900000 3200000 -24500000 -27500000 -4400000 -2100000 9700000 1700000 -10300000 -18700000 54700000 30900000 23400000 10000000.0 2200000 0 -25600000 -10000000.0 12400000 4400000 10000000.0 0 500000 400000 0 600000 13400000 21500000 -100000 -100000 -35400000 -26200000 400000 -900000 -5900000 -6200000 110100000 130100000 104200000 123900000 28000000.0 23300000 Business Description and Basis of Presentation<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Description</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of March 31, 2023, the results of operations of the Company for the three months ended March 31, 2023 and 2022, and the cash flows of the Company for the three months ended March 31, 2023 and 2022. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements included in the Company’s 2022 Form 10-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards and Disclosures</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.</span></div> <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of March 31, 2023, the results of operations of the Company for the three months ended March 31, 2023 and 2022, and the cash flows of the Company for the three months ended March 31, 2023 and 2022. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2023.</span></div>When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards and Disclosures</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.</span></div> AcquisitionsAssets acquired and liabilities assumed in a business combination are recorded at their estimated fair value on the date of the acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prior Acquisitions</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company acquired the following business:</span></div><div style="text-indent:18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"/><td style="width:27.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.789%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Acquisition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revint Holdings, LLC (“Cloudmed”)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider of revenue intelligence solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased all outstanding equity interests in exchange for shares of common stock of the Company and cash. The shares of common stock received by the Cloudmed sellers are subject to an 18-month lock-up period, which expires December 21, 2023. In addition, the Company replaced certain pre-acquisition awards held by certain Cloudmed sellers with restricted stock units (“RSUs”) of the Company.</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price has been provisionally allocated to assets acquired and liabilities assumed based on their fair value as of the acquisition date. The fair value estimate of assets acquired and liabilities assumed is pending the completion of various elements, including gathering further information to ensure the completeness of assets acquired and liabilities assumed and the finalization of an independent appraisal of their respective fair values, which is subject to final review by the Company’s management. Accordingly, management considers the balances shown in the following table to be preliminary, and there could be adjustments to the consolidated financial statements, including changes in our amortization expense related to the valuation of intangible assets acquired and their respective useful lives, among other adjustments. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary fair value of assets acquired and liabilities assumed is:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.217%"><tr><td style="width:1.0%"/><td style="width:72.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.294%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,281.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation of consideration to assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,366.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,093.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,281.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement period adjustments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had various measurement period adjustments due to additional information received since December 31, 2022. The significant adjustments included a reduction to deferred income tax liabilities and a corresponding decrease to goodwill of $9.8 million related to updated tax return information.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RevWorks</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company purchased certain assets relating to the RevWorks services business from Cerner Corporation. In accordance with the purchase agreement, the Company paid the first deferred payment of $12.5 million in the third quarter of 2021. The remaining deferred payment of $12.5 million was payable on the second anniversary of the closing date (August 2022) and is included in other accrued expenses on the Consolidated Balance Sheet as of March 31, 2023 as it had not been paid as of such date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two deferred payments related to the RevWorks acquisition were contractual obligations of the Company; however, they are refundable to the Company if certain RevWorks customer revenue targets defined in the purchase agreement for the first two years following the acquisition are not achieved.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties are currently engaged in arbitration to finalize the remaining deferred payment and contingently refundable consideration amounts. The contingently refundable consideration is stated at an amount approximating the amount expected to be realized and is included in other current assets on the Consolidated Balance Sheet as of March 31, 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pro Forma Results</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed acquisition had occurred as of January 1, 2021.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.897%"><tr><td style="width:1.0%"/><td style="width:37.584%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:58.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments were made to earnings to adjust depreciation and amortization to reflect the fair value of identified assets acquired, to adjust share-based compensation expense for awards granted in connection with the acquisition, to record the effects of extinguishing the debt of the acquired company and replacing it with the debt of the Company, to adjust timing of acquisition related costs incurred by the Company, and to record the income tax effect of these adjustments.</span></div> <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company acquired the following business:</span></div><div style="text-indent:18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"/><td style="width:27.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.789%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Acquisition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revint Holdings, LLC (“Cloudmed”)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider of revenue intelligence solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased all outstanding equity interests in exchange for shares of common stock of the Company and cash. The shares of common stock received by the Cloudmed sellers are subject to an 18-month lock-up period, which expires December 21, 2023. In addition, the Company replaced certain pre-acquisition awards held by certain Cloudmed sellers with restricted stock units (“RSUs”) of the Company.</span></div></td></tr></table></div> P18M <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary fair value of assets acquired and liabilities assumed is:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.217%"><tr><td style="width:1.0%"/><td style="width:72.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.294%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,281.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation of consideration to assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,366.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,093.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,281.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3281600000 32100000 61800000 68200000 5000000.0 25300000 23800000 1366600000 2093900000 6700000 31900000 3300000 93400000 25400000 235600000 12200000 3281600000 -9800000 -9800000 12500000 12500000 2 P2Y <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed acquisition had occurred as of January 1, 2021.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pro forma results are not necessarily indicative of the actual consolidated results had the acquisition occurred as of that date or of the future consolidated operating results for any period. Pro forma results are:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.897%"><tr><td style="width:1.0%"/><td style="width:37.584%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:58.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 486400000 1400000 Revenue RecognitionRevenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved. Revenue Recognition<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the following table, revenue is disaggregated by source of revenue: </span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.967%"><tr><td style="width:1.0%"/><td style="width:37.383%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Modular and other (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Modular and other revenue primarily consists of $125.8 million in service fees related to Cloudmed for the three months ended March 31, 2023, revenue integrity solutions, practice management (“PM”) services, physician advisory services (“PAS”), and software subscription revenue. </span></div><div style="padding-left:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about contract assets, net and contract liabilities from contracts with customers:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.051%"><tr><td style="width:1.0%"/><td style="width:45.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Current contract liabilities include $8.8 million and $7.6 million classified in the current portion of customer liabilities and $2.2 million and $2.1 million classified in the current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Non-current contract liabilities include $5.2 million and $5.0 million classified in the non-current portion of customer liabilities and $13.2 million and $13.7 million classified in the non-current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract assets, net balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets, net for the three months ended March 31, 2023 were as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"/><td style="width:52.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts billed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Other primarily includes adjustments made during the period to the allowance for credit losses.</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.897%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced billings - January 1, 2023 (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced billings recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Company records advanced billings to contract liabilities and accounts receivable on the first day of the respective service period, which are earned during the quarter.</span></div><div style="padding-left:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"/><td style="width:34.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.004%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incentive fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">    </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts presented in the table above include variable fee estimates of the Company’s physician groups revenue cycle management (“RCM”) services contracts, fixed fees, and forecasted incentive fees. Fixed fees are typically recognized ratably as the performance obligation is satisfied and forecasted incentive fees are measured cumulatively over the contractually defined performance period.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates of revenue expected to be recognized in future periods exclude unexercised customer options to purchase services within the Company’s PAS contracts that do not represent material rights to the customer. </span></div>The Company does not disclose information about remaining performance obligations with an original expected duration of one year or less and has elected an exemption to the disclosure requirements related to estimate variable consideration and an exemption where the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date. In the following table, revenue is disaggregated by source of revenue: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.967%"><tr><td style="width:1.0%"/><td style="width:37.383%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Modular and other (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1) Modular and other revenue primarily consists of $125.8 million in service fees related to Cloudmed for the three months ended March 31, 2023, revenue integrity solutions, practice management (“PM”) services, physician advisory services (“PAS”), and software subscription revenue. 361000000.0 322800000 23600000 30200000 161000000.0 32700000 545600000 385700000 125800000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about contract assets, net and contract liabilities from contracts with customers:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.051%"><tr><td style="width:1.0%"/><td style="width:45.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Current contract liabilities include $8.8 million and $7.6 million classified in the current portion of customer liabilities and $2.2 million and $2.1 million classified in the current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Non-current contract liabilities include $5.2 million and $5.0 million classified in the non-current portion of customer liabilities and $13.2 million and $13.7 million classified in the non-current portion of customer liabilities - related party as of March 31, 2023 and December 31, 2022, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract assets, net balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets, net for the three months ended March 31, 2023 were as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"/><td style="width:52.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts billed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Other primarily includes adjustments made during the period to the allowance for credit losses.</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.897%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced billings - January 1, 2023 (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced billings recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Company records advanced billings to contract liabilities and accounts receivable on the first day of the respective service period, which are earned during the quarter.</span></div> 81800000 83900000 37300000 32000000.0 119100000 115900000 11000000.0 9700000 18400000 18700000 29400000 28400000 8800000 7600000 2200000 2100000 5200000 5000000 13200000 13700000 115900000 86000000.0 82600000 -200000 119100000 28400000 91300000 91300000 3900000 2900000 29400000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"/><td style="width:34.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.004%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incentive fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 90000000.0 33000000.0 78100000 0 45700000 0 35600000 0 31200000 0 29800000 0 83600000 0 394000000.0 33000000.0 Accounts Receivable and Allowance for Credit LossesAccounts receivable is comprised of invoiced and unbilled balances due from modular services and end-to-end RCM customers, which are presented net after considering cost reimbursements owed to end-to-end RCM customers.<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and business and industry factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the allowance for credit losses related to accounts receivable are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.551%"><tr><td style="width:1.0%"/><td style="width:63.646%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (recoveries)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The 2023 balance includes an allowance for credit losses related to a physician customer of $10.1 million that was established in the third quarter of 2022. Management continues to monitor collections and the financial condition of this customer. No changes were made in the current period. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired contract assets through the Cloudmed acquisition. As of March 31, 2023, there was an allowance for credit losses of $2.6 million against total contract assets.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the allowance for credit losses related to accounts receivable are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.551%"><tr><td style="width:1.0%"/><td style="width:63.646%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (recoveries)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) The 2023 balance includes an allowance for credit losses related to a physician customer of $10.1 million that was established in the third quarter of 2022. Management continues to monitor collections and the financial condition of this customer. No changes were made in the current period. 15200000 2500000 1100000 0 200000 100000 16100000 2400000 10100000 2600000 Debt<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of debt consist of the following:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"/><td style="width:53.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.918%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.920%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Revolver (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A Loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) As of March 31, 2023, the Company had $90.0 million in borrowings, $0.9 million letters of credit outstanding, and $509.1 million of availability under the $600.0 million senior secured revolving credit facility (“Senior Revolver ”).</span></div><div style="padding-right:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Amended and Restated Senior Secured Credit Facilities</span></div><div style="padding-right:22.5pt"><span><br/></span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, the Company, R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), and certain of its subsidiaries entered into a second amended and restated senior credit agreement (the “Second A&amp;R Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan,” and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan,” and together with the Term A Loans, the “Senior Term Loans”), and the $600.0 million Senior Revolver. In conjunction with entering into the Second A&amp;R Credit Agreement, the Company incurred $7.2 million and capitalized $6.4 million of debt issuance costs.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate as of March 31, 2023 was 7.31%</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the Term A Loans and Senior Revolver and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.81% for the Term B Loan.</span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second A&amp;R Credit Agreement contains a number of financial and non-financial covenants. The Company was in compliance with all of the covenants in the Second A&amp;R Credit Agreement as of March 31, 2023. The obligations under the Second A&amp;R Credit Agreement are secured by a pledge of 100% of the capital stock of certain domestic subsidiaries owned by the Company and a security interest in substantially all of the Company’s tangible and intangible assets and the tangible and intangible assets of certain domestic subsidiaries.</span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Maturities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of the Company’s long-term debt are summarized as follows:</span></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.346%"><tr><td style="width:1.0%"/><td style="width:46.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Maturities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further details on the Second A&amp;R Credit Agreement, refer to Note 10 of the Company’s 2022 Form 10-K.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of debt consist of the following:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"/><td style="width:53.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.918%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.920%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Revolver (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A Loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) As of March 31, 2023, the Company had $90.0 million in borrowings, $0.9 million letters of credit outstanding, and $509.1 million of availability under the $600.0 million senior secured revolving credit facility (“Senior Revolver ”).</span></div> 90000000.0 100000000.0 1200300000 1211400000 497500000 498700000 22500000 23600000 1765300000 1786500000 58300000 53900000 1707000000 1732600000 90000000 900000 509100000 600000000 691300000 540000000 500000000 600000000 7200000 6400000 0.0731 0.0781 1 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of the Company’s long-term debt are summarized as follows:</span></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.346%"><tr><td style="width:1.0%"/><td style="width:46.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Maturities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 41500000 67000000.0 67000000.0 708300000 430200000 5000000.0 468800000 1787800000 Derivative Financial Instruments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes cash flow hedges to manage its currency risk arising from its global business services centers. As of March 31, 2023, the Company has recorded $1.1 million of unrealized gains in accumulated other comprehensive loss related to foreign currency hedges. The Company estimates that $1.1 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 9 months. Amounts reclassified into cost of services were a net</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gain of $0.3 million and $0.2 million during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company’s foreign currency forward contracts have maturities extending no later than December 31, 2023, and had a total notional value of $90.2 million.</span><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also utilizes cash flow hedges to reduce variability in interest cash flows from its outstanding debt. As of March 31, 2023, the Company has recorded $9.9 million of unrealized gains in accumulated other comprehensive loss related to interest rate swaps. The Company estimates that $8.3 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into interest expense were a net gain of $1.9 million and a net loss of $0.3 million</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company’s interest rate swaps extend no later than June 30, 2025, and had a total notional value of $500.0 million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"/><td style="width:50.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign current forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the accumulated gain, net of tax, recognized in accumulated other comprehensive loss was $8.2 million and $9.9 million, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies cash flows from its derivative programs as cash flows from operating activities in the Consolidated Statements of Cash Flows. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 5, 2022, the Company and Sutter Health (“Sutter”) entered into an agreement regarding the potential purchase of a business that would expand the Company’s service capabilities (the “Sutter Put Right Agreement”). This agreement is effective through approximately the end of 2023 and allows Sutter to sell the business to the Company for $150.0 million, subject to the negotiation of a definitive agreement and the satisfaction of agreed upon closing conditions, including the requirement that the purchase price be deemed to be fair value at the time of the potential transaction. Assuming an agreement is reached, the Company and Sutter would also need to reach agreement as to whether the purchase price would be paid in cash or shares of the Company’s common stock.</span></div> 1100000 1100000 300000 200000 90200000 9900000 8300000 1900000 -300000 500000000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"/><td style="width:50.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign current forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1100000 100000 0 500000 1100000 600000 8300000 8700000 1600000 5000000.0 0 0 9900000 13700000 8200000 9900000 150000000 Share-Based Compensation <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share-based compensation expense relating to the Company’s stock options, RSUs, and performance-based restricted stock units (“PBRSUs”) for the three months ended March 31, 2023 and 2022 was $12.3 million and $10.1 million, respectively, with related tax benefits of approximately $2.6 million and $1.8 million, respectively.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense and included in operating activities. The Company recognized $0.5 million and $2.5 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation costs that have been included in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.955%"><tr><td style="width:1.0%"/><td style="width:72.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.704%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share-Based Compensation Expense Allocation Details:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Included in the share-based compensation expense above is $1.8 million of CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense for the three months ended March 31, 2023. See further discussion below. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. The volatility for the options was calculated based on an analysis of historical volatility. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations. A Monte Carlo simulation was used to estimate the fair value of the Unvested Units (as defined below), which are being amortized over a period of 4 years on a straight-line basis. The volatility for the Unvested Units was calculated based on an analysis of historical and implied volatility.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the options activity during the three months ended March 31, 2023 is shown below:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.929%"><tr><td style="width:1.0%"/><td style="width:64.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104,413 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878,095 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855,175 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080,069 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted stock units and performance-based restricted stock units    </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU and PBRSU activity during the three months ended March 31, 2023 is shown below:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.141%"><tr><td style="width:1.0%"/><td style="width:50.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PBRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PBRSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance factor adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,286,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291,832 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926,225 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the three months ended March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the three months ended March 31, 2023 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the three months ended March 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the three months ended March 31, 2022 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the Cloudmed acquisition, outstanding restricted units of Cloudmed were replaced by an aggregate 1,536,220 RSUs of the Company. The Company also issued an aggregate of 3,173,184 inducement RSUs and PBRSUs to certain employees of Cloudmed under Nasdaq Listing Rule 5635(c)(4) pursuant to its newly adopted 2022 Inducement Plan. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s RSU and PBRSU agreements allow employees to surrender to the Company shares of common stock upon vesting of their RSUs and PBRSUs in lieu of their payment of the required personal employment-related taxes. Shares surrendered for payment of personal employment-related taxes are held in treasury.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding PBRSUs vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, modular sales revenue, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 9,852,450.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CoyCo 2, L.P. Limited Partnership Units    </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the transactions contemplated by the Cloudmed acquisition, equity awards held by certain employees of Cloudmed (“Former Class P Units”) were modified, through a series of transactions, into awards (“Management Units”) of CoyCo 2. The Management Units issued by CoyCo 2 are treated as share-based compensation under ASC 718, Compensation — Stock Compensation.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Former Class P Units were originally issued to employees of Cloudmed and its affiliates (“Participants”) in connection with and as a part of the compensation and incentive arrangements between Cloudmed and such Participants prior to the consummation of the Cloudmed acquisition. A portion of the Former Class P Units immediately vested upon the closing of the Cloudmed acquisition; however, certain Former Class P Units that were subject to performance-based vesting conditions did not become vested upon the closing of the Cloudmed acquisition (“Unvested Units”). In connection with the Cloudmed acquisition, Cloudmed caused the Former Class P Units, including the Unvested Units, to be converted into Management Units. At the time of the closing of the Cloudmed acquisition, 97,875 Unvested Units were converted into 514,986 Management Units.</span></div>In general, Unvested Units vest upon the achievement of certain performance criteria, including achievement by CoyCo 2’s owner, New Mountain Capital, L.L.C. (“New Mountain”), of (i) specified multiples of Base Equity Value (“BEV”) (i.e., generally the aggregate equity value of New Mountain’s investment in Cloudmed as of the original grant date), or (ii) specified Multiples on Invested Capital (“MIC”) with respect to New Mountain Capital’s pre-Cloudmed acquisition investment in Cloudmed, and subject to continued service with the Company and its affiliates, including Cloudmed through the applicable vesting date. The Unvested Units are not awards of the Company and the participants will receive no additional shares of the Company upon satisfaction of the vesting criteria. However, GAAP requires the Company recognize the cost of share-based compensation granted by an investor (CoyCo 2) to the Company’s employees and service providers for services that benefit the Company’s operations (hereafter, “CoyCo 2 share-based compensation expense”), and a corresponding capital contribution because the costs are incurred on the Company’s behalf. 12300000 10100000 2600000 1800000 -500000 -2500000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation costs that have been included in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.955%"><tr><td style="width:1.0%"/><td style="width:72.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.704%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share-Based Compensation Expense Allocation Details:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Included in the share-based compensation expense above is $1.8 million of CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense for the three months ended March 31, 2023. See further discussion below. 6900000 4300000 5400000 5800000 12300000 10100000 1800000 P4Y <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the options activity during the three months ended March 31, 2023 is shown below:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.929%"><tr><td style="width:1.0%"/><td style="width:64.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104,413 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878,095 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855,175 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080,069 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3104413 3.38 0 0 180453 3.05 45865 2.59 0 0 2878095 3.41 2855175 3.26 3080069 3.23 A summary of the RSU and PBRSU activity during the three months ended March 31, 2023 is shown below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.141%"><tr><td style="width:1.0%"/><td style="width:50.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PBRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PBRSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance factor adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,286,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291,832 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926,225 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the three months ended March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the three months ended March 31, 2023 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the three months ended March 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the three months ended March 31, 2022 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table> 3232002 6876797 19.07 19.48 192268 0 10.95 0 0 792189 0 15.95 21705 2286886 20.21 15.95 110733 455875 20.56 20.28 3291832 4926225 18.54 20.48 6908 903658 100000 13100000 2198 725570 0 18700000 1536220 3173184 0 2 9852450 97875 514986 Other Expenses <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the other expenses recognized for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.589%"><tr><td style="width:1.0%"/><td style="width:69.928%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition costs (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration costs (2)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic initiatives (3)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global business services center expansion project in the Philippines (4)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility-exit charges (5)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (6)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) These are costs, including legal, consulting, and bank fees, that are directly related to the closing of business acquisitions and include changes to contingent consideration, if applicable.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective and to achieve synergies expected from business acquisitions. Costs include consulting fees, IT vendor spend, severance, retention, and certain payroll costs. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines was the first new organic global business services center country expansion by the Company in approximately 15 years. The Company completed the expansion project in 2022. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) For the three months ended March 31, 2023 and 2022, other includes $5.5 million and $1.1 million, respectively, of expenses related to the Company’s ongoing litigation matters. For further details, refer to Note 11, Commitments and Contingencies.</span></div> The following table summarizes the other expenses recognized for the three months ended March 31, 2023 and 2022.<div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.589%"><tr><td style="width:1.0%"/><td style="width:69.928%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition costs (1)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration costs (2)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic initiatives (3)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global business services center expansion project in the Philippines (4)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility-exit charges (5)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (6)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) These are costs, including legal, consulting, and bank fees, that are directly related to the closing of business acquisitions and include changes to contingent consideration, if applicable.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective and to achieve synergies expected from business acquisitions. Costs include consulting fees, IT vendor spend, severance, retention, and certain payroll costs. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines was the first new organic global business services center country expansion by the Company in approximately 15 years. The Company completed the expansion project in 2022. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) For the three months ended March 31, 2023 and 2022, other includes $5.5 million and $1.1 million, respectively, of expenses related to the Company’s ongoing litigation matters. For further details, refer to Note 11, Commitments and Contingencies.</span></div> 100000 6300000 15800000 400000 8000000.0 300000 0 3100000 1200000 4800000 5100000 2200000 30200000 17100000 P15Y 5500000 1100000 Income Taxes<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized income tax expense for the three months ended March 31, 2023 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for foreign taxes, state taxes, non-deductible expenses, and discrete items. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized income tax expense for the three months ended March 31, 2022 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible expenses, and discrete items.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2019 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg2NGQ0ZDA1NDQ1MjRiYzZhNjUwM2Y0ZGUyYWM1ZDdjL3NlYzo4NjRkNGQwNTQ0NTI0YmM2YTY1MDNmNGRlMmFjNWQ3Y182Ny9mcmFnOmM3MDVmNWUxNzMyZDQ1ZWViOWNkMWU4ZDljYmY5ZmExL3RleHRyZWdpb246YzcwNWY1ZTE3MzJkNDVlZWI5Y2QxZThkOWNiZjlmYTFfMTc3MA_383960ea-6e3d-4f5d-9893-e85daba1d07c">three</span> to six years. </span></div>At December 31, 2022, the Company had gross deferred tax assets of $147.6 million, of which $50.0 million related to net operating loss (“NOL”) carryforwards. The Company expects to be profitable, allowing the Company to utilize its NOL carryforwards and other deferred tax assets. 0.21 0.21 P6Y 147600000 50000000 Earnings Per Share<div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the weighted average number of common shares outstanding during the period. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share is calculated by adjusting the denominator used in the basic net income per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options and shares issuable upon vesting of RSUs and PBRSUs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per common share are calculated as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.192%"><tr><td style="width:1.0%"/><td style="width:60.315%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,346,840 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,747,261 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Effect of dilutive equity awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Effect of dilutive warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,957,744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,823,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,925,789 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,043,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per common share (basic)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per common share (diluted)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Because of their anti-dilutive effect, 768,030 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three months ended March 31, 2023. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, 43,206</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>common share equivalents have been excluded from the diluted earnings per share calculation because of their anti-dilutive effect. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per common share are calculated as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.192%"><tr><td style="width:1.0%"/><td style="width:60.315%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,346,840 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,747,261 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Effect of dilutive equity awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Effect of dilutive warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,957,744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,823,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,925,789 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,043,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per common share (basic)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per common share (diluted)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 300000 300000 29400000 29400000 417346840 278747261 4621205 6472685 30957744 35823425 452925789 321043371 0 0.11 0 0.09 768030 43206 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC. Both complaints allege that TCP-ASC, Ascension Health (“Ascension”), and TowerBrook Capital Partners (“TowerBrook”) controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contain provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The cases have since been consolidated into a single action. All defendants have answered the complaint and discovery has commenced.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2022, plaintiffs filed a supplement to their complaint, naming certain additional defendants and asserting additional claims related to the Company’s agreement to acquire Cloudmed, which was announced on January 10, 2022. The additional claims assert that: (i) TCP-ASC, Ascension, and TowerBrook, along with the Company’s directors (“Individual Defendants”), breached their fiduciary duties by causing the Company to enter into and approving the Cloudmed acquisition, respectively, which plaintiffs claim will perpetuate TCP-ASC’s, Ascension’s, and TowerBrook’s control over the Company and entrench the Individual Defendants by virtue of certain agreements entered into as part of the transaction, including a Second Amended Investor Rights Agreement with TCP-ASC (the “Seconded Amended Investor Rights Agreement”) and an Investor Rights Agreement with Cloudmed (the “Cloudmed Investor Rights Agreement”); and (ii) Cloudmed’s stockholders aided and abetted such breaches. Plaintiffs also allege that certain provisions in the Cloudmed Investor Rights Agreement and the Second Amended Investor Rights Agreement are void under the Company’s charter, bylaws, and the Delaware General Corporation law. The plaintiffs seek a declaratory judgment and an unspecified amount of damages, as well as attorneys’ fees and costs. Trial is scheduled for November 2023. The Company believes it has meritorious defenses to all claims against it and intends to vigorously defend itself against these claims. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago and was presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties have completed damage and expert discovery. Additional dispositive motions are expected to extend into 2023, with trial, if necessary, likely to be scheduled in 2024. The Company believes it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims.</span></div> 2 Related Party Transactions <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the Master Professional Services Agreement, including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company’s agreements with Ascension, see Note 1 and Note 19 of the Company’s 2022 Form 10-K. In conjunction with the Cloudmed acquisition, New Mountain became a new related party. There were no material transactions with New Mountain subsequent to the Cloudmed acquisition.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net services revenue from services provided to Ascension, as well as corresponding accounts receivable and customer liabilities are presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) and the Consolidated Balance Sheets. Since Ascension is the Company’s largest customer, a significant percentage of the Company’s cost of services is associated with providing services to Ascension. However, due to the nature of the Company’s global business services and information technology operations, it is impractical to assign the dollar amount associated with services provided to Ascension.</span></div> Segments and Customer Concentrations<div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has a single operating segment in accordance with the way that management operates and views the business. All of the Company’s significant operations are organized around the single business of providing management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one operating and reportable segment. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers comprising greater than 10% of net services revenue are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.121%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer Name</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ascension and its affiliates</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intermountain Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of customers within the Ascension health system or Intermountain network could have a material adverse impact on the Company’s operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the Company had a concentration of credit risk with Ascension, representing 10% of accounts receivable.</span></div> 1 1 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers comprising greater than 10% of net services revenue are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.121%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer Name</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ascension and its affiliates</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intermountain Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.40 0.56 0.11 0.14 0.10 0.10 Supplemental Financial Information<div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.455%"><tr><td style="width:1.0%"/><td style="width:56.851%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization expense was $50.1 million and $7.1 million for the three months ended March 31, 2023 and 2022, respectively. Amortization expense for intangible assets is included in cost of services on the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.455%"><tr><td style="width:1.0%"/><td style="width:56.851%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15500000 11500000 400000 300000 15900000 11800000 50100000 7100000 <div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 6200000 3400000 3100000 6000000.0 EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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�+(L"B)^W$#.#TO'=XX3CS3;*C/AQHL=R6 -ZNON0>B1VZ"DM F*6=( MP&;I?/*O5WYD'*S%GQ0.LG6/#)4GSK^9P5VZ=#P3$>20* -!]&4/*\AS@Z3C M^+<&=9IW&L?V_1']LR6OR3P1"2N>_T53M5TZ

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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 138 295 1 false 49 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.r1rcm.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Consolidated Balance Sheets Sheet http://www.r1rcm.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnauditedParenthetical Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 0000009 - Disclosure - Business Description and Basis of Presentation Sheet http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentation Business Description and Basis of Presentation Notes 9 false false R10.htm 0000010 - Disclosure - Acquisitions Sheet http://www.r1rcm.com/role/Acquisitions Acquisitions Notes 10 false false R11.htm 0000011 - Disclosure - Revenue Recognition Sheet http://www.r1rcm.com/role/RevenueRecognition Revenue Recognition Notes 11 false false R12.htm 0000012 - Disclosure - Accounts Receivable and Allowance for Credit Losses Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses Accounts Receivable and Allowance for Credit Losses Notes 12 false false R13.htm 0000013 - Disclosure - Debt Sheet http://www.r1rcm.com/role/Debt Debt Notes 13 false false R14.htm 0000014 - Disclosure - Derivative Financial Instruments Sheet http://www.r1rcm.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 14 false false R15.htm 0000015 - Disclosure - Share-Based Compensation Sheet http://www.r1rcm.com/role/ShareBasedCompensation Share-Based Compensation Notes 15 false false R16.htm 0000016 - Disclosure - Other Expenses Sheet http://www.r1rcm.com/role/OtherExpenses Other Expenses Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://www.r1rcm.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Earnings Per Share Sheet http://www.r1rcm.com/role/EarningsPerShare Earnings Per Share Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and Contingencies Sheet http://www.r1rcm.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Related Party Transactions Sheet http://www.r1rcm.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 0000021 - Disclosure - Segments and Customer Concentrations Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrations Segments and Customer Concentrations Notes 21 false false R22.htm 0000022 - Disclosure - Supplemental Financial Information Sheet http://www.r1rcm.com/role/SupplementalFinancialInformation Supplemental Financial Information Notes 22 false false R23.htm 0000023 - Disclosure - Business Description and Basis of Presentation (Policies) Sheet http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies Business Description and Basis of Presentation (Policies) Policies 23 false false R24.htm 0000024 - Disclosure - Acquisitions (Tables) Sheet http://www.r1rcm.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.r1rcm.com/role/Acquisitions 24 false false R25.htm 0000025 - Disclosure - Revenue Recognition (Tables) Sheet http://www.r1rcm.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.r1rcm.com/role/RevenueRecognition 25 false false R26.htm 0000026 - Disclosure - Accounts Receivable and Allowance for Credit Losses (Tables) Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesTables Accounts Receivable and Allowance for Credit Losses (Tables) Tables http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses 26 false false R27.htm 0000027 - Disclosure - Debt (Tables) Sheet http://www.r1rcm.com/role/DebtTables Debt (Tables) Tables http://www.r1rcm.com/role/Debt 27 false false R28.htm 0000028 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.r1rcm.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables 28 false false R29.htm 0000029 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.r1rcm.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.r1rcm.com/role/ShareBasedCompensation 29 false false R30.htm 0000030 - Disclosure - Other Expenses (Tables) Sheet http://www.r1rcm.com/role/OtherExpensesTables Other Expenses (Tables) Tables http://www.r1rcm.com/role/OtherExpenses 30 false false R31.htm 0000031 - Disclosure - Earnings Per Share (Tables) Sheet http://www.r1rcm.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.r1rcm.com/role/EarningsPerShare 31 false false R32.htm 0000032 - Disclosure - Segments and Customer Concentrations (Tables) Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsTables Segments and Customer Concentrations (Tables) Tables http://www.r1rcm.com/role/SegmentsandCustomerConcentrations 32 false false R33.htm 0000033 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.r1rcm.com/role/SupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.r1rcm.com/role/SupplementalFinancialInformation 33 false false R34.htm 0000034 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.r1rcm.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 34 false false R35.htm 0000035 - Disclosure - Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 35 false false R36.htm 0000036 - Disclosure - Acquisitions - Pro Forma Results (Details) Sheet http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails Acquisitions - Pro Forma Results (Details) Details 36 false false R37.htm 0000037 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) Details 37 false false R38.htm 0000038 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails Revenue Recognition - Schedule of Contract Balances (Details) Details 38 false false R39.htm 0000039 - Disclosure - Revenue Recognition - Changes to Contract Assets (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails Revenue Recognition - Changes to Contract Assets (Details) Details 39 false false R40.htm 0000040 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) Details 40 false false R41.htm 0000041 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) Details 41 false false R42.htm 0000042 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Narratives (Details) Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails Accounts Receivable and Allowance for Credit Losses - Narratives (Details) Details 42 false false R43.htm 0000043 - Disclosure - Debt - Carrying Amounts of Debt (Details) Sheet http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails Debt - Carrying Amounts of Debt (Details) Details 43 false false R44.htm 0000044 - Disclosure - Debt - Narrative (Details) Sheet http://www.r1rcm.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 44 false false R45.htm 0000045 - Disclosure - Debt - Scheduled Maturities of Long-Term Debt (Details) Sheet http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails Debt - Scheduled Maturities of Long-Term Debt (Details) Details 45 false false R46.htm 0000046 - Disclosure - Derivative Financial Instruments - Narrative (Details) Sheet http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails Derivative Financial Instruments - Narrative (Details) Details 46 false false R47.htm 0000047 - Disclosure - Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) Sheet http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) Details 47 false false R48.htm 0000048 - Disclosure - Share-Based Compensation - Narrative (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation - Narrative (Details) Details 48 false false R49.htm 0000049 - Disclosure - Share-Based Compensation - Compensation Expense Allocation (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails Share-Based Compensation - Compensation Expense Allocation (Details) Details 49 false false R50.htm 0000050 - Disclosure - Share-Based Compensation - Stock Options Activity (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails Share-Based Compensation - Stock Options Activity (Details) Details 50 false false R51.htm 0000051 - Disclosure - Share-Based Compensation - Other Than Stock Options Activity (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails Share-Based Compensation - Other Than Stock Options Activity (Details) Details 51 false false R52.htm 0000052 - Disclosure - Other Expenses - Schedule of Other Expenses (Details) Sheet http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails Other Expenses - Schedule of Other Expenses (Details) Details 52 false false R53.htm 0000053 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 53 false false R54.htm 0000054 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) Details 54 false false R55.htm 0000055 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://www.r1rcm.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 56 false false R57.htm 0000057 - Disclosure - Segments and Customer Concentrations - Narrative (Details) Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails Segments and Customer Concentrations - Narrative (Details) Details 57 false false R58.htm 0000058 - Disclosure - Segments and Customer Concentrations - Concentration Risk by Customer (Details) Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails Segments and Customer Concentrations - Concentration Risk by Customer (Details) Details 58 false false R59.htm 0000059 - Disclosure - Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 59 false false R60.htm 0000060 - Disclosure - Supplemental Financial Information - Narrative (Details) Sheet http://www.r1rcm.com/role/SupplementalFinancialInformationNarrativeDetails Supplemental Financial Information - Narrative (Details) Details 60 false false R61.htm 0000061 - Disclosure - Supplemental Financial Information - Schedule of Supplemental Cash Flow Information Related to Leases (Details) Sheet http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails Supplemental Financial Information - Schedule of Supplemental Cash Flow Information Related to Leases (Details) Details 61 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept AccountsReceivableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ah-20230331.htm 4 [dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ah-20230331.htm 4 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: ah:StatuteOfLimitationsMinimum, dei:EntityRegistrantName, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 - ah-20230331.htm 4 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 - ah-20230331.htm 4 ah-20230331.htm ah-20230331.xsd ah-20230331_cal.xml ah-20230331_def.xml ah-20230331_lab.xml ah-20230331_pre.xml exhibit102-formofrsuawarda.htm exhibit103-formofrsuawardf.htm exhibit311-q12023.htm exhibit312-q12023.htm exhibit321-q12023.htm exhibit322-q12023.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ah-20230331.htm": { "axisCustom": 0, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 519, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 138, "dts": { "calculationLink": { "local": [ "ah-20230331_cal.xml" ] }, "definitionLink": { "local": [ "ah-20230331_def.xml" ] }, "inline": { "local": [ "ah-20230331.htm" ] }, "labelLink": { "local": [ "ah-20230331_lab.xml" ] }, "presentationLink": { "local": [ "ah-20230331_pre.xml" ] }, "schema": { "local": [ "ah-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 456, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 7, "http://www.r1rcm.com/20230331": 1, "http://xbrl.sec.gov/dei/2022": 6, "total": 14 }, "keyCustom": 47, "keyStandard": 248, "memberCustom": 22, "memberStandard": 25, "nsprefix": "ah", "nsuri": "http://www.r1rcm.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.r1rcm.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Acquisitions", "menuCat": "Notes", "order": "10", "role": "http://www.r1rcm.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "11", "role": "http://www.r1rcm.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Accounts Receivable and Allowance for Credit Losses", "menuCat": "Notes", "order": "12", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses", "shortName": "Accounts Receivable and Allowance for Credit Losses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Debt", "menuCat": "Notes", "order": "13", "role": "http://www.r1rcm.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Derivative Financial Instruments", "menuCat": "Notes", "order": "14", "role": "http://www.r1rcm.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "15", "role": "http://www.r1rcm.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Other Expenses", "menuCat": "Notes", "order": "16", "role": "http://www.r1rcm.com/role/OtherExpenses", "shortName": "Other Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "17", "role": "http://www.r1rcm.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "18", "role": "http://www.r1rcm.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://www.r1rcm.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "20", "role": "http://www.r1rcm.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Segments and Customer Concentrations", "menuCat": "Notes", "order": "21", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrations", "shortName": "Segments and Customer Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Supplemental Financial Information", "menuCat": "Notes", "order": "22", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformation", "shortName": "Supplemental Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Business Description and Basis of Presentation (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies", "shortName": "Business Description and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Acquisitions (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.r1rcm.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Revenue Recognition (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.r1rcm.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Accounts Receivable and Allowance for Credit Losses (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesTables", "shortName": "Accounts Receivable and Allowance for Credit Losses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Debt (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.r1rcm.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.r1rcm.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Share-Based Compensation (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.r1rcm.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Other Expenses (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.r1rcm.com/role/OtherExpensesTables", "shortName": "Other Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.r1rcm.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Segments and Customer Concentrations (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsTables", "shortName": "Segments and Customer Concentrations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Supplemental Financial Information (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformationTables", "shortName": "Supplemental Financial Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i0d1bfc6dd62f47a28890b346a5425fc4_D20220621-20220621", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Acquisitions - Narrative (Details)", "menuCat": "Details", "order": "34", "role": "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i37673d84f5004c5c9fa88e2ea5f6af53_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "ah:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "menuCat": "Details", "order": "35", "role": "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "ic88693c1c9324272916ea9dccc7dbe51_I20220621", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i8aaab8121ab440588151e85c92619e8f_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Acquisitions - Pro Forma Results (Details)", "menuCat": "Details", "order": "36", "role": "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "shortName": "Acquisitions - Pro Forma Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i8aaab8121ab440588151e85c92619e8f_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details)", "menuCat": "Details", "order": "37", "role": "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "shortName": "Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i85783c6990dc485083e358d8d87ece9b_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details)", "menuCat": "Details", "order": "38", "role": "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails", "shortName": "Revenue Recognition - Schedule of Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "lang": "en-US", "name": "ah:ContractWithCustomerLiabilityIncludingRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "id47c97755ae145a789827574ebf566c1_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Revenue Recognition - Changes to Contract Assets (Details)", "menuCat": "Details", "order": "39", "role": "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails", "shortName": "Revenue Recognition - Changes to Contract Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "ah:ContractWithCustomerAssetRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "iae539497cd744c8aace47593e8eaaaa7_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details)", "menuCat": "Details", "order": "40", "role": "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails", "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "iae539497cd744c8aace47593e8eaaaa7_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "id47c97755ae145a789827574ebf566c1_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Rollforward (Details)", "menuCat": "Details", "order": "41", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "shortName": "Accounts Receivable and Allowance for Credit Losses - Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "id47c97755ae145a789827574ebf566c1_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Narratives (Details)", "menuCat": "Details", "order": "42", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails", "shortName": "Accounts Receivable and Allowance for Credit Losses - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Debt - Carrying Amounts of Debt (Details)", "menuCat": "Details", "order": "43", "role": "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "shortName": "Debt - Carrying Amounts of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "icbffa02671d144fba0baebd79696555c_I20220621", "decimals": "INF", "first": true, "lang": "en-US", "name": "ah:DebtInstrumentCovenantSecuredObligationPledgedEquityCertainDomesticSubsidiariesPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Debt - Narrative (Details)", "menuCat": "Details", "order": "44", "role": "http://www.r1rcm.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "icbffa02671d144fba0baebd79696555c_I20220621", "decimals": "INF", "first": true, "lang": "en-US", "name": "ah:DebtInstrumentCovenantSecuredObligationPledgedEquityCertainDomesticSubsidiariesPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Debt - Scheduled Maturities of Long-Term Debt (Details)", "menuCat": "Details", "order": "45", "role": "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails", "shortName": "Debt - Scheduled Maturities of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i563b4ed9af684e75baea0d76d26fda74_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Derivative Financial Instruments - Narrative (Details)", "menuCat": "Details", "order": "46", "role": "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "shortName": "Derivative Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i6dbfbd909efd488ea78cb33bc82373b3_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details)", "menuCat": "Details", "order": "47", "role": "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails", "shortName": "Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i6dbfbd909efd488ea78cb33bc82373b3_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Share-Based Compensation - Narrative (Details)", "menuCat": "Details", "order": "48", "role": "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Share-Based Compensation - Compensation Expense Allocation (Details)", "menuCat": "Details", "order": "49", "role": "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "shortName": "Share-Based Compensation - Compensation Expense Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i09833d2b660a44aa911970d80c5515df_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnauditedParenthetical", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "id47c97755ae145a789827574ebf566c1_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Share-Based Compensation - Stock Options Activity (Details)", "menuCat": "Details", "order": "50", "role": "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails", "shortName": "Share-Based Compensation - Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "id47c97755ae145a789827574ebf566c1_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i777afb72b4d04b2486d7d4d46780feac_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Share-Based Compensation - Other Than Stock Options Activity (Details)", "menuCat": "Details", "order": "51", "role": "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails", "shortName": "Share-Based Compensation - Other Than Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i777afb72b4d04b2486d7d4d46780feac_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Other Expenses - Schedule of Other Expenses (Details)", "menuCat": "Details", "order": "52", "role": "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails", "shortName": "Other Expenses - Schedule of Other Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Income Taxes - Narrative (Details)", "menuCat": "Details", "order": "53", "role": "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details)", "menuCat": "Details", "order": "54", "role": "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails", "shortName": "Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Earnings Per Share - Narrative (Details)", "menuCat": "Details", "order": "55", "role": "http://www.r1rcm.com/role/EarningsPerShareNarrativeDetails", "shortName": "Earnings Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i98aac2c400e64d0195f2eb99fa9bed0c_D20210413-20210419", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Commitments and Contingencies - Narrative (Details)", "menuCat": "Details", "order": "56", "role": "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i98aac2c400e64d0195f2eb99fa9bed0c_D20210413-20210419", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Segments and Customer Concentrations - Narrative (Details)", "menuCat": "Details", "order": "57", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails", "shortName": "Segments and Customer Concentrations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i295468b81ee742e6a5e01c660076ca13_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Segments and Customer Concentrations - Concentration Risk by Customer (Details)", "menuCat": "Details", "order": "58", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "shortName": "Segments and Customer Concentrations - Concentration Risk by Customer (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i295468b81ee742e6a5e01c660076ca13_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "ah:DepreciationDepletionAndAmortizationExcludingIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "59", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "ah:DepreciationDepletionAndAmortizationExcludingIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i1a16668489c646b0bfd32ca57c9e0963_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i1a16668489c646b0bfd32ca57c9e0963_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Supplemental Financial Information - Narrative (Details)", "menuCat": "Details", "order": "60", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformationNarrativeDetails", "shortName": "Supplemental Financial Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Supplemental Financial Information - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "menuCat": "Details", "order": "61", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails", "shortName": "Supplemental Financial Information - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "ifa74449d8328419cb022781e0b52cb8e_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "ifa74449d8328419cb022781e0b52cb8e_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "8", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Business Description and Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentation", "shortName": "Business Description and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20230331.htm", "contextRef": "i681f4e6c84864b608002883775ee875f_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "ah_AccountsReceivableCreditLossExpenseReversalNetOfWriteOffs": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs", "label": "Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs", "terseLabel": "Provision for credit losses" } } }, "localname": "AccountsReceivableCreditLossExpenseReversalNetOfWriteOffs", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_AcquisitionEvaluationAndIntegrationCosts": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquisition Evaluation And Integration Costs", "label": "Acquisition Evaluation And Integration Costs", "terseLabel": "Strategic initiatives" } } }, "localname": "AcquisitionEvaluationAndIntegrationCosts", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ah_AscensionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ascension [Member]", "label": "Ascension [Member]", "terseLabel": "Ascension and its affiliates" } } }, "localname": "AscensionMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableReplacementEquityAwardsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares", "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares", "terseLabel": "Replacement awards issued to Cloudmed equity award holders (in shares)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableReplacementEquityAwardsShares", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ah_BusinessCombinationLockUpPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Lock-Up Period", "label": "Business Combination, Lock-Up Period", "terseLabel": "Lock-up period" } } }, "localname": "BusinessCombinationLockUpPeriod", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "ah_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability", "negatedTerseLabel": "Decrease in deferred income tax liability" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill", "negatedTerseLabel": "Decrease in goodwill" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsContractWithCustomer": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer", "terseLabel": "Current portion of contract assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsContractWithCustomer", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCompensationAndBenefits": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 12.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits", "negatedTerseLabel": "Accrued compensation and benefits" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCompensationAndBenefits", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCustomerLiabilities": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities", "negatedTerseLabel": "Customer liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCustomerLiabilities", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsContractWithCustomer": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer", "terseLabel": "Non-current portion of contract assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsContractWithCustomer", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantEquipmentAndSoftware": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software", "terseLabel": "Property, equipment and software" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantEquipmentAndSoftware", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_CloudmedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cloudmed Acquisition", "label": "Cloudmed Acquisition [Member]", "terseLabel": "Cloudmed" } } }, "localname": "CloudmedAcquisitionMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_CloudmedAndVisitPayAcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cloudmed And VisitPay Acquisitions", "label": "Cloudmed And VisitPay Acquisitions [Member]", "terseLabel": "Cloudmed and VisitPay Acquisitions" } } }, "localname": "CloudmedAndVisitPayAcquisitionsMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "domainItemType" }, "ah_CloudmedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cloudmed", "label": "Cloudmed [Member]", "terseLabel": "Cloudmed" } } }, "localname": "CloudmedMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "domainItemType" }, "ah_ContractWithCustomerAssetAmountsBilled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Amounts Billed", "label": "Contract With Customer, Asset, Amounts Billed", "negatedTerseLabel": "Amounts billed" } } }, "localname": "ContractWithCustomerAssetAmountsBilled", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerAssetOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Other", "label": "Contract With Customer, Asset, Other", "terseLabel": "Other" } } }, "localname": "ContractWithCustomerAssetOther", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerAssetRevenueRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Revenue Recognized", "label": "Contract With Customer, Asset, Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerAssetRevenueRecognized", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Asset", "label": "Contract with Customer, Asset [Roll Forward]", "terseLabel": "Contract with Customer, Asset [Roll Forward]" } } }, "localname": "ContractWithCustomerAssetRollForward", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "stringItemType" }, "ah_ContractWithCustomerLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Liabilities [Rollfarward]", "label": "Contract with Customer, Liabilities [Abstract]", "terseLabel": "Contract with Customer, Liabilities [Roll Forward]" } } }, "localname": "ContractWithCustomerLiabilitiesAbstract", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "stringItemType" }, "ah_ContractWithCustomerLiabilityAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Additions", "label": "Contract With Customer, Liability, Additions", "negatedTerseLabel": "Additions" } } }, "localname": "ContractWithCustomerLiabilityAdditions", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityAdvancedBillings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability Advanced Billings", "label": "Contract With Customer, Liability Advanced Billings", "negatedTerseLabel": "Advanced billings" } } }, "localname": "ContractWithCustomerLiabilityAdvancedBillings", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityAdvancedBillingsRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability Advanced Billings Recognized", "label": "Contract With Customer, Liability Advanced Billings Recognized", "terseLabel": "Advanced billings recognized" } } }, "localname": "ContractWithCustomerLiabilityAdvancedBillingsRecognized", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityCurrentExcludingAdvancedBillings": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Current, Excluding Advanced Billings", "label": "Contract With Customer, Liability, Current, Excluding Advanced Billings", "terseLabel": "Current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrentExcludingAdvancedBillings", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityIncludingRelatedParty": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including Related Party", "label": "Contract With Customer, Liability, Including Related Party", "totalLabel": "Total contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityIncludingRelatedParty", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityIncludingRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 1.0, "parentTag": "ah_ContractWithCustomerLiabilityIncludingRelatedParty", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including Related Party, Current", "label": "Contract With Customer, Liability, Including Related Party, Current", "verboseLabel": "Current" } } }, "localname": "ContractWithCustomerLiabilityIncludingRelatedPartyCurrent", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityIncludingRelatedPartyNoncurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 2.0, "parentTag": "ah_ContractWithCustomerLiabilityIncludingRelatedParty", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including Related Party, Noncurrent", "label": "Contract With Customer, Liability, Including Related Party, Noncurrent", "terseLabel": "Non-current" } } }, "localname": "ContractWithCustomerLiabilityIncludingRelatedPartyNoncurrent", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityNoncurrentExcludingAdvancedBillings": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings", "label": "Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings", "terseLabel": "Non-current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityNoncurrentExcludingAdvancedBillings", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Related Party, Current", "label": "Contract With Customer, Liability, Related Party, Current", "terseLabel": "Current portion of customer liabilities - related party" } } }, "localname": "ContractWithCustomerLiabilityRelatedPartyCurrent", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityRelatedPartyNoncurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Related Party, Noncurrent", "label": "Contract With Customer, Liability, Related Party, Noncurrent", "terseLabel": "Non-current portion of customer liabilities - related party" } } }, "localname": "ContractWithCustomerLiabilityRelatedPartyNoncurrent", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_CoyCo2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CoyCo 2", "label": "CoyCo 2 [Member]", "terseLabel": "CoyCo 2" } } }, "localname": "CoyCo2Member", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "ah_CustomerNotAffiliatedwithAscensionHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Not Affiliated with Ascension Health [Member]", "label": "Customer Not Affiliated with Ascension Health [Member]", "terseLabel": "Intermountain Healthcare" } } }, "localname": "CustomerNotAffiliatedwithAscensionHealthMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "domainItemType" }, "ah_DebtInstrumentCovenantSecuredObligationPledgedEquityCertainDomesticSubsidiariesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent", "label": "Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent", "terseLabel": "Debt covenant, secured obligation pledged, capital stock of certain domestic subsidiaries, percent" } } }, "localname": "DebtInstrumentCovenantSecuredObligationPledgedEquityCertainDomesticSubsidiariesPercent", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_DepreciationDepletionAndAmortizationExcludingIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation, Depletion, And Amortization, Excluding Intangible Assets", "label": "Depreciation, Depletion, And Amortization, Excluding Intangible Assets", "terseLabel": "Total depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortizationExcludingIntangibleAssets", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ExistingSeniorSecuredTermLoanAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing Senior Secured Term Loan A", "label": "Existing Senior Secured Term Loan A [Member]", "terseLabel": "Existing Term A Loan" } } }, "localname": "ExistingSeniorSecuredTermLoanAMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_FacilityCostsIncludedInAcquisitionEvaluationAndIntegrationCosts": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Facility Costs, Included In Acquisition Evaluation And Integration Costs", "label": "Facility Costs, Included In Acquisition Evaluation And Integration Costs", "terseLabel": "Global business services center expansion project in the Philippines" } } }, "localname": "FacilityCostsIncludedInAcquisitionEvaluationAndIntegrationCosts", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ah_FormerClassPUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Class P Units", "label": "Former Class P Units [Member]", "terseLabel": "Former Class P Units" } } }, "localname": "FormerClassPUnitsMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_GainLossOnDispositionOfAssetsAndRightOfUseAssetWriteDowns": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs", "label": "Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs", "negatedLabel": "Loss on disposal and right-of-use asset write-downs" } } }, "localname": "GainLossOnDispositionOfAssetsAndRightOfUseAssetWriteDowns", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_IncentiveFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Fees [Member]", "label": "Incentive Fees [Member]", "terseLabel": "Incentive fees", "verboseLabel": "Incentive fees" } } }, "localname": "IncentiveFeesMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "ah_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Lease Liabilities", "label": "Increase (Decrease) In Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_IncrementalSeniorSecuredTermLoanAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental Senior Secured Term Loan A", "label": "Incremental Senior Secured Term Loan A [Member]", "terseLabel": "Incremental Term A Loan" } } }, "localname": "IncrementalSeniorSecuredTermLoanAMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_LeaseExpenseNoncash": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease Expense, Noncash", "label": "Lease Expense, Noncash", "terseLabel": "Non-cash lease expense" } } }, "localname": "LeaseExpenseNoncash", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_ManagementUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management Units", "label": "Management Units [Member]", "terseLabel": "Management Units" } } }, "localname": "ManagementUnitsMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_ModularAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Modular And Other", "label": "Modular And Other [Member]", "terseLabel": "Modular and other" } } }, "localname": "ModularAndOtherMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "domainItemType" }, "ah_NetOperatingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Fees [Member]", "label": "Net Operating Fees [Member]", "terseLabel": "Net operating fees", "verboseLabel": "Net operating fees" } } }, "localname": "NetOperatingFeesMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "ah_NumberOfYearsSinceNewCountryEntry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Years Since New Country Entry", "label": "Number Of Years Since New Country Entry", "terseLabel": "Number of years since new country entry" } } }, "localname": "NumberOfYearsSinceNewCountryEntry", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "durationItemType" }, "ah_PaymentsToAcquireBusinessNumberOfPaymentsRefundPeriodIfCircumstancesMet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met", "label": "Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met", "terseLabel": "Payments to acquire business, number of payments, refund period, if circumstances met" } } }, "localname": "PaymentsToAcquireBusinessNumberOfPaymentsRefundPeriodIfCircumstancesMet", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "ah_PaymentsToAcquireBusinessesGrossFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Businesses, Gross, Financing Activities", "label": "Payments To Acquire Businesses, Gross, Financing Activities", "terseLabel": "Payments to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGrossFinancingActivities", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ah_PaymentsToAcquireBusinessesNumberOfPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Businesses, Number Of Payments", "label": "Payments To Acquire Businesses, Number Of Payments", "terseLabel": "Number of deferred payments" } } }, "localname": "PaymentsToAcquireBusinessesNumberOfPayments", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ah_PhysicianCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physician Customer", "label": "Physician Customer [Member]", "terseLabel": "Physician Customer" } } }, "localname": "PhysicianCustomerMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "domainItemType" }, "ah_PotentialBusinessCombinationPriceOfAcquisitionExpected": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Business Combination, Price Of Acquisition, Expected", "label": "Potential Business Combination, Price Of Acquisition, Expected", "terseLabel": "Potential business combination, expected purchase price" } } }, "localname": "PotentialBusinessCombinationPriceOfAcquisitionExpected", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ah_RestrictedStockUnitsRSUsAndPerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units (RSUs) And Performance Shares", "label": "Restricted Stock Units (RSUs) And Performance Shares [Member]", "terseLabel": "RSUs and PBRSUs" } } }, "localname": "RestrictedStockUnitsRSUsAndPerformanceSharesMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_RevWorksAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RevWorks Acquisition", "label": "RevWorks Acquisition [Member]", "terseLabel": "RevWorks" } } }, "localname": "RevWorksAcquisitionMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_ScheduleOfDepreciationAndAmortizationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Depreciation And Amortization [Table Text Block]", "label": "Schedule Of Depreciation And Amortization [Table Text Block]", "terseLabel": "Summary Depreciation and Amortization Expense" } } }, "localname": "ScheduleOfDepreciationAndAmortizationTableTextBlock", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "ah_SecondARCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second A&R Credit Agreement", "label": "Second A&R Credit Agreement [Member]", "terseLabel": "Second A&R Credit Agreement" } } }, "localname": "SecondARCreditAgreementMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_SeniorSecuredTermLoanAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Term Loan A", "label": "Senior Secured Term Loan A [Member]", "terseLabel": "Term A Loans" } } }, "localname": "SeniorSecuredTermLoanAMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_SeniorSecuredTermLoanBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Term Loan B", "label": "Senior Secured Term Loan B [Member]", "terseLabel": "Term B Loan" } } }, "localname": "SeniorSecuredTermLoanBMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_SeniorTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Term Loan", "label": "Senior Term Loan [Member]", "terseLabel": "Senior Term Loan" } } }, "localname": "SeniorTermLoanMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesVestingIfTargetConditionsMetPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement, By Share Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Conditions Met, Percentage", "label": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Target Conditions Met, Percentage", "terseLabel": "Number of shares vesting if targets conditions met, potential percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesVestingIfTargetConditionsMetPercentage", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period", "terseLabel": "Performance factor adjustment (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriod", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value", "terseLabel": "Performance factor adjustment (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsConvertedInTransactionAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement", "terseLabel": "Number of units converted in Transaction Agreement (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsConvertedInTransactionAgreement", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ah_ShareBasedPaymentArrangementNoncashExpenseFromAcquisition": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Noncash Expense From Acquisition", "label": "Share-Based Payment Arrangement, Noncash Expense From Acquisition", "terseLabel": "CoyCo 2 share-based compensation" } } }, "localname": "ShareBasedPaymentArrangementNoncashExpenseFromAcquisition", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsMaximumExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable", "terseLabel": "Maximum exercisable (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsMaximumExercisable", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ah_StatuteOfLimitationsMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Statute Of Limitations Maximum", "label": "Statute Of Limitations Maximum", "terseLabel": "Statute of limitations maximum" } } }, "localname": "StatuteOfLimitationsMaximum", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "durationItemType" }, "ah_StatuteOfLimitationsMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Statute Of Limitations Minimum", "label": "Statute Of Limitations Minimum", "terseLabel": "Statute of limitations minimum" } } }, "localname": "StatuteOfLimitationsMinimum", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "durationItemType" }, "ah_TCPASCRecapitalizationLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TCP-ASC Recapitalization Litigation", "label": "TCP-ASC Recapitalization Litigation [Member]", "terseLabel": "TCP-ASC Recapitalization Litigation" } } }, "localname": "TCPASCRecapitalizationLitigationMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_ThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party", "label": "Third Party [Member]", "terseLabel": "Third Party" } } }, "localname": "ThirdPartyMember", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_TreasuryStockExcludingRelatedToShareBasedCompensationSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired", "label": "Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired", "negatedTerseLabel": "Repurchases of common stock (in shares)" } } }, "localname": "TreasuryStockExcludingRelatedToShareBasedCompensationSharesAcquired", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ah_TreasuryStockExcludingRelatedToShareBasedCompensationValueAcquiredCostMethod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method", "label": "Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "TreasuryStockExcludingRelatedToShareBasedCompensationValueAcquiredCostMethod", "nsuri": "http://www.r1rcm.com/20230331", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filter Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r475", "r555", "r567", "r568", "r569" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "netLabel": "Related Party" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r185", "r186", "r284", "r311", "r479", "r481" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r247", "r495", "r554", "r579" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r266", "r267", "r268", "r269", "r342", "r442", "r465", "r476", "r477", "r492", "r502", "r508", "r550", "r572", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r266", "r267", "r268", "r269", "r342", "r442", "r465", "r476", "r477", "r492", "r502", "r508", "r550", "r572", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r247", "r495", "r554", "r579" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r244", "r444", "r493", "r507", "r545", "r546", "r554", "r578" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r244", "r444", "r493", "r507", "r545", "r546", "r554", "r578" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r266", "r267", "r268", "r269", "r340", "r342", "r370", "r371", "r372", "r441", "r442", "r465", "r476", "r477", "r492", "r502", "r508", "r541", "r550", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r266", "r267", "r268", "r269", "r340", "r342", "r370", "r371", "r372", "r441", "r442", "r465", "r476", "r477", "r492", "r502", "r508", "r541", "r550", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r185", "r186", "r284", "r311", "r480", "r481" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r506" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Allowance for Credit Losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r249", "r250" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of $16.0 million and $15.1 million allowance as of March\u00a031, 2023 and December\u00a031, 2022, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r132", "r133", "r159", "r527" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Accounts receivable, net of $0.1 million and $0.1\u00a0million allowance - related party as of March\u00a031, 2023 and December\u00a031, 2022, respectively" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r25", "r26", "r160", "r461", "r470", "r471" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r23", "r26", "r104", "r434", "r466", "r467", "r516", "r517", "r518", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental Financial Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r506" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r380", "r381", "r382", "r529", "r530", "r531", "r564" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "terseLabel": "Cost of shares surrendered for taxes" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r88", "r89", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r161", "r251", "r254", "r255", "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r161", "r251", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, allowance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r30", "r303", "r427", "r524" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r44", "r62", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Intangible asset amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive common share equivalents (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r135", "r143", "r157", "r182", "r231", "r235", "r240", "r252", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r406", "r408", "r419", "r506", "r548", "r549", "r570" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r152", "r162", "r182", "r252", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r406", "r408", "r419", "r506", "r548", "r549", "r570" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r404", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r93", "r94", "r404", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of Pro Forma Results" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax": { "auth_ref": [ "r402", "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax", "terseLabel": "Net income" } } }, "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r402", "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Net services revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r92" ], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business acquisition costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r97", "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r100", "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 13.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "negatedTerseLabel": "Operating lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 14.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]", "terseLabel": "Allocation of consideration to assets acquired and liabilities assumed:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 15.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedTerseLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r95" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r44" ], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility-exit charges" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r47", "r48", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property, equipment and software purchases not paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "auth_ref": [ "r259" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.", "label": "Capitalized Contract Cost, Net, Noncurrent", "terseLabel": "Non-current portion of deferred contract costs" } } }, "localname": "CapitalizedContractCostNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r46", "r154", "r478" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r41", "r46", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r41", "r126" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "verboseLabel": "Gains to be reclassified within next 12 months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r66", "r263", "r264", "r474", "r547" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r529", "r530", "r564" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r72" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r506" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01\u00a0par value, 750,000,000\u00a0shares authorized, 442,439,169 shares issued and 418,176,363 shares outstanding at March\u00a031, 2023; 750,000,000 shares authorized, 439,950,125 shares issued and 416,597,885 shares outstanding at December\u00a031, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r27", "r170", "r172", "r176", "r458", "r462" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Consolidated statements of comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r53", "r54", "r123", "r124", "r247", "r473" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r53", "r54", "r123", "r124", "r247", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r53", "r54", "r123", "r124", "r247", "r473", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r53", "r54", "r123", "r124", "r247" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r51", "r53", "r54", "r55", "r123", "r125", "r473" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r53", "r54", "r123", "r124", "r247", "r473" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": { "auth_ref": [ "r254", "r255", "r258", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Allowance for Credit Loss", "terseLabel": "Contract assets, allowance" } } }, "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Classified [Abstract]", "terseLabel": "Contract assets, net" } } }, "localname": "ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Contract Assets and Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r313", "r315", "r336" ], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Balance as of March\u00a031, 2023", "periodStartLabel": "Balance as of December\u00a031, 2022", "totalLabel": "Total contract assets, net" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r313", "r315", "r336" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerAssetNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Current portion of contract assets, net", "verboseLabel": "Current" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r313", "r315", "r336" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_ContractWithCustomerAssetNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Non-current portion of contract assets, net", "verboseLabel": "Non-current" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r313", "r314", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "negatedPeriodEndLabel": "Balance as of March\u00a031, 2023", "negatedPeriodStartLabel": "Balance as of December\u00a031, 2022" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r313", "r314", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r313", "r314", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Non-current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r33", "r444" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of services", "verboseLabel": "Cost of services" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r31" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r52", "r247" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r71", "r181", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r297", "r304", "r305", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r136", "r137", "r142", "r187", "r281", "r282", "r283", "r284", "r285", "r287", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r428", "r487", "r488", "r489", "r490", "r491", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r137", "r142", "r308" ], "calculation": { "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total", "verboseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r17", "r282" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r18", "r187", "r281", "r282", "r283", "r284", "r285", "r287", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r428", "r487", "r488", "r489", "r490", "r491", "r525" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r18", "r73", "r74", "r75", "r76", "r127", "r128", "r130", "r141", "r187", "r281", "r282", "r283", "r284", "r285", "r287", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r306", "r428", "r487", "r488", "r489", "r490", "r491", "r525" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r129", "r293", "r309", "r488", "r489" ], "calculation": { "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized discount and issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "terseLabel": "Debt issuance costs incurred" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "terseLabel": "Debt issuance costs, capitalized" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r384", "r385" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "verboseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r384", "r385" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r45" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "verboseLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r91", "r558" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Deferred tax assets related to operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r44", "r229" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset, current" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative asset, noncurrent" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Derivative, fair value, net" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r563" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Derivatives, net gain (loss) reclassified" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r112", "r114", "r116", "r117", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r122", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r110", "r112", "r116" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r163", "r164", "r418", "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r561", "r562" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r106", "r107", "r108", "r110", "r111", "r115", "r116", "r118", "r119", "r120", "r414" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r335", "r493", "r494", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregated Revenue By Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r347", "r376", "r377", "r379", "r383", "r503" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Net income per common\u00a0share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r177", "r193", "r194", "r195", "r196", "r197", "r201", "r204", "r215", "r216", "r217", "r221", "r416", "r417", "r459", "r463", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income per common share (basic) (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r177", "r193", "r194", "r195", "r196", "r197", "r204", "r215", "r216", "r217", "r221", "r416", "r417", "r459", "r463", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income per common share (diluted) (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r218", "r219", "r220", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r420" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes in cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r183", "r387", "r396" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r556", "r557" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "negatedLabel": "Income tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Share-based compensation expense capitalized to deferred contract costs" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Nonvested award, cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Related tax benefits" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r72", "r150", "r173", "r174", "r175", "r188", "r189", "r190", "r192", "r198", "r200", "r223", "r253", "r312", "r380", "r381", "r382", "r392", "r393", "r415", "r421", "r422", "r423", "r424", "r425", "r426", "r434", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts", "verboseLabel": "Foreign Currency Hedges" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r155", "r260", "r457", "r486", "r506", "r538", "r539" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r110", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r28", "r134", "r139", "r148", "r231", "r234", "r239", "r242", "r460", "r485" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income tax provision" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r183", "r388", "r389", "r391", "r394", "r397", "r399", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r184", "r199", "r200", "r230", "r386", "r395", "r398", "r464" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r43" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r523" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedTerseLabel": "Contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r443", "r523" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Customer liabilities and customer liabilities - related party" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r43" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r43" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r43" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r43" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable and related party accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r205", "r206", "r207", "r217" ], "calculation": { "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Add: Effect of dilutive warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r205", "r206", "r208", "r217", "r346" ], "calculation": { "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Add: Effect of dilutive equity awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r61", "r63" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "negatedLabel": "Net interest expense" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]", "terseLabel": "Investor" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r182", "r252", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r407", "r408", "r409", "r419", "r484", "r548", "r570", "r571" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r138", "r146", "r506", "r526", "r536", "r565" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r153", "r182", "r252", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r407", "r408", "r409", "r419", "r506", "r548", "r570", "r571" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit agreement, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Borrowing availability" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation expenses" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a company, excluding disclosure for allowance for credit losses. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Also excludes disclosure for financing receivables.", "label": "Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]", "terseLabel": "Accounts Receivable and Allowance for Credit Losses" } } }, "localname": "LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r137", "r144", "r294", "r310", "r488", "r489" ], "calculation": { "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedTerseLabel": "Less: Current maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r69", "r187", "r551" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 7.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r69", "r187", "r299" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r69", "r187", "r299" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2028" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r69", "r187", "r299" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r69", "r187", "r299" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r69", "r187", "r299" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r528" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r158" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Total long-term debt", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r18", "r70" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r67", "r68", "r265", "r266", "r267", "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of complaints filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r180" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r180" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r41", "r42", "r45" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r29", "r45", "r140", "r147", "r151", "r168", "r171", "r175", "r182", "r191", "r193", "r194", "r195", "r196", "r199", "r200", "r213", "r231", "r234", "r239", "r242", "r252", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r417", "r419", "r485", "r548" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r193", "r194", "r195", "r196", "r201", "r202", "r214", "r217", "r231", "r234", "r239", "r242", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income (loss) available to common stockholders, basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r203", "r209", "r210", "r211", "r212", "r214", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income (loss) available to common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards and Disclosures" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r231", "r234", "r239", "r242", "r485" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r430" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r430" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r431", "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r429" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Business Description and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r156" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r101", "r102", "r103" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r166" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net change on derivatives designated as cash flow hedges, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Net change on derivatives designated as cash flow hedges, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r165", "r166", "r410", "r411", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "verboseLabel": "Unrealized gains reported in accumulated other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Accumulated gain, net of tax, recognized in other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r101", "r102", "r103", "r169", "r172" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralExpense": { "auth_ref": [ "r36" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.", "label": "Other General Expense", "terseLabel": "Other expenses", "totalLabel": "Total other expenses" } } }, "localname": "OtherGeneralExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r80", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Expenses" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r44" ], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r519", "r520" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r39" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r179" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Shares withheld for taxes" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r37" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property, equipment, and software" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PBRSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r515" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r521", "r522" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r38", "r86" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of vested stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r540", "r566" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property, equipment and software, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r178", "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision (recoveries)", "verboseLabel": "Increase in allowance" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]", "terseLabel": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r341", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r341", "r437", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r569" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r435", "r436", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r40" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-Term Lines of Credit", "negatedLabel": "Repayment of senior secured debt and Repayments on revolver" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r77", "r145", "r469", "r471", "r506" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r150", "r188", "r189", "r190", "r192", "r198", "r200", "r253", "r380", "r381", "r382", "r392", "r393", "r415", "r466", "r468" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r227", "r228", "r233", "r237", "r238", "r244", "r245", "r247", "r334", "r335", "r444" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net services revenue ($216.8\u00a0million and $216.7\u00a0million for the three months ended March 31, 2023 and 2022, from related party, respectively)", "verboseLabel": "Net services revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r339", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r325", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r32", "r149", "r272", "r273", "r274", "r278", "r279", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Net services revenue, from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue expected to be recognized in the future related to unsatisfied performance obligations, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "terseLabel": "Schedule of Transaction Price Allocated to the Remaining Performance Obligation" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Senior Revolver" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r433", "r505" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r247", "r533" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r93", "r94", "r404" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Fair Value of Total Consideration Paid and Schedule of Acquisitions" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Carrying Values Long-Term Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Income (Loss) Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r85", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Scheduled Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.", "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]", "terseLabel": "Schedule of Other Expenses" } } }, "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.", "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "terseLabel": "Schedule of Non-Options Awards Activity" } } }, "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Fair Value of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r56", "r57", "r58", "r60" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r343", "r345", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r81", "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r51", "r53", "r54", "r55", "r123", "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Customer Concentration, Net Services Revenue" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r224", "r225", "r226", "r231", "r232", "r236", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segments and Customer Concentrations" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r35" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r43" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding and unvested at end of period (in shares)", "periodStartLabel": "Outstanding and unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding and unvested at end of period (in dollars per share)", "periodStartLabel": "Outstanding and unvested at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted- Average\u00a0Grant Date\u00a0Fair\u00a0Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Outstanding, vested and exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Outstanding, vested and exercisable at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled/forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Canceled/forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "verboseLabel": "Shares surrendered for taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r20", "r72", "r150", "r173", "r174", "r175", "r188", "r189", "r190", "r192", "r198", "r200", "r223", "r253", "r312", "r380", "r381", "r382", "r392", "r393", "r415", "r421", "r422", "r423", "r424", "r425", "r426", "r434", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r188", "r189", "r190", "r223", "r444" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r4", "r5", "r72", "r77" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to share-based compensation plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r5", "r72", "r77", "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of vested stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r20", "r72", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of vested stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r59", "r506", "r526", "r536", "r565" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "negatedPeriodEndLabel": "Ending Balance (in shares)", "negatedPeriodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r22", "r78", "r79" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury Stock, Common, Value" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r5", "r72", "r77" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Acquisition of treasury stock related to share-based compensation plans (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r72", "r77", "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Acquisition of treasury stock related to share-based compensation plans" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r203", "r217" ], "calculation": { "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average common shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares used in calculating net income per common share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r201", "r217" ], "calculation": { "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average common shares (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r511": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r512": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r513": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r514": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 82 0001628280-23-015496-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-015496-xbrl.zip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®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